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ABSTRACT 
This study evaluates the costs and effectiveness of preventive 
and curative procedures currently available for Tuberculosis (TB) 
control purposes. The procedures examined are as follows : 
i) BCG vaccinations; 
ii) Secondary chemoprophylaxis; 
iii) Health education; 
iv) Mass screening campaigns; 
v) Investigation of contacts of infectious TB cases and symptomatic 
persons, i.e. suspects; and 
vi) Treatment regimens for notified TB patients. 
/ 
The analysis is largely based on data!from the records of 300 randomly 
selected TB patients, treated at clinics in the Cape Divisional 
Council area in 1983. 
The major finding of this study is that resources available for 
TB control should be reallocated in the direction of secondary 
chemoprophylaxis, BCG vaccination administration in the Black and 
Coloured populations, investigation of contacts and suspects, and 
ambulatory treatment of notified TB patients. Conversely, vaccinating 
the White population, mass screening campaigns and hospitalisation 
of TB patients should be given relatively less emphasis in the 
overall TB control programme. In addition, the proportion of 
patients confirmed as TB cases by means of bacteriological examin-
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There were two major motivating factors for undertaking this 
particular study: 
i) Dr Coogan, the Medical Officer of Heal th for the Cape Town 
City Council, is reported as having said that TB is 
the biggest 





health problem we have· and the 
not responding to control measures 
going up by about a third every 
(The Argus, January 16, 1984 1) 
Resources available for combatting TB are limited and there 
are a range of possible preventive and curative procedures 
for TB. In addition, there . is a relative dearth of data on 
TB procedures in S.A., although an increasing number of studies 
have been initiated over the past few years. 
These factors suggested that a cost-effectiveness analysis, 
based on statistics gathered in a random sample of TB patients, 
might provide a useful framework for policy-makers' reassessment 
of the procedures currently employed in TB prevention and 
treatment. 
Although broad guidelines concerning TB procedures are presented 
in the Department of Heal th and Welfare's (now the Department 
of National Health and Population Development) National TB 
control programme, there is some degree of flexibility in 
the implementation of this programme at the loal authority 
/ 
2 
level. As a result, the outcomes and effectiveness of TB 
programmes differ between local authorities. 
It was originally planned that the cost-effectiveness ratios 
of procedures implemented by the Cape Town City Council (CCC) 
would be compared with the ratios for the Cape Divisional 
Council (CDC). Regrettably, access to CCC data was restricted. 
It was felt nevertheless that evaluation of the CDC procedures 
only would still be feasible and useful, both for the CDC 
and for other local authorities who would be enabled to assess 
their procedures in relation to the CDC cost-effectiveness 
ratios. It is important to note in this regard that the CDC 
was one of the first local authorities to experiment with 
new TB procedures such as shorter treatment regimens. 
ii) Cost-benefit analysis (CBA) and cost-effectiveness analysis 
{CEA) have been extensively used overseas as frameworks for 
heal th project evaluation. As yet, no studies of this nature 
have been published in S.A. Thus a secondary obj ec ti ve of 
this study is to demonstrate the usefulness of CEA as a 
technique for health project evaluation. 
This dissertation is divided into five chapters which can be summer-
ised as follows: 
CHAPTER I The theoretical frameworks of CBA and CEA are presented 
and compared. The selection of CEA as the most appropriate method 
~-
for evaluation of TB procedures is motivated. Past applications 
of these techniques to heal th project evaluation are then assessed. 
/, 
\ \ ,,, 
3 
Appendix A contains a more extensive theoretical exposition of 
CBA. 
CHAPTER II The incidence of TB and the preventive and curative 
procedures available for its control are discussed in some detail. 
This is necessary for two reasons: a) to highlight the extent 
of the TB problem, and b) to provide sufficient information about 
TB to ensure that the content of later chapters will be intelligble 
to readers who have no medical expertise. 
CHAPTER III The results of a random sample of 300 CDC TB patief}t 
records are presented. The sample was performed to estimate the 
value of certain factors that influence the costs and effectiveness 
of TB procedures and for which insufficient data was available. 
Figures reflecting some of the sample findings are contained in 
Appendix B. 
CHAPTER IV The cost-effectiveness ratios of preventive and curative 
• 
procedures for TB in the CDC .are calculated. Appendices C - F 
describe cost da£a and its manipulation in greater detail. 
CHAPTER V : These cost-efectiveness ratios are evaluated and compared 
to determine what combination of preventive and curative procedures 
should be implemented. In particular, the practical implications 
of the call for greater hospitalisation of TB patients by certain 
local authorities, other than the CDC, are evaluated. There is 
some discussion of what policy decisions the ratios point towards, 
but the emphasis is on providing a groundwork for the health author-
ities' own assessment of each procedure's economic feasibility, 
I 





THE THEORY OF COST-BENEFIT ANALYSIS (CBA) AND COST-EFFECTIVENESS 
ANALYSIS (CEA) AND THEIR APPLICATION TO THE EVALUATION OF HEALTH 
PROJECTS 
Introductory Note: 
A very brief and general discussion of the CBA and CEA frameworks 
will be presented in the initial sections of this chapter with 
a more extensive theoretical exposition of CBA in Appendix A. 
The emphasis in this chapter is on examining the CBA and CEA 
techniques in the context of health project evaluation. 
,,. 
1. Cost-Benefit analysis and Cost-effectiveness analysis theory: 
1.1 The Framework of CBA: 
CBA is primarily a tool to assist decision makers in the assessment 
of proposed projects. It facilitates decision making by enumerating, 
and wherever possible, evaluating in monetary units, all costs 
and benefits associated with the projects under review and thereby 
explicitly brings all practically relevant factors into consideration. 
The broad definitions of costs and benefits that will be used in 
this study are: A benefit is any utility or welfare gain resulting 
from the project under consideration. A cost is any loss of utility 
or welfare resulting from the project. 
The present values of the costs /and benefits 
I 
\ ,y 
are combined in 
5 
equation form to determine firstly whether each project is 
economically feasible, and secondly to rank alternative projects 
if a limited budget exists. The most common form of the CBA decision 
rule is: 






t = l t = ' 
Benefits in time period t, 
Costs in time period t, 
discount rate, 







Projects are ranked according to the magnitude by which the sum 
of the present value of benefits exceeds the sum of the present 
value of costs. If there is a budget constraint, those with the 
largest differences are given priority. 
The result of any CBA calculation must be balanced by the judgement 
of decision makers. As Frost (1971:20) has pointed out, CBA 
" ... should not be regarded as a machine for decisions 
but rather as an aid to judgement." 
1.2 The Framework of CEA: 
The major factor which distinguishes CEA from CBA is that benefits 
are not expressed in monetary units, but in terms of a predetermined, 
1 
common unit of outcome. 
6 
Thus, CEA is generally used to evaluate 
different ways of achieving the same objective, while CBA tends 
to be used to assist in the selection of one or more projects from 
a range of possible projects which may have different objectives, 
but for which limited resources are available. CEA is also the 
preferred framework for evaluating social programs, where often, 
no generally accepted methods of assigning monetary values to benefits 
are available. 
In CBA, the analyst makes various value judgements in ascribin[ 
values, which may be subject to interpersonal and intertemporal 
fluctuations, to certain benefits. With a CEA, these value judgements 
are made by policy-makers. The role of the analyst in a CEA is 
not to conclusively determine whether a project is economically 
feasible, but to provide results in terms of cost per unit of outcome 
and to indicate what policy conclusions various value assignments 
point towards. The ultimate decision as to whether the cost per 
unit is justified or worthwhile then rests with !the policy-makers 
and planners. (Thompson & Fortess 1980:554-555). 
1 It is important to define the terms 'output' and 'outcome', 
to clarify their usage in this study. Output is the expected 
result of a project while outcome is the desired effect of the 
output. To illustrate these definitions with reference to heal th 
projects, output could for example be the provision of a particular 
heal th service while outcome could be the improvement in heal th 
status of the recipients of this heal th service. Cost per unit 
of output reflects the efficiency of a project while cost per 
unit of outcome reflects the effectiveness of a project. 




CEA is however able to rank alternative projects. This can be 
presented in two ways: i) according to the lowest cost per unit 
of outcome, or ii) according to the greatest outcome per unit of 
cost. 
2. CBA and CEA in health project evaluation: 
I 
\ 
2 .1 A brief overview of past applications of CEA and CBA to the 
evaluation of health projects: 
The following table, reproduced from the study conducted by Warner 
and Hutton (1980), shows the trends in CBA health projects literature: 
Table 1.1 
Trends in Health Care CBA/CEA, 1966~1973 and 1974-1978 
1. Average annual number of CBA/CEA publications 
2. Publications in medical journals as .. % of tot.al 
journal publications 
3. CEAs as% of CEAs & CBAs 































(Warner & Hutton 1980:1076) 
8 
Al though this study only covers the period 1966 - 1978, it does 
highlight three important trends which have continued to the present: 
a) There has been a substantial increase in the number of heal th 
projects evaluated within the framework of CBA or CEA, over 
the past decade. This is a reflection of the concern of those 
involved with the provision and planning of health services 
with the rising costs of health care. While attempting to minimise 
costs, health professionals are also continually striving to 
improve the quality and effectiveness of heal th care. Another 
factor promoting the growth of this literature is the statutory/ 
legislative requirements in the U.S.A., which compel health 
agencies to use either the CBA framework or a similar multiple 
consideration balancing technique for project evaluation. 
( Baram 1980). 
As the number of studies has increased, so the range of aspects 
of health care evaluated within the framework of CBA or CEA 
' 
has broadened. 2 
2. A few examples of these publications are mentioned here to 
illustrate the range of medical procedures evaluated: 
Surgery techniques Barnes 1977 and Barnes 1982; Curative 
regimens Culyer & Maynard 1981; Weisbrod 1981 and Ludbrook 
1981; Preventive regimens - Cutting 1980, Epstein et al 1981, 
Hagard & Carter 1976, Lave & Lave 1978, Mooney 1982, Patrick 
& Woolley 1981 and Ponninghaus 1980; Technological advances 
in heal th care Paterson 1983; Medical pol icy research 
techniques - Roid 1982; Rehabilitation care Swint & Nelson 
1977; Clinics as providers of heal th care - Kriedel 1980; and 
of particular concern for this study, aspects of TB prevention 
and treatment - Feingold 1975, McNeil et al 1980 and Stilwell 
1976. 
b) In addition to studies which present results of CBA or CEA in 
heal th care projects, there are a number· of articles which have 
the objective of explaining CBA and CEA techniques to medical 
t •t• 3 prac 1 1oners. As a result, the proportion of CEA and CBA 
studies of heal th care pro.jects conducted by heal th professionals 
has increased, which partly explains the increasing proportion 
of such publications in medical journals. 
Although it is encouraging to see that medical practitioners 
actively support the use of CBA and CEA in heal th care project 
evaluations, the framework is often applied in an uncritical 
way. Underlying assumptions and value judgements are not 
explicitly stated and there is thus seldom any indication of 
how the results would be affected by changes in these factors. 
One of the most frequent criticisms of these studies is that 
direct costs as determined by heal th departments or hospitals, 
are the only costs of the medical procedure being evaluated 
taken into consideration. The indirect and sometimes intangible 
costs to the patient and society as a whole are ignored. 
Despite these qualifications regarding certain studies, health 
project evaluations have been facilitated by the application 
of CBA and CEA frameworks. With increased co-operation between 
economists and providers of medical services, a suitably balanced 
application of economic theory and practical aspects in the 
provision of health services can be achieved. 
3. Drummond 1981, Thompson & Fortess 1980, yo:lpin 1980 and Weinstein & 
Stason 1977. \ 
\ 
10 
c) CEA is now used more frequently than CBA in the evaluation of 
health projects. 
2, 2 Critical assessment of CEA and CBA as techniques for evaluating 
health projects: 
As the benefits of health care most often used as criteria of 
clinical success, such as increased life expectancy and amelioration 
of pain, are not easily expressed in monetary terms, CEA is usually 
given preference over CBA for the evaluation of health projects. 
This section will attempt to assess whether this emphasis is valid 
by examining the respective arguments advanced for i) using CBA 
and calculating all heal th benefits in monetary uni ts and ii) using 
CEA and expressing the benefits in terms of a preselected common 
unit of outcome. 
2.2.1 CBA in health project evaluation -Valuing a life: 
I 
Much of the discussion around the monetarisation of heal th benefits 
is centred on a lively debate about the 'value' of a human life. 
In general, the primary objective of heal th care projects is the 
extension of life span and thus the monetary valuation of life 
years is an important aspect in a CBA of these projects. 
There are three major theoretical approaches to life valuation: 
a) the Human capital approach, b) the willingness-to-pay approach 







a) The Human capital approach bases the value of a human life on 
the net present value of future earnings. (Mishan 1972: 101, 
Conley 1976:45, Landefeld & Seskin 1982:556 and pardis 1981:50-51). 
In some instances, people involved in non-market activities 
eg. housewives, are included in the calculations by imputing 
a value to their services. 
The primary critic ism of this approach is that the value of a 
human life is determined by the value to society in terms of 
a loss in production potential rather than the value to the 
person or population who face the risk of being injured or dying 
prematurely, i.e. critics argue that the perspective of the 
valuation is incorrect. (Mishan 1972:101, Linerooth 1979:53 
and Dardis 1981:51). It also does not account for any pain 
and suffering not reflected in a change in productivity but 
which nevertheless affects the quality of life. 
Another result of the emphasis on earnings is that children 
and people who have retired are 'discriminated' against, in 
that the value of their lives are understated relative to people 
who are employed. In the case of children, this effect is 
magnified if relatively high discount rates are selected by the 
analyst. (Landefeld & Seskin 1982:556 and Dardis 1981:51-52). 
In spite of these deficiencies, the Human capital approach is 
still a popular method of evaluation. This is largely due to 
availability of data on earnings, labour force participation 




b) The willingness-to-pay approach to life valuation shifts the 
basis of evaluation to the perspective of the individuals who 
face the risk of premature death. It attempts to estimate what 
these irldividuals would be 'willing-to-pay' for a reduction 
(or receive as compensation for an increase) in mortality risk. 
The sum of these estimates indicates the value, to the population 
at risk, of a programme which saves 'statistical' lives, i.e. 
lives which are not identifiable ex-ante. The value of a life 
is thus the value of the programme divided by the number of 
lives saved by the programme. 
Alternative practical applications of this approach have been 
attempted- which fall broadly -into three categories: 
i) Questionnaires: An example of this method is the survey 
conducted by Jones-Lee (1976) with regard to safety in airline 
I 
travel. f 
ii) Estimating the implicit value of life as revealed in the labour 
market, through the income compensation required by workers 
in high risk occupations. 
iii) Estimating the implicit value of life as reflected in consump-
tion activity. A few examples of this method are: Blomquist 
(1979) estimated the 'willingness-to-pay' for a reduction 
in mortality risk by analysing seat-belt use; Dardis ( 1980) 
by analysing the purchases of smoke detectors; and most recently, 
Ippolito & --Ippolito (1984) by analysing the changes in 
cigarette consumption patterns due to improved availability 





The major problem with this theoretical approach is that it 
cannot be assumed that everyone will be 'willing-to-pay' the 
estimated amount for a reduction in mortality risk. Thus, life 
or risk reduction valuations will vary according to the group 
of people surveyed and the situation studied. In addition, 
a person's ability to pay will affect their 'willingness-to-pay'. 
(Landefeld & Seskin 1982:557). 
c) The 'societa 1 valuation' approach attempts to establish either 
the life valuation implicit in past governmental policy/programme 
decisions or the explicit valuations reflected in court awards/ 
decisions. Life valuation estimates based on this approach 
have been criticised as they are not consistent and reflect 
the valuation of policy makers or court officials rather than 
the people who are affected by the decisions. (Dardis 1981:49). 
Some advocates of the monetary valuation of life procedure have 
attempted to establish a relationship between the Human capital 
and 'willingness-to-pay' approaches. In general, the methods proposed 
to achieve this are based on the concept of 'willingness-to-pay' 
for the economic effects of a change in mortality risk. (Landefeld & 
Seskin 1982:559). 
In summary, most studies are concerned with the valuation of life 
or life years and largely exclude consideration of other health 
benefits such as a reduction in injuries or morbidity, unless the 
effects of these factors are explicitly reflected in terms of 
productivity losses. 
14, 
The results of any CBA based on life valuations which exclude 
'quality of life•
4 
considerations could be seriously distorted, 
because, as Dardis (1981:58) has pointed out, 
"A study of life safety in England found that certain 
types of injuries were viewed as worse than death (paralysis, 
brain damage) while severe burning and loss of limb were 
given a severity value equal to ten percent of the severity 
value given to death." 
Taking all the above-mentioned deficiencies into account, and 
particularly the fact that a wide range of life valuation estimates 
have been produced, both within and between different approaches, 
it would be prudent to avoid the use of such techniques to determine 
the value of a life using data specific to S.A., given the limitations 
of this study. 
2.2.2 CEA in health project evaluation Health Status Indeces: 
Section 1. 2 indicated that if the framework of QEA is used, the 
' time consuming and inconclusive life valuation procedure outlined 
above will be unnecessary. The technique that replaces this valuation 
process, is the selection of a unit of outcome in which to express 
health benefits. 
A range of possible 'outcome units' exist for every project. For 
example, the benefits of a screening program ( to detect or diagnose 
a disease) could be expressed in terms of the number of people 
4. 'Quality of life' refers to the heal th status of an individual 
i.e. whether a person is heal thy and free of. any symptoms of 




screened, the number of ·cases of the disease found, the number 
of lives saved, the life years extended and so on. 
Thompson and Fortess ( 1980: 554) suggest that the following guide-
lines should be used: 
"Choice among the alternative output measures and, 
hence among alternative cost-effectiveness ratios should 
be based on ( 1) data availability and ( 2) the goal of 
describing the program as accurately as possible for 
decision makers." 
In health care project evaluation, the outcome units most frequently 
used are 'number of lives saved' or 'years of life extended'. 
As with most of the CBA techniques, these measures do not take 
the quality of life into account. However, a number of studies 
have been directed towards the development of measures of heal th 
outcome for use in CEA, which express both mortality and morbidity 
factors. This is achieved through the determination and application 
of a 'Health Status Index'. 4a 
I 
Most of these studies base the expression of a person's health 
status on that person's ability to function biologically and socially 
in relation to their riorinal daily activities. 
The first step in deriving a Heal th Status Index (HSI) is to define 
an ordinal scale of function/dysfunction by isolating and describing 
a number of heal th or functional states, ranging from well-being
5 




to CEA literature in recent years. It was thus felt that an exposition 
of this framework should be included for the sake of completeness,despite 
the fact that the conditions of this study exclude its use in the analysis. 
The ideal .state of health is defined in the Preamble to the 
Wo:i'ld Health Organisation (WHO) Constitution as "a state of 
<Yomplete physical, mental and social wellbeing and not merely 
1,he absence of disease or infirmity." {Quoted in Holland et 
"'l 1Q7Q•?7) 
16 
to death. Then, a relative weight6 is ascribed to each state and 
thus a cardinal scale of function/dysfunction is obtained. (Fanshel 
& Bush 1970:1029-1048). (An example of a schedule consi ting of 
different function levels and functional or social preference wetghts, 
is provided in Addendum I). 
With the assistance of medical experts, the probability of 'being 
classified at a particular functional level and the duration that 
a person would be in that level, can be determined for a given 
disease. 
The HSI of an individual can then be calculated as follows: 
; 
where :£.. T 
j j 
= T s T 0 
and E(H) = HSI for an individual/mean function level (for the re-
mainder of that individual's standard life (Ts»; 
Pj = probability of being in level j; 
Tj duration in level j; 
Ts = standard ideal life duration (specified by the analyst 
e.g. 90 years); 
To = current age 
Fj = function weight for level j. (See Footnote 6 and 
Addendum I) 
6. This can be done by assuming and specifying a functional relation-
ship between each state or by obtaining consumer~rated measures 
of relative importance. The set of weights can either be function-
al weights (i.e. Wellbeing = 1 and death = 0) or dysfunctional 
weights (i.e. wellbeing = 0 and death = 1) (Fanshel & Bush 1970: 







(Note: ~ P . T . F . 
J J J J 
is an expression of expected 'quality adjusted 
years of life' . ) 
(Bush et al 1972:53-54) 
The HSI of a population (E(H)n) can also be determined: 
E(H) N 
~p. T. F. N. = J J J J J 
~ T. N. 
J J J 
where Nj = number of persons in level j. 
(Bush et al 1972:55) 
Kaplan et al {1976:478-479) note that a HSI is an important tool 
for evaluating di verse heal th programmes, for aggregating different 
outcomes from many different health problems on a single scale 
and for comparing the health status of different populations at 
different times. 
The present study does not fall into any of th~se categories as 
it is concerned with one specific disease, Tuberculosis {TB). 
It would require unrealistic effort and resources to consult TB 
experts to determine acceptable estimates of P j and Tj values and 
which function levels a TB patient would be in at various stages 
of the disease. It was decided that these considerations outweighed 
the benefit of having a single measure for mortality and morbidity. 
3. Summary: 
CBA and CEA have the same theoretical basis. Al though benefits 
are not expressed in monetary terms in a CEA, the same procedure 
I 
/ .' 
\ . 9""' 
18 
for evaluating costs is used in both CBA and CEA. (See Appendix A). 
CEA has been selected as the framework of analysis in this study 
for two reasons: i) CEA is now widely accepted as the preferred 
evaluation technique for health projects and ii) The practical 
problems involved in the monetarisation of certain benefits, 
especially with respect to the 'value of life', could not be overcome 
within the limited scope of this study. 
Although it is preferable to use a HSI in a cost-effectiveness 
analysis, the absence of Tuberculosis specific estimates for certain 
HSI variables prevented its use in the present study. Thus, a 






Addendum I 19 
Table 1. Function Level$: Combinations of Steps on Mobility, Physical Activity, and ~cipl Activity Scoles, with Associated Levels 
of Well-being (Social Preference Weights), F 1 . .. ' 
~nm!,er'i in p,;.tn:ntlw,t·'\ il.H' 'i'.tcp numlH·rs nu tJu- lhn·C' ~cales. 
· .. -~\ 







L •!3 Drove car anti usctl L11s 
or train without help ( 5) 
L 42 Drove car ancl usl'd lms 
or train without help ( 5) 
L 41 J)ro\"c e1r mid u~t·tl lms 
or trnin witlumt lwlp ( 5) 
I, ·10 Drove ,·ar and metl hus 
or train without help ( 5) 
L 39 Drove car and 11,~tl bus 
or train without 1 ... lp (5) 
L 38 Drovc,car and used bus 
or train without help ( 5) 
L 37 Dro\'e car anti used bus 
or train without help (5) 
L36 Drove car and used lrns 
or tr:iin without help ( .5) 
L 35 Dro\'e car a11tl rn,i·tl bus 
or train without h<"lp ( 5) 
L~I l)rovc car and u:-.c,d bus 
or train witliuut 1,clp (5) 
L 33 Drove ('ar and used hus 
or train witliout 1,l'lp (5) 
L 32 Diel not drh·!). or had l,clp 
to 111.;<• hus or ti :du ( ,I) 
L 31 Did not drive, or },ad help 
to use bus or train (4) 
L 30 Did not drive, or had help 
to use bus or train ( 4) · 
L 29 Ditl not drive, or ha,1 help 
to me bus (?r irnin ( 4) · 
L 26 Did not drive, or had help 
to use bu5 or train (4~ 
L 27 Did not drh·e, or h,d help 
to use b!1s or train (4) 
L 26 Diel not drh·e, or had help 
to nsc h11s or train ( 4) 
L25 Did not drive, or haa help 
to use bus or train ( 4) 
. L 24 Did not dri\'e, or had help 
to use bus or train { 4) 
L23 In house (3} 
L 22 In J1011SC' (3) 
L 21 ln house (3} 
\ 
In _house • L 20 (31 
L 19 In h01,se ·(3) 
L 16 ·. In.house {3) 
L 17 In house (3) 
I. J(j In hou~c (3) 
L 15 In house (3) 
I 
{, 1-1 i 1} ]IOUSC ' ( tJ) 
I. 13 111,l,ospilal (2) 
L 12 In J,ospit;,I (2) 
I. J I 111 l,o~pilal (2) 
L JO In l,ospital (2) 
I. !) In hospital (2) 
L 8 In hospital (2) 
I. 7 In l,ospital (2) 
). (j In l10,pit:1l (2) 
I. .'; 111 ~})tTiaf l".ttT 1111il (]) 
I. ·I I,, s1wl'ial t';ltt' 1111il (]) 
I. 3 111 SJ)('('iaJ l';}l"C' 1111il (l•) 
J. 2 In ·~pl'dal c.irc 1111i( (]) 
I. In s1wcial (';II"(' 1111il (l) 
I. 0 D,·.1<l (0) 
··--------- --··---·--· --- --
Scale 
.Ph,·sical 
activity Soci.11 activity 
1':0 SY!\11'1'0~1/l'JU>UU:.!\f CO~fPLEX 
Walked without 
physkal problems ( 4) 
Di<l work, s('hool, or housework, 
and other activities ( 5) 
SYMJ'TOM/rno11LEM CO~tPLEX pl\£SE1\T 
\Valketl without 
phrskal probl,•ms ( 4) 
\\'alk,·,1 willio11t 
physical problems ( 4) 
Walked without 
physical problems ( 4) 
\Vall.rel without 
phrsieal problems ( 4) 
'Walked witho11t 
physical prohll'ms ( 4) 
Walked with physical 
limitations ( 3) 
Walked with physical 
limitations (3) 
Wall.rel with physical 
li111itati11ns (3) 
\\'alb,cl with physical 
li111itations ( 3) 
\\'alkl'll with phrsical 
limilatio11s (3) 
\Valkl'd without / 
physical pml,lcms (.1) 
\\'alkcd \\'ilhout , 
,· pl,ysical problems ( ,1) 
Walked will,out 
physic-al problem's ( 4) 
Walh·cl without 
r,hrsical pri,l,lc-ms (·I) 
\Valkcd will, physical 
limitations (3) 
W,,lkl'<l with physical 
limitations (3) 
\Valk eel with physical 
li111itali11ns (3) 
'.\lon,d own \\1,celdwir 
without l1Plj> ( 2) 
~IO\·cd own wheclcl,air 
without h<'lp ( 2) 
\Vall:ecl without 
pl,ysi.-al pro!.lc-ms ( ·1) 
\Vul!-,·,I wilh1111t 
physical prol,l;•111s ( 4) 
\\'all:rcl wi1h· physical 
li111ilatiuns (3) 
\Valkecl with pl,y,ical 
limitations (3) 
\\'ailed with physical 
limitations ( 3) 
~ , \Valkl'cl with physical 
limitatious ( 3) 
!\lc,vcd own wheelchair 
without help ( 2) 
--- · --~-~-~i,-1-n:il O\\;ii --whet•khair 
witho11t help (2) 
In lwd or ,·hair ( l ) 
In hl'd or d,air ( 1) 
\\'alh·cl without 
pl,ysical prol,lnns (-I) 
\\'alkt'd willinul 
pl,yskal ptA,ll'111s (,I) 
\Valk,·d "ith pl,ysical 
li111itatio11s (3) 
\Valk,·d with pl,ysil'al 
li111ilations ( 3) 
~lun.·cl own \\)1Pl·ld1.tir 
with1111t lll'lp (2) 
~lo\.l'll C.iwn wJ1t't·kh:lir 
without help (2) 
In !)('ti or d,air (I) 
Jn 1,<'d or chair ( 1) 
\Valk.·d ·will,out 
pliysil'al pnol>lc111s (·I) 
\ValL·d wi1!i,11Jt 
pl,).,ic.11 prnl,ll'111S (·I) 
Walk,·,! will, pl,ysil'al 
!i11iil.1:io11~ { :~) 
\Valk,·d with physical 
1i111ilalio11.s ( :~ \ 
Ju lwd m : 1;_,;, ( l ) 
D,::"1 (O) 
Did work, school, or housework, 
oml other activities ( 5) 
Did work, school, or housework, 
but other nctivitics limited ( 4) 
Limited in amount or kind of 
work, school, or housework ( 3) 
Performed self-care, but not 
work, school, or housework ( 2) 
Had help \\·ith seU-carc 
activities (I} 
Did' work, school, or housework, 
and other activities ( 5) 
Did work, school, or housework, 
but other activities limited ( 4) 
Li111itcd in :nnount or kind of 
work, school, orJ,mi,:ework ( 3) 
Pcrfonncd self-care, bi:t not 
work, school, or housework ( 2) · 
Had l,dp with self-care _ 
activities ( l) 
Did wor1', school, or houseworl.:, 
but other adivitics limited ( 4) 
Limited in amount or killll nf 
work, school, or housework ( 3) 
Performed self-care, hut n,,t 
"''ork, sch<x,l, or housework ( 2) 
Had help with self-care 
• activities ( 1) 
Di,l wo,k, school, or housework, 
b11t other adivilics li111itr,l (·I) 
Limited in amount or ii11<l of 
work, sch,.,!, 1•r ho11·,rwc , 1: ( 3) 
Perforni<~r sdf-carr, l"'l not 
wo1 k, sl'houl, or honSt'\\'Ork ( 2) 
Limited in amo11nt o,· kind of 
work, scl,ool, or l,rmscwork ( 3) 
Pcrfom,~tl self-cam, hnt not 
\\:OJ k, school, or homework ( 2) 
Pcrform('d self-care, hut not 
\\'Ork, sd1oot or l1n11•.r·worl ( 2) 
11:ul lwlp wit!, s..Jr.,.,,.,, 
aclivitil's (I) 
Did wnrl, ~dmu1. or Tm11st"work, 
1111( otlwr :tdivili1·:,; 1i111il1•(1 (r1) 
Limited in mnon11l nr kind of 
· work, sdJC,.,l, or l1011sc·\\·'irk ( 3) 
Performer! self-car<', !mt not 
'la'Ork, sd,onl, or ho11s.wmk ( 2) 
Had hdp with s,·lf-care 
activities (I) 
Performed sdf-l'are, hut not 
1\·ork, sc,hool, or hnn,ewnrk ( 2) 
flaJ h<"lp with self-care 
:1<·ti\'ili,·s ( l) 
Pl•rfonncll !'-<'l£-can·, hut not 
,nirk. sdu•,l, or hn11sl'\l'01k (2) 
llacl 1,dp with self-mre 
:>di,·itil'S ( J) 
Pt~1f,1mH'tl s<"Jf-C'are hut not 
u·ork, sc:hool, or Ju;uscwml ( 2) 
ll:ul hdp with St·lf-C"an• 
:><:tivili,·s (1) ·· · 
J•,·rfon,wtl ~l'lf-(·;,uc, 1ml not 
1.,ml, selmol, or ho11 ... <:\\'0r~ (2) 
Ila.I h~lp with ,elf-l'arc 
::tc:tivilics (I) 
rl'rfon11ed self-care:, hut not 
11.-ork, selwo!, nr how,:~work ( 2) 
lb<l lwlp with sclf-C'are· 
2l'tidtk-s { 1} 
l',·!fon11,·d self-care, hut not 
,.-u, l. sd1o<Jl, or housework ( 2) 
ltid help ,vitli sclf-C"a1<1 
2di,·iti1.·s (]) 
ft·1frn1m·,l .,:·lf-carc, h11t not 
""'k, ,clio,,J, or lwus,·work (2) 
ll.1tl l"'lp "ilh self-care 
a:,:ti,·iti,·s ( l) 
r,.-rf,ur111l•tl !-~·If-car(', but n;1t 
,u,,..._, ~1...·!,11«11\ "[.·. J1ousc,\·t1rK ( 2 j 
lbd h..lp with,self-c:arc 
•,n,tivif1,•,.; / 1 \ ' > · / 
·u,,J ll<'il' ,;·ith ,df-l'arc
0 
31·ti1·ilil'S ( ]) / 
f· 
O,·,ul (_O) \ . ->¥ ·--· ·- ---· ... --



















































THE NATURE AND INCIDENCE OF TUBERCULOSIS 
AND MEASURES FOR ITS CONTROL 
1. Basic characteristics of TB: 
Tuberculosis is defined by Glatthaar (1982a:1) as: 
" a chronic ( sometimes acute or sub-acute) infectious 
disease, caused by specific mycobacteria and characterised 
by the formation of lesions in any tissue or organ of 
the body, but mainly in the lungs." 
A few facts concerning TB can be drawn from this definition and 
elaborated upon. 
i) The tubercle bacilli (M tuberculosis) is transmitted largely 
through inhalation and ingestion. (Glatthaar 1982a:7). This 
occurs when a person with infectious TB cbughs or spits/ 
expectorates, and another person then either inhales droplets 
containing the bacilli or ingests them in dust particles. 
This applies in the majority of cases and infection is said 
to have resulted from human bacilli. Very occasionally, 
infection may occur when bovine bacilli are ingested through 
drinking unpasteurised milk from infected cattle. 
ii) The tubercle bacilli, once transmitted to a previously un-
infecte-d person. cause a 'primary infection' in the mid-lung 





in one of a number of possible tissues and organs (see 
Figure II ,.1), In the majority of cases this occurs in the apices 
of the lungs and is thus called pulmonary tuberculosis. 
FIGURE 11.1 
The Natural cycle of TB disease 
Endogenous Reactivation 


























etc. (Adapted from Glatthaar 1982a:12) 
( 
iii) As Figure II.1 indicates, most people are able to combat the 
infection with their cellular defence mechanisms and develop 
a natural resistance to further infection. In some cases 
this process is not completed and living bacilli may remain 
in the lesion which could be reactivated at a later stage 
if certain predisposing factors, as listed in Figure 11.1, 
are present. If the infected person is unable to develop 




To summarise the process described above, the transmission of 
M tuberculosis from person to person results in active TB if the 
recipient has never before been exposed to tubercle bacilli, either 
through natural infection or through a BCG vaccination and developed 
a cellular immunity. This usually applies to children. Other 
cases of active TB are generally a result of endogenous reactivation 
of dormant bacilli in a person who has been previously infected 
as applies to the majority of adult TB sufferers. 
It is important to emphasize the role of socio-economic factors 
in this process. Glatthaar (1982a:5) states that: 
' .. 
"Tuberculosis is truly a disease directly influenced 
by unfavourable socio-economic conditions. Poor housing, 
overcrowding, malnutrition, lack of hygiene, emotional 
or physical stress, long hours of work, loss of sleep, 
lowered resistance, unpasteurised milk, etc., are all 
factors that favour I the development and spread of 
Tuberculosis". 
2. Indices of Tuberculosis infection: 
Note: Most of the data presented in this section relates specifi-
cally to the Cape Divisional Council (CDC) area, (see Map 1). 
Occasionally, figures for South Africa will be referred to. 
1. Toman (1979:5) clarifies this concept 
the purposes of tuberculosis control, 
discharging tubercle bacilli". 
/: 
\ ,,,,, 
by stating that " ... for 
a "case" is an individual 
23 
/ 
MAP 1 "Cape Pe,ninsula Divisional Council showing Cape and Cape 









The previous section indicated that there are two distinct groups 
of people which TB health workers attempt to monitor and control: 
i) Infectious TB cases and ii) Infected persons, i.e. those who 
have dormant bacilli which can be reactivated in the future. Figure 
II. 2, which illustrates the re.lationship between these two groups, 
is based on the findings of prevalence studies conducted in South 
Africa. 












Infected Persons -- -
(Adapted from Glatthaar 1982a:2) 
There are a number of different measures which can be used to 
determine and reflect the impact of TB on a given population. 





2.1 Incidence rates: 
The incidence of a disease is the proportion of a population that 
contracts the disease within a specified time interval (e.g. a year). 
Incidence rates are generally expressed in terms of a base, e.g. 
X cases of TB per 100 000 population, to formulate a rate with 
a value that exceeds unity. ( Peterson and Thomas 1978: 1-2, 16) . 
2.1.1 Notification rate: 
Data on the annual TB notifications
2 
is readily available and is 
thus the measure used most frequently to indicate the incidence 
of TB. However, as depicted in Figure II. 2, notification rates 
understate TB incidence. Notification data only accounts for the 
I 
TB cases detected by the heal th au:);h'ori ties and is thus an indication 
/ I 
of the success of case-finding efforts rather than of the total 
incidence of infectious TB cases. 
I 
Despite these drawbacks, notification rates will form the basis 
of this analysis of TB incidence in the CDC as it is the only measure 
for which comprehensive and consistent data is available. 
Table 11.1 and Figures 11.3 and 11.4 show the trends in annual 
notifications and notification rates for the CDC during the past 
decade. 
2. In terms of Section 45 of the Heal th Act t Act 63 of 1977, all 
forms of TB, except cases diagnosed solely on the basis of 
clinical signs and symptoms and/or a positive tuberculin test 
must be notified to the Department of National Health and Popula-
tion Development (formerly Department of Health and Welfare). 
(City of Cape Town 1983:161 and Glatthaar 1982a:19). 
26 






















































































































































































































































(DIVISIONAL COUNCIL OF THE CAPE 1984: 152) 
)TE: Black population estimates are determined by the Cape Peninsula Administration Board, 
1d were based on Census figures until 1982. White and Coloured population estimates are 
?termined by the c~n. c. 













ANNUAL NOTIFICATIONS IN CDC (1976 - 1984) 
Coloureds 
Blacks 
.... ~~~ .... --~~~.-----._..,. ________ ... ____ ~...,.. ..... ----......... ______ ..,...,_ ______ ,.. Whites 













ANNUAL NOTIFICATIONS PER 100 000 in CDC (1976 - 1984) 
Blacks 
.....__ .........._ • _______... ,,.. -Coloureds 
• I ,, I .. I 
l Whites 
I I i I i I I I I 




There have been mild fluctuations both in the total number of 
notifications and in the notification rates, which are of relatively 
insignifica~t magnitude in the white population. 
There has been a consistent and significant increase in the number 
of notifications in the black and coloured populations over the 
past decade. This can partly be ascribed to population increases. 
As notification rates are expressed in terms of a common base, 
which accounts for differences and changes in\ population levels, 
this measure is more functional than the number of notifications 
in that it permits comparison both between annual f1gures within 
each race group and between race groups. 
The number of 
a faster rate 
n:tifications of (o/oureds has been increasing at 
than the increase in the coloured population which 
has resulted in a steady increase in the coloured notification 
r 
rate from 322 ( 1975) to 415.35 per 100 000 populatio/'(1984). 
The fluctuations in Black notification rates require a more detailed 
explanation. It is important to note that the Black population 
in Cape Town is very transient with a continual influx from and 
outflow to the Transkei and Ciskei. It is possible that some of 
these migrants come to Cape Town with the express purpose of obtaining 
treatment for TB due to the deficiencies in heal th facilities in 
the.se areas. (Shasha 1982). 







"One quarter of the latter [Black] cases are imported 
i.e. they have lived for less than 6 months in our area". 
(Divisional Council of the Cape 1982:6) 
It could be argued that the Black notification rates in the CDC 
are following a normal epidemiological trend and that the TB situation 
in the Black population is slowly improving. 
However, there has been a massive influx of 'illegal' migrants 
from the Transkei and Ciskei during the 1980 1 s 3 and thus the decrease 
in the Black notification rates is largely a result of the rapid 
population growth, although the rate of increase in the number 
of Black notifications has diminished. 
Taking into acc,ount the fact that, /1 large proportion of these new 
/ 
migrants settled· in squatter cam'ps (either Crossroads, KTC, Nyanga 
Bush, etc.) where socio-economic conditions which would facilitate 
the spread of TB exist, it is surprising that the notification 
r 
rates have fallen so sharply since 1982. Two possible qualifications 
should thus be considered. Firstly, part of the increase in popul-
ation figures may be attributable to improved measurement/data 
3. In the 1984 Race Relations Survey, the Chief Director of the 
Western Cape Development Board, Mr J Gunther, was reported as 
stating that the number of 'illegal' Blacks in the Western Cape 
had risen to approximately 100 000. (Half of these 'illegals' 
resided in the Crossroads squatter camp alone) (South African 
Institute of Race Relations 1984:352). In 1986, the deputy 
City Engineer for housing, Mr Neville Riley, estimated that 
the influx of Blacks into the Cape Town metropolitan area had 
risen from 1000 monthly in 1980 to 9000 in February 1985. 
(The Argus 13/5/86) 
31 
collection procedures and secondly, the increased population placed 
additional pressures on the staff and facilities at the Nyanga 
and Crossroads clinics which could have resulted in a relatively 
lower proportion of TB cases being found. 
The trends in TB notification rates for the various race groups 
have been summarised in the following observation from a report 
on the 1985 Tuberculosis Research Institute (TBRI) symposium: 
"According to one theoretical model, the morbidity rate 
due to TB takes the predictable form of an epidemic wave 
which increases, reaches a peak, and then falls, running 
its course in about 300 years. This wave has probably 
reached a late stage in whites ... , and an intermediate 
stage in blacks. Among coloureds the epidemic wave may 
still be in its ascending stage." 
,· (Townshend and Aalbers 1985:8) 
! 
Another significant feature of the data presented in Table II .1 
and Figure 11.4, is that black notification rates are substantially 
higher than coloured notification rates. In 19$3, 43. 3% of the 
total notifications for the CDC arose from the black population 
which comprised a mere 12.3% of the total population. 
Al though this situation may partly be explained in terms of the 
coloured and black populations being at different stages of the 
TB epidemiological trend, another important reason for the notifi-
cation gap is the difference in socio-economic conditions. The 
influence of socio-economic factors is illustrated in Table 11.2. 
A few of the CDC coloured areas, for which data was available are 







TABLE II.2 Relationship between TB notification rate and socio-
economic indicators 
Notification Rate Density per Personal Income (Rand 
Per 100 000 Dwelling/ per Month) 
Population people per Males Females 
Habitable room 
Belhar 411.6 1.31 328.91 148.65 
Bishop Lavis 343.3 1.84 178.02 109.25. 
Kasselsvlei 416.9 1.95 250.81 182.96 
(Bellville South) 
Elsi es River 515.4 1.81 182.98 122.57 
Uitsig 743.9 1.93 197.73 184.37 
Ravensmead 617.6 1. 93 209.15 129.07 
Grassy Park ) 1.38 279.71 158.26 
) 175.7 
Lotus River ) / 
l 
1.54 257.34 139.26 
I 
Ocean View 204.1 1.81 206.23 106.85 
Nyanga 983.3 2.62 132.46 87.57 
I 
(Notification data from 1983 CDC Notification register and unpublished 








SJcio-economic indicators and the TB notification rate is not 
altogether consistent within the coloured areas, this information 
does provide some indication of the role of socio-economic factors, 
especially when comparing the coloured areas with the black area. 
2.1.2 Mortality rate: 
Annual mortality rates are another index of disease incidence, 
al though they do not have as strong a correlation with the total 
number of infectious TB cases as some other measures, and are 
influenced by variations in the effectiveness of treatment regimens. 
Table II.3 TB Mortality ~.CDC (1980 - 1984) 
,( 
Year 
Race 1980 1981 1982 1983 1984 
Whites 0 2 1 ! 2 2 
Coloureds 27 46 37 41 38 
Blacks 7 35 14 13 26 
TOTAL 34 83 52 56 66 
(Divisional Council of the Cape 1980:45, 1981:40, 
1982:54, 1983:48, 1984:47) 
Except for 1981, there has been a steady increase in the mortality 
due to TB in the five years from 1980 to 1984. 
34 
2 .1. 3 Annual risk of tuberculous infection: 
4 
Styblo (quoted in Fourie 1983) defines the risk of tuberculous 
infection as: 
" the proportion of the population which will be 
primarily infected, or reinfected (in those who have 
been previously infected) with tubercle bacilli in the 
course of 1 year, and is usually expressed as a percentage 
or as a rate." 
(Fourie 1983:182) 
This measure thus attempts to estimate a broader group of people 
than that reflected in notification data. 
The Tuberculosis Research Institute (TBRI) of the South African 
Medical Research Council (MRC) has./conducted extensive tuberculin 
tests5 since 1972, to establish figures for the risk of TB 
infection in specified years and the annual change in this risk. 
The results of these surveys are summarised in Figure 11.5 and 
Table II.4. 
4. Styblo, K. 1980 Recent advances in epidemiological research 
in Tuberculosis. Advances in Tuberculosis Research, 20,1. 
5. The Mantoux test was used in these surveys which entails the 
intradermal injection of Tuberculin PPD (Purified Protein Deriva-
tive). If a person has been previously infected with tubercle 
bacilli, an induration, i.e. hardened swelling, will develop 
at the injection site within abput 72 hours. Whether the person 
has developed cellular immunity or not and whether they are 
possible infectious cases is determined according to the size 









Figure 11.5 Estimated Risks of Tuberculosis Infection and their 
trends in South Africa between 1970 & 1990. TBRI 




197tl 1975 1980 1985 1990 
YEAR 
(Reproduced from Fourie:19E 
36 









6.9 13 713 









Black (Coastal) 76.2 7.2 8 262 
82.2 7.2 3 788 1.6% -6.2% 
(Reproduced from Fourie & Knoetze 1986) 
* Periods of Data Intake- : 1972-78 and 1979-85 
Mean year necessary as different areas surveyed in different 
years e.g. CDC surveyed in 1978 & 1979, Durban in 1976 & 1977. 
Mean age refers to the age of children included in survey. 
The figures for the group Black (Coastal) are based largely on 
surveys conducted in the Eastern Cape, Durban and the Cape Divisional 
Council. 
The following observations, based on data gathered in the TBRI 
surveys, were made in the 1983 MRC annual report : 
"Coloured children in Pretoria and in the Cape Divisional 
Council area have similar incidence rates of 13 per 
1 000 (RSA 9 per 1 000), which are decreasing slowly 
at the rate of no more than 3% annually. However, the 
annual birth rate of 2% cancels out the effect of this 
slight downward trend and there may very well be an increase 
in the number of TB infections and disease cases. The 
annual rate of TB infection for Blacks in the Cape 
Divisional Council (CDC) area is 16 per 1000, which 
compares favourably with the RSA rate of 13 per 1 000. 
The annual downward trend in this group is 5-7%." ! 
I 





These findings support the general trends derived from the notifi-
cation data. 
2.2 Prevalence rates: 
The prevalence of a disease is defined as the proportion of a 
population with the disease at a particular point in time, (Peterson 
and Thomas 1978:1) and can either be expressed as a percentage 
or in terms of a predetermined base (as with incidence rates). 
Prevalence is an indication of the total burden of a disease on 
the population being studied (Peterson and Thomas 1978:14), and 
thus TB prevalence statistics include both infectious and infected 
persons (see Figure II.2). 
Figure II. 6 shows the differences in prevalence rates for different 
age groups of children, estimated from the TBRI tuberculin surveys. 
Figure II. 6 Average Prevalence rates of TB infection in S. A. over 
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Table II. 5 gives the prevalence estimates based on data for the 
5-9 years age group. As vaccination of school-going children occurs on 
a large scale now, the size of indurations of children in the 5-9 
years age group who will only have been vaccinated at birth, are 

































*Periods of Data Intake: 1972-78 and 1979-85 
(Reproduced from Fourie & Knoetze 1986:387) 
It is evident from these figures that there has been a noticeable 
reduction in TB infection prevalence in S. A. over the past decade. 
6. Sensi ti vi ty to Tuberculin PPD can either be induced by previous 
vaccination with BCG or by natural infection with tubercle bacilli. 
TB prevalence data attempts to estimate the latter category 
of infected persons (Fourie 1983:182-183). 
2.3 Summary of TB infection indices: 
The risk of tuberculous infection is decreasing in the CDC, al though 
almost negligibly in the case of Coloureds, and thus there is a 
decrease in the rate at which tlte pool of infected persons is being 
supplemented (see Figure II.2). In addition, the TB infection 
prevalence is decreasing which indicates that the combined pool 
of infected and infectious persons is being supplemented at a slower 
rate. Until such time as these pools actually begin to decrease 
in size, it is to be expected that more people will be notified 
each year, al though the increased notifications could also indicate 
an improvement in the TB case-finding methods. 
3. Preventive measures and curative regimens for the control of TB. 
Much of this discussion refers specifically to South Africa or the 
CDC. It is important to note, however, that this information is 
based on international research and experience in the field of 
TB prevention and treatment. The procedures implemented in South 
Africa are in line with generally accepted international practices. 
The most comprehensive summary of TB research findings is contained 




The only TB procedure on which international agreement has not 
been reached is the BCG vaccination. Studies conducted in various 
parts of the world found that BCG vaccinations provide effective 
protection against tuberculosis infection in up to 80% of the 
vaccinated population in some cases, while providing no protection 
in other cases. (See Section 1.1.2 of Chapter IV). These findings 
have resulted in considerable debate as to how 'useful' it is to 
vaccinate an entire population. In addition, certain organisations, 
such as the British Thoracic and Tuberculosis Association (1975), 
are trying to estimate at what point a BCG vaccination programme 
is no longer justified, in terms of cost-effectiveness criteria. 
{Stilwell 1976). 
The Department of Heal th and Welfare (now the Department of 
National Health and Population Development) proposed a national 
TB control programme in 1979. Four measures were regarded as 
priorities i) TB health education to encourage greater community 
im,olvement, ii) treatment of notified cases must contain the drug 
Rifampicin and be fully supervised, iii) case-finding efforts must 
be increased once the previous two measures have been impleme:lted, 
and iv) all children must receive BCG vaccinations. ( GJatthaar 
1982a:22) and Glatthaar 1982b:39). 
The aim of these measures, which are currently being implemented 
by heal th authorities in S. A., is to reduce the pool of infectious 




TB infection by means .of BCG immunisation. (Glatthaar 1982a:23) 
Once these measures are iri force in most areas, a second phase 
- -: 
of the national· programme. will be· ambark~d on; which will focus 
on attempts to reduce the pool of infected persons ( see Fig II ~2) and 
to reduce the risk of endogenous reacti vc:ti,on. This can be achieved 
by improving socio-economic conditions and providing secondary 




Many of the national TB control programme measures have been an 
integral part of the CDC TB control programme for a number of years 
already. 
3.1 BCG vacination: 
It is compulsory in S.A. for all children to be vaccinated before 
6 months of age. (Gfatthaar 1982a:19). The vaccination policy 
of the CDC is as follows: Children are vaccinated at birth, at 
the age of 3 months if no BCG scar is visible, when they enter 
school (Pre-school or Sub A) and in Std 5 (Coloured) or Std 8 (White). 
(Divisional Council of the Cape 1982:191 and Thomson & Myrdal 
1984a:8-9). 
7. Positive tuberculin reactors with the possibility of the 
existence of active tubercle bacilli can be treated with a drug 
such as Isoniazid (INH) to ensure complete sterilization of 





3.2 Health Education: 
One of the main objectives of heal th education is to create a greater 
awareness of the symptoms of TB within the broader community, in 
an attempt to encourage people displaying these symptoms to present 
themselves at a clinic for investigation at an early stage, and 
to thus facilitate passive case-finding. More generally, with 
increased knowledge of the nature of TB and its predisposing 
factors, much of the stigma attached to this disease can be 
averted and the community can play a role in improving socio-economic 
conditions and assisting with the supervision of treatment. 
As reported in a survey undertaken by Thomson and Myrdal (1984a: 10) 
the CDC conducts general TB education 
" ... at bus stop queui:·s, in the street, 
' anywhere ' , .... " 
Particular attention is paid to educating and enlisting the support 
of 1.eachers and employers who can provide supervision for the 
treatment of TB patients at school and work. It is felt that if 
employers are aware that TB sufferers are rendered uninfectious 
within one or two weeks of starting treatment, they will be less 
inclined to dismiss workers who contract the disease. 
Health education is also directed specifically at TB patients. 
This takes place at clinics and during house visits, to motivate 
them to attend for supervised therapy on a regular basis. 






day-hospital doctors and paramedics with the objective of alerting 
them to the possibility of TB in persons presenting with certain 
symptoms, given the high incidence of this disease at present. 
Medical practitioners are encouraged to X-ray such patients and 
to refer them to CDC clinics without delay. ( Thompson and Myrdal 
1984a:10, and Divisional Council of the Cape 1982:188-189). 
3.3 Screening and Case-finding: 
3.3.1 Diagnostic Techniques 
i) Chest X-rays - the CDC posessr=s two mobile radiographic uni ts 
which produce miniature (lOOmm) X-rays for screening and to 
assess the progress of patients during treatment. 
ii) Bacteriological investigation Adult patients and suspects 
are asked to produce a sputum specimen which is sent to the 
State Heal th Laboratory in Cape Town for investigation. 
The sputum undergoes two examinations to establish whether 
tubercle bacilli are present, which would confirm that a person 
is an infectious TB case. In the first test (Direct Microscopy), 
a slide of a smear of the sputum is prepared and microscopically 
examined soon after the specimen is obtained, while in the 
second test (Sputum culture) a culture of the sputum is derived 
before examination. In addition, a Differential test may 
be performed on a sputum culture to confirm that the bacilli 
are M tuberculosis. 
iii) Tuberculin testing CDC uses the Heaf tuberculin test in 
the screening and diagnosis of children. Tuberculin PPD is 
injected into the epidermis by means of a spring-loaded 'gun' 
and a grading system is used to classify the result, according 
to the size of the ind,uration (Grade O for a negative result 
Grade IV for a strongly positive reaction) . (See also 
' footnote 5). 
Radiological investigation is used extensively by the CDC in their 
screening procedures and it is thus important to highlight the 
inadequacies of this technique. Lesions visible on a chest X-ray 
may not necessarily be attributable to TB, as sorrce other lung 
diseases have a similar 2-ppearance. ( Toman 1979: 28). In addi tit,n, 
it cannot be indisputably determined on the basis of c-in X-ray 
alone, that active tubercle bacilli are present in a lung lesion. 
Several studies have been conducted to assess the reliabilj ty of 
chest X-rays as a means of diagnosing TB. In these studies, a 
number of persons, trained in the reading of X-rays, were asked 
to read a set of X-rays ( in some cases this procedure was repeatEod 
at a later stage). It was found that 
"The level of disagreement between readers was about 
27-30% and a single reader was likely to disagree with 
himself in about 19-24% of cases". 
(Toman 1979:32). 
The practical implications of these discrepancies can be illustrated 
by the following findings of a study, as reported in Toman (1979:35 -
36). 
"If treatment had been restricted to patients in whom 
50% or more of the readers judged cavitation to be present, 
I 
/1 





only one-third of those with positive sputum would have 
received treatment. On the other hand, among those who 
were regarded by 50% or more readers ai:; probably tuber-
culous and in need of treatment, about four or five times 
as many bacteriologically negative persons as sputum-
positive patients would have received treatment ••• " 
Thus, there is a possibility of two types of diagnostic errors 
if diagnosis is based purely on an ·X-ray: False negative/non-
diagnosis and false positive/misdiagnosis. The cost-effectiveness 
implications of this are discussed in Section 4.2.1 of Chapter V. 
With regard to bacteriological tests, sputum culture examination 
yields two or three times as many cases as direct microscopy, which 
detects mainly those TB sufft~rt,rs who discharge a high concen-
tration of bacilli (i.e. the more infectio~s cases). Various studies 
have shown that the level of agreement in the results of sputum 
smear investigations performed by trained microscopists can be 
as high as 93%. 
The greater reliability of b£•cteriological tests in TB case-finding, 
has been stressed by both the World Health Organisation (WHO) and 
the International Union Against Tuberculc-,sis ( IUAT). ( Toman 1979: 47). 
The generally accepted and recommended caf;e-finding procedure is 
summarised in GJatthaar (1982a:15): 
"While bacteriology may suffice for the diagnosis of 
TB, radiological investigation must always be accompanied 
by bacteriological investigation to reduce misdiagnosis" 
3.3.2 Case-finding regimens in the CDC 




that the following tests be conducted on persons who are 
referred to or present themselves at a CDC clinic with symptoms 
indicative of TB. Children under the age of' 15 years are 
to have a Heaf test and radiological examination. Direct 
microscopy, sputum culture and X-rays are to be used in the 
diagnosis of adults, based on the assumption that persons 
who are 15 years of age and older, are capable of producing 
a sputum specimen. 
It is policy in the CDC clinics to begin treatment of a patient 
on the basis of a positive radiological and clinical examination, 
without awaiting bacteriological confirmation of the diagnosis. 
( Thompson and Myrdal 1984a: 4) . The implications of this are 
discussed in Section 4.2.1 of Chapter V. 
ii) Management of contacts - Clinic staff are advised to record 
the names of family members and other persons who have been 
in contact with recently notified TB cases (e.g. fellow 
employees) and to whom tubercle bacilli may have been transmitted. 
Contacts are then requested to present themselves at a CDC 
clinic for investigation, by means of home visiting or by 
phoning or writing to employers. The prescribed investigation 
procedure for contacts is the same as for suspects. 
It should be noted that the primary determinant of the risk 
of infection in contacts, is not the intimacy of contact 
with an infected patient, but the bacteriological status of -
the patient. This risk is highest where the pa\ient has a 
positive direct microscopy result (i.e. is discharging a high 





iii) Mass screening campaigns -
Mass X-ray screening campaigns on a regul~r basis (e.g. annually) 
are no longer conducted. Studies have shown that most TB 
cases develop within a relatively short period of time (a 
few months) and most cases would thus probably not be detected 
by this case-finding procedure. (Toman 1979:60-61) 
The CDC provides a pre-employment radiological screening service 
for employers. Jbwever, through educating businessmen about 
the symptoms and nature of TB, the CDC has attempted over 
the past few years to reduce the demand for screening of workers. 
( See Addendum II ) . In 1983, approximately 6 256 X-rays were 
performed during pre-employment screening, whereas in 1984, 
there was no record of mass radiological screening of workers. 
In 1984, only those workers with TB symptoms who were referred 
to clinics by employers, were X-rayed as TB 'suspects'. 
(Divisional Council of the Cape 1983:153 and 1984:157). 
In addition, the CDC conducted an experimental mass X-ray 
screening campaign in Leonsdale ( a coloured residential area 
adjoining Elsi es River) in 1983. ( The results of this survey 
are discussed in Section 1.5.1 of Chapter IV). 
Mass tuberculin testing of children at schools was discontinued 
in 1982. The current procedure is to identify scholars who 
are underweight ( loss of weight is a symptom of TB) by routine 
weighing procedures,- and to refer them to a clinic. 




assess their relative effectiveness. The results of their survey, 
conducted in the large South African cities, were as follows: 
"The mean case yield achieved when screening an entire 
work force, regardless of symptoms, was 0.3%. Examination 
of family contacts of known TB ,.cases gave a mean yield 
of 5% and selective screening of symptomatic cases gave 
a similar yield of 4%. Passive case-finding, i.e. screening 
self-presenting cases, gave a mean yield of 7%. These 
yields relate to cases wr.ich are radiologically positive 
for TB, but the yield of the priority cases - those which 
ar1'! actually infecti<>US - will only be about a quarter 
of this." 
(S.A. Medical Research Council 1A84:14) 
3.4 TB treatment regimens: 
Prior to the introduction of Rifampicin ( a powerful bactericidal 
drug i.e. a drug that kills/sterilizes TB baciLli), most curative 
regimens for TB consisted of lsoniazid (!NH)' Streptomycin, 
Pyrazinamicle (PZA) and possibly Para-aminosalicylic acid (PAS), 
Thioacetazone or Ethambutol (EMB), administered for n period of 
about 12 months ( in some cases, for 24 months). Currently, short-
course regimens lasting for 6 months or more, and containing 
Rifampicin, are the preferred means of treatment for TB. In gene1 ·al, 
short-course regimens consist of two phases; during the first or 
intensive phase, daily treatment comprised of four drugr; is 
administered for at least 2 months and during the second or con-
tinuation phase, one or more drugs are taken on a daily or inter-
mittent basis. 
Short-course treatment regimens are an important development as 
they relieve the work-load of clinic staff ( especially if treatment 
is fully supervised) and reduce the rate of patient default, as 
49 " 
it is easier to motivate a patient to i)ttenc~ for regular treatment 
for a shorter period of time. (Angel 1983:2). 
Numerous controlled trials have been undertaken to assess the 
effectiveness of various short-course regimens. The studies have 
shown that short-course therapy can achieve similar, and in some 
cases better, results in terms of cure rates c:nd relapse rates, 
than standard/conventional regimens. (Angel 1983, Aquinas 1982, 
Toman 1~79 and Tibbit 1982.) 
The CDC was the first South African local authority to introduce 
short-course TB treatment in 1973. This is r:ow the recommended 
treatment regimen in terms of the National TB control programme. 
The short-course regimen prescribed by the Medical Officer of Health 
for the CDC is as follows 
Daily, fully superised administration of 100 doses of Isoniaz~d 
(INH) and Pyrazinamide (PZA) and 60 doses of Rifampicin and Strepto-
mycin to adults, and 100 doses of INH and Ethambutol and 60 doses 
of PZA and Rifampicin, to children. 
3.5 Secondary Chemoprophylaxis: 
CDC policy is to treat infected children with positive Heaf tests, 
and in particular, child contacts of cases who have positive bacteria-
logical results, (Thomson and Mydral 1984a 5&7) in an attempt 
to · steralize tubercle bacilli and thus preventing the development 




4. Summary and formulation of problem to be evaluated in this study: 
As explained earlier, the overall aim of the current phase of the 
national TB policy is to reduce the pool of infectious TB cases 
and to provide protection against TB infection. 
Changes in the annual rate of TB infection can be used to illustrate 
the practidal implications of this programme. Kleeberg (1982:22) 
has stated that studies have established that the rate of TB 
infectic:n decreased by about 5-8% per year until 1977, and there-
after by 11-13% per year. Fig II. 7 indj c.:ates the projected trends 
based on two different estimates. 
Klee- berg (1982:22) examines some possible causes of the declining 
annuaJ rate of infection, based on the findings of international 
research: 
"Of thii::: annual decrease in the infection risk 2-3% is 
probably due to the intensive BCG campaign, 5% of 
the annual decrease is usually caused by improvements 
in living standards, which are particularly marked in 
towns. The remaining 4-6% of the annual decrease must 
surely be due to the effect of 20-30 years of case--
finding and chemotherapy". 
As these various preventive and curative procedures for TB are 
implemented more extensively and their effectiveness is increased, 







Figure II. 7 Annual rif::kf: of TB infection and their trends in South 
Africa. ( SAMRC Tuberculosis Research Institute survey 
data 1974 - 1980). 
Trend using 5-8% 
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The problem to be evaluated in this study can now be presented : 
Given i) the limited economic resources available for· the control 
of TB, and ii) the range of preventive procedures and curative 
regimens that can be employed to combat TB, the most cost-effective 
combination of preventive and curative procedures for the mass 





The desired outcome ( improved control of TB) can be more explicitly 
stated in terms of the above-mentioned TB measure, as, attempting 
to achieve the greatest possible decrease in the annual risk of 
TB infection through the implementation of a coherent TB programme, 
determined using cost-effectiveness criteria. 
The method by which the most cost-effective combination of preventive 
and curative procedures is determined, must be examined in more 
detail. 
It is necessary to differentiate between the roles of each procedure. 
This is achieved by demonstrating their respective applications 
to three defined groups of people who face different levels of 
risk with respect to TB a) The general population, b) Infected 
persons and c) Infectious persons. 
Figure II.8 presents a flow chart of the relationship between 
these groups and the relevant preventive or curative intervention 
procedures which can be implemented in each case. 
The preventive and curative procedures listed in Figure II.8 can 
be seen as 'catch-nets' , i.e. methods of preventing a person from 
proceeding to a higher risk level. Examples of this process are : 
An infected person may become infectious, i.e. progress to overt 
disease, if the tubercle bacilli infection is not combatted through 
natural, cellular defence mechanisms or sterilized through pro-
phylactic treatment; while an infectious person may face the risk 
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There are two major considerations when determining what combination 
of these procedures to implement: 
i) The effectiveness of each procedure, e.g. even if an entire 
population were given BCG vaccinations, some would proceed 
to the next level of risk as the protection afforded by BCG 
against tuberculous infection is not 100%. (Explained further : 
Section 1.1.2 of Chapter IV). 
ii) The cost of the procedure may be so great that it would not 
justify the application of the procedure to the entire population 
of each risk level. 
These two considerations will be combined in the form of a cost-
effectiveness ratio for each procedure. It can then be determined 
how comprehensive/extensive each 'catch-net' should be i.e. what 
priority each procedure should be given and what combination of 
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THE DIVISIONAL COUNCIL OF THE CAPE 
COMBINED HEALTH CONTROL SCHEME 
Including the Municipal uees of Bellville, 
Ourbanville. Fish Hoek, Goodwood, Milnerton, 
Perow, Pineland• and Simon's Town. 
44 WALE STREET 
CAPE TOWN 
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MEDICAL OFFICER OF HEAL TH 
Telephone: 24·2200 ext. 





TUBERCULOSIS CASE ?INDING AND EMPLOYERS 
Routine p~riodic screening ~f employee populations for tuber-
culosis by mass miniature x~Ray programmes has not been found 
_to be cost ·effective and is no longer recommended by the World 
Health-Or~anisation·or the Tuberculosis Research Institute in 
South Africa. This is in line with our own ~xperience in the 
Western Cape where the pickup rate of active TB in mass minia-
ture chest X-Ray screening has been.less than 2 per l 000. . . . 
The presen~ policy of the Divisional Council of the Cape is to 
take· chest X-Rays : 
(1) In those who report symptoms - chronic cough, weight 
loss or night sweat$ : 
(2) Of close contacts {i.e. those who share accommodation) 
(3) As part of the pre-employment process in Coloureds and 
. Blacks (being at higher risk than Whites of developing 
-TB) wh6 have not had a recent chest X-Ray. 
(4)" Those not'X-Rayea prior to taking up their present em-
ployment. 
-~mployers can help •in the fight against tuberculosis by : -
(a) I ; 
"(b) 
( c) 
Not discharging a worker with TB. Provided he takes his 
treatment regularly he will not infect others. 
Encouraging those who have a chronic cough to report 
for a Chest X-Ray examination 
Inviting a health ed;icator to. come and talk to your 
staff about tuberculosis~ 
X-Rays are usually arranged thro~gh Mrs. Slingsby of the X-Ray 
Section at Vasco (021) 591-5152. 
Any f~rther information may be obtained by te~ephoning the Health 
Department in Cape Town (021) 24-2200. 
--Yours. faithfully, 
-1~)-J~ 
MEDICAL OFFICER OF HEALTH. C· 
- c 
... 
Hierdie bd~f sal in die ander amprclik.0 taal aan u geaddressccr word indicn skrift,._'ik vers·oek binne sewJ-.'cfac vanaf bovc_rmelde daium. 






SAMPLE OF CDC TUBERCULOSIS PATIENTS 
Introductory Note: 
Despite the fact that Tuberculosis is recognised as the most serious 
heal th problem facing authorities in the Cape Peninsula at present, 
very few published statistics relating to the treatment of TB 
patients are available. For this reason, it was decided that a 
sample of the records of TB patients, treated at the CDC clinics 
during 1983, should be examined. 
The results of this sample indicated that the treatment regimen 
prescribed by CDC Health authorities is not strictly adhered to 
by the clinics. Clinic doctors are permitted a certain amount 
of flexibility in the application of the prescribed regimen. 
The data provided by this sample is used in the cost-effectiveness 
analysis presented in Chapter IV, as it best describes the treatment 
regimen actually implemented at CDC .clinics. Thus, the sample 
results are presented in some detail in this chapter. 
1. Methodology: 
1.1 Sample Population: 
The only composite record of TB patients treated within the CDC 






compiled chronologically and divided into the respective residential 
areas which comprise the Combined Health Control Scheme of the 
CDC. A random sample of 300 patients, which constituted 12% of 
all notified cases of pulmonary TB in 1983 (9.3% of white TB patients, 
12. 95% of coloured TB patients and 10. 9% of Black TB patients), 
was drawn from the register and their personal details (name, address, 
age and sex) were recorded. 
The treatment records of the selected patients were then examined 
at the 16 major CDC clinics, during August 1985. ( The patient 
records of satellite clinics are housed at the central clinic in 
each area). Before this data collection process could be completed, 
access to the Black townships of Nyanga and Crossroads was restricted 
and the clinics in these areas were temporarily closed. CDC doctors 
have not entered these areas since August 1985, and X-ray machines 
were only authorised to enter Nyanga again in July 1986. As a 
result it was difficult to obtain permission to complete the data 
collection at Nyanga Clinic until early in 1986. This has not 
significantly affected the data, as most follow-up work on cases 
notified in 1983 had been completed by the time of the initial 
data collection (i.e. August/September 1985). 





Table III.1 Breakdown of sample population according to clinic 






Ravensmead (including Uitsig) 
Elsies River (including Leonsdale) 





Lotus River/Grassy Park 




TOTAL SAMPLE POPULATION 






































1.2 Replacements to the Original Sample: 
40 records of patients included in the sample could not be found 
at the clinic located in the area in which they were resident, 
and were replaced by other patients' records selected at random 
at the respective clinics. 
The CDC Notification Register does not state the source of notifi-
cation and thus it is difficult to trace a patient who is treated 
at a clinic in an area other than that recorded in the register 
as his/her residential address. This often applies to patients 
who are treated at their workplace. In addition, patients who 
were notified while being treated at a hospital may not have reported 
for treatment at a clinic after being discharged, for a variety 
of reasons: i) Treatment may have been completed at the hospital 
and the patient failed to report to a clinic for follow-up surveill-
ance; ii) The patient may have defaulted from treatment on discharge 
from the hospital; or iii) The patient's residential address may 
have changed in the period between notification by a hospital and 
reporting at a clinic for further treatment. 
1.3 Information Recorded from Patient Folders 
The form used to record information from patient folders is re-
produced in Addendum III. 
In summary, the details recorded were 





b) Process by which the TB case was discovered; 
c) Results of diagnostic tests (to determine, in the case of 
adults, how many patients were bacteriologically confirmed 
as suffering from active TB); 
d) Length of 'bed stay' if a patient was hospitalised; 
e) Treatment regimen; 
f) Number and results of tests during treatment; 
g) Compliance rates; 
h) Default rates; 
i) Relapse rates; 
j) Details of follow-up surveillance. 
2. Results: 
Data on the demography of the sample is presented first, mainly 
to describe the composition of the sample population. Some of 
this data is used in the cost-effectiveness analysis calculations. 
Thereafter, information pertaining to the treatment of patients 
in the sample is presented. The data is not discussed in detail 
as it is evaluated, in terms of its relevance to the cost-effective-
ness analysis, in chapters IV and V. 
2.1 Demography of sample: 
Results of the total sample population and racial breakdowns will 
be presented in this section. 
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2.1.1 Racial distribution 
The racial distribution of the sample is shown in Table III.2. 
















2.1.2 Age Distribution 
a) Total Sample Population: Ages ranged from less than 1 year 
to 80 years, with a mean age of 24 years (S.D. = 18.2 years). 







Table 111.3 Age Distribution - Total sample population. 
Age No. of Patients % of Sample Population 
0 4 years 75 25.0 
• 
5 - 9 years 17 5.7 
10 - 14 years 7 2.3 
15 - 19 years 23 7.7 
20 - 29 years 68 22.7 
30 - 39 years 45 15.0 
40 - 49 years 38 12.7 
50 - 59 years 17 5.7 
60 - 69 years 5 1.6 
Over 70 years 5 1.6 
TOTAL 300 
This data is represented graphically in Figure 111.1. 
The most significant aspect of this distribution in relation to 
the cost-effectiveness analysis, is that 50.4% of the patients 
in the sample are between the ages of 20 and 50 years. These are 
the 'prime working years' and this has economic implications in 
terms of possible losses in productivity/economic performance as 
a result of contracting TB. 
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FIGURE 111.1 



























b) Racial breakdown: The mean age of Whites in the sample was 
43.3 years (S.D. = 18.9 years), of Coloureds 23 years (S.D. 
= 16.5 years) and of Blacks 24.8 years (S.D. = 20.3 years). 
The breakdown of ages according to race is shown in Table 111.4. 
Table 111.4 Age distribution acording to race 
AGE 
0 - -.4::YFS 
5 - 9 yrs 
10 - 14 yrs 
15 - 19 yrs 
20 - 29 yrs 
30 - 39 yrs 















No. of % No. of % 
Patients P,atients 
0 0 39 21.9 
0 0 11 6.2 
0 0 5 2.8 
0 0 18 10.1 
1 25 47 26.4 
1 25 25 14.0 
1 25 21 11.8 
0 0 9 5.1 
1 25 2 1.1 
0 0 1 0.6 
4 178 
BLACKS 














2.1.3 Sex Distribution 
The sex distribution as shown in Table III. 5 does not significantly 
influence the cost-effectiveness calculations but is included for 
general information purposes. 




SEX No. of - % No-.- -of-:'- .. -% No. of % No. of % 
Patients Patients Patients Patients 
Male 165 55 1 25 98 55.1 66 55.9 
Female 135 45 3 75 80 44.9 52 44.1 
TOTAL 300 4 178 118 
2.2 Employment and disability grant statistics: 
62% of the sample population (186 patients) were classified as 
being of employable age, assuming that this category consists of 
people between the ages of 18 and 65 years. 
The employment status of these patients is shown in Table III.6. 
66 




Not stated on 
patient file 
TOTAL (patients of 




employable age) 186 





11. 3% ( 21) of the patients in the sample who were of employable 
age received disability grants as a result of contracting TB. 
The mean length of time for which these grants were received was 
5.9 months (S.D. = 2.6 months). 
2.3 Details of Diagnostic Procedures: 
2.3.1 Method of discovery of patients 
Details of the means by which a patient came to be examined as 
a potential TB case were recorded on 79% (237) of the patient 
folders. 
There were three main methods by which TB cases were discovered 







Table 111.7 Method of discovery of patients in sample. 
Method of Discovery 
Self presentati~n 
Contact investigation 








% of patients whose 





Patients were included in the category 'self presentation' if it 
was noted on their folder that they had either been referred to 
a clinic by a hospital or private doctor to whom they had presented 
themselves for investigation of TB.symptoms, or if they had approached 
the clinic directly. 
Mass screening campaigns were undertaken in two residential areas 
in 1983: i) An experimental screening campaign of the community 
of Leonsdale was conducted and ii) Employees on farms in the Philippi 
area were screened as part of the CDC's service to employers in 
the Cape Peninsula. (These campaigns are discussed in greater 
detail in section 1. 5 of Chapter IV. ) 
It is significant that the majority of TB cases were discovered 
through the investigation of suspects, i.e. self-presenting 
symptomatic cases, and contacts. Mass screening is a very costly 
/; and relatively ineffective TB case-finding procedure. This is 
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discussed further in section 1,5 of Chapter IV. 
2.3.2 Results of Diagnostic Tests 
Note: In this section, results for clinics in the coloured areas 
( which include the 4 white patients and a few Black patients) and 
results for Nyanga and Crossroads (the two clinics which treat 
only Black patients) are presented after the results for the total 
sample population, to highlight certain important differences. 
All patients in the sample underwent at least one initial radiological 
examination. In the majority ·of cases, evidence of either cavitation 
in the lung/s or pleural effusion on the X-ray, was noted in the 
patient's folder. 
As the age of a patient determines which additional tests are per-
formed to confirm diagnosis of TB, the following results are 
presented according to age group. 
I) ADULTS (15 years and older). 





Table 111.8 Results of Bacteriological tests Total sample 
Population. 







































Table III.9 Results of Bacteriological tests - Coloured Clinics. 







RESULTS OF SPUTUM CULTURE 
































Table 111.10 Results of Bacteriological tests - Black clinics. 








































The information presented in Tables 111.8, 111.9 and 111.10 is 
summarised in Table 111.11 to highlight some important differences 
in the results between clinics which are not easily detectable 
from the above format. The results of bacteriological testing 
b£ adults in the sample (in terms of number and proportion of patients) 
are presented according to three general categories: 
i) Patients in whom TB was bacteriologically confirmed, i.e. 
those patients who had a positive direct microscopy and/or 
a positive sputum culture result, 
ii) Patients whose sputum was sent to the laboratory for bacteria-
logical examination and the sputum was found to be contaminated, 
or at least one of the test results was negative and the other 
test result was not positive, and 
iii) there was no record of either a sputum culture or a direct 
microscopy test being conducted. 
Table 111.11 Summary of Bacteriological test results. 
TOTAL SAMPLE 
POPULATION 
RESULT OF BACTERIO No. of % 
-LOGICAL TESTS Patients 
i) Bacteriologi-
cally 
confirmed 109 54.2 
ii) Sputum con-
taminated or 
negative 40 19.9 
iii) No record 


























*Two ~of these patients had results for tuberculin tests despite 
the fact that they were over the age of 15 years. 
It is significant that only 54. 2% of the adult patients in the 
sample were bacteriologically confirmed i.e. active tubercle bacilli 
were observed in their sputum specimen. In the case of patients 
with a negative result, there was no evidence of the presence 
of active tubercle bacilli, despite a radiological examination 
indicating the possibility of TB, and it could thus be argued 
i 




It is also 
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important to note that a relatively large proportion of patients, 
particularly at the Black clinics, had no results for bacteriological 
tests. This was largely attributable to clinic staff shortages. 
Section 3. 3 .1 of Chapter II indicated that bacteriological tests 
are essential in the diagnosis of TB patients. The implications 
of these findings are examined in section 4.2.1 of Chapter V. 
In addition to the sputum culture and direct microscopy tests, 
28 (13.9%) adults had results for differential tests. 
II) CHILDREN (Under 15 years). 
The results of the tuberculin tests are summarised in Table 
III.12. 
Table 111.12 Summary of Tuberculin test results 
RESULT OF TUBER-
CULIN TESTS 
Grades 0, 1 & 2 
Grades 3 & 4 











































*Three of these patients had results for bacteriological examinations 
although they were under 15 years of age. 
These were as follows: 
Positive sputum c~lture; no direct microscopy result 1 
Negative sputum culture; no direct microscopy result 1 
Negative sputum culture; negative direct microscopy 1 
A significant proportion of children were diagnosed as TB cases 
on the basis of an X-ray, i.e. either no tuberculin test was per-
formed or the tuberculin test indicated that tubercle bacilli were 
not viable, i.e. active ( Grades o·, 1 & 2). (Glatthaar 1982a:10). 
Once again, it may be argued that these patients were treated 
'unnecessarily' . 
2.4 Details of Treatment: 
2.4.1 Hospitalisation 
9.3% (28) of the patients in the sample were hospitalised. The 
mean length of hospitalisation of these patients was 9.6 weeks 
(S.D. = 6.1 weeks). 
As hospitalisation is relatively more expensive than clinic treatment, 
it is important to note that very few CDC TB patients were hospital-
ised in 1983. This is examined further in section 4. 3 of Chapter 
v. 




Table III.13 Hospitalisation of TB patients according to length 
of stay. 
Length of Hospitalisation 
< 6 weeks 
6 - 9 weeks 
10 - 13 weeks 
> 13 weeks 
TOTAL 














The distribution of patients according to whether they have completed 
the prescribed treatment regimen at a CDC clinic or defaulted 
from treatment, the CDC definition of a defaulter being a patient 
who absconds from treatment for a period of two months, is shown 
in Table III.14. 
Table 111.14 Rates of default and treatment completion. 
REASON FOR TERMINATION OF No. of 
TREATMENT Patients % 
Treatment regimen completed 230 76.7 
Defaulted I 63 21.0 
' 






*The reasons why these 7 patients were not included in one of the 
other categories are: 
2 Coloured patients were sent to hospital with serious health 
problems unrelated to TB, and the clinic had no further involvement 
in their TB treatment. 
5 Black patients returned to the Transkei with the knowledge of 
clinic staff and were referred to various health facilities there. 
Patients who defaulted did not complete the regimen prescribed 
for them. This affects both the costs and the effectiveness of 
TB treatment. Thus, it is important to record the details of 
treatment for both those patients who completed treatment and 
those who did not. These results will form the basis of the cost-
effectiveness analysis of the curative regimen as presented in 
section 2 of Chapter IV. For the purposes of this analysis, the 
results for patients who defaulted and patients who did not complete 
treatment for reasons other than default are combined. 
2.4.3 Number of treatment doses given 
It was found that a wide range of drug regimens were administered 
to patients as clinic doctors were permitted a certain degree of 
flexibility in the application of the drug regimen specified by 
CDC Health authorities. Different combinations of four of the 
five possible drugs were used and in some cases, all five drugs 
were administered at some stage during treatment. The number of 
doses administered varied substantially and there was no clearly 
dominant regimen. The only method of establishing an 'average' 
regimen was to calculate the mean number of doses of each of the 
five drugs. 
In this section, data will be presented according to whether the 
patient was an adult or a child. 
( 
I) ADULTS (15 years and older). 
The means and standard deviations of the number of doses, 
of each of the five drugs used by the CDC, that were actually 
administered to patients in the sample, are presented in 
Table III.15. 
































drug for the total adult sample population, is shown in Figures 
B.1 - B.5 in Appendix B. 
II) CHILDREN (under 15 years of age). 
The means and standard deviations of the number of doses, 
of each of the four . drugs used by the CDC in the treatment·oi' 
children, that were actually administered to patients in the 
sample, are shown in Table III,16. 











Rifampicin 61.2 32.8 27.2 20.9 
PZA 70.2 37.8 27.8 23.8 
Ethambutol 64.2 43.1 31.3 26.9 
Only two patients under the age of 15 years were treated with 
Strwtomycin. They received 50 and 60 doses respectively. 
The mean number of Streptomycin doses is thus 1.5 (S.D. = 9.0). 
The distribution of the number of treatment doses of each 
drug for the total child sample population is shown in Figures 
B.6 - B.9 in Appendix B. 
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2.4.4 Changes to the drug regimen 
23 ( 7. 7%) of the patients in the sample requir:ed changes to the 
drug. regimen originally prescribed for them, due to an adverse 
reaction to ,one or more of the dr,;gs. 9 experienced side-effects 
resulting from Streptomycin, 10 from PZA and 4 from both Streptomycin 
and PZA. In addition, 2 patients who were originally prescribed 
a regimen which included Streptomycin, were placed on a different 
regimen to facilitate the supervision of their treatment at their 
workplace, where there was no qualified person available to administer 
the Streptomycin injection daily. 
The side-effects to these drugs were as follows: 
Skin rashes 7 
Gastro-intestinal I nausea 8 
Dizziness 1 
Joint pains 2 
Hearing problems 2 
Pain at injection sites 2 
Skin rash and joint pains 1 
23 
The suffering or discomfort resulting from these adverse reactions 
are an indirect cost of the drug regimen. It is thus important 
to note the nature of these side-effects to permit an assessment 
of the magnitude of this cost. This is discussed further in section 





\ ' .y 
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2.4.5 Compliance with treatment 
A compliance rate was calculated for each patient in the sample. 
The compliance rate is expressed in terms of the number of days 
on which drugs were administered, as a percentage of the number 
of possible treatment days. In the case of patients who did not 
complete treatment, the number of possible treatment days was 
calculated as the number of week-days between the start of treatment 
and the date on which they were classified as defaulters. 
The mean of the compliance rates was 89.4% (S.D. = 11.3%) for patients 
who completed treatment and 70.4% (S.D. = 26.4%) for patients who 
did not complete treatment. 




Table Ill .17 Distribution of Compliance Rates. 
PATIENTS WHO ·PATIENTS WHO DID NOT 
COMPLETED TREATMENT COMPLETE TREATMENT 
COMPLIANCE No. of No. of 
RATE Patients % Patients % 
1 - 10".il, 3 4.3 
11 20% 
21 - 30% 3 4.3 
31 40% 6 8.6 
41 50% 2 2.9 
51 - 60"'6 6 2.6 4 5.7 
61 - 70% 10 4.3 14 20.0 
71 - 80% 31 13.5 7 10.0 
81 - 90% 45 19.6 5 7.1 
91 -100";6 138 60.0 26 37.1 
TOTAL 230 70 
These findings indicate that in general, patients who did not complete 
the prescribed regimen attended clinics for daily treatment less 
frequently than patients who completed the regimen. The impact 
of these rates on the effectiveness of treatment received by the 
two groups of patients is evaluated in section 2. 2 of Chapter IV. 
2.4.6 Tests conducted during treatment 
The progress of patients is evaluated by means of the tests performed 
~1 
after 60 drug doses have been administered and again after 100 
doses. 
i) Number of tests per patient: 
ADULTS The means and Standard deviations of the number of 
tests per patient during the course of treatment are given 
in Table .III.18. 





















It is important to note that the prescribed procedure of performing 
two radiological and bacteriological tests (i.e. after 60 drug 
doses have been administered and again after 100 doses) on each 
patient who completes treatment, is not strictly applied by clinic 







- patients who are considered to be cured on the basis of an X-ray 
may in fact still have active tubercle bacilli which can only be 
determined by a bacteriological test, and may thus subsequently 
relapse. 
CHILDREN : The mean number of x-rays per patient during treatment, 
was 2.0 (S.D. = 1.0) for those who completed treatment and O. 76 
(S.D. = 1.0) for those who did not complete treatment. 
ii) Results of tests after 60 doses: 
Bacteriological and radiological tests are conducted after 
60 doses of the prescribed treatment have been administered, 
to assess the patient's response to treatment. 
It was very difficult to classify the observations from X-ray 
as either satisfactory or unsatisfactory, without any medical 
expertise. Thus, only , the results of the bacteriological 
tests (performed on adults who completed treatment) are presented 
in Table III .19. 
Table III .19 Results of bacteriological tests performed during 
treatment - Adults. 
RESULTS OF RESULTS OF SPUTUM CULTURE 
DIRECT No Result Positive Negative Contaminated TQTAL 
MICROSCOPY 
No result 62 0 34 0 96 
Positive 1 1 2 0 4 
Negative 13 1 40 1 55 
Con~aminated 0 1 0 0 1 
-r, 
'T'K'T'AT. 7F. ~ 7f, 1 156 
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In summary, 39. 7% ( 62) of the adult patients in the sample 
who completed · the prescribed treatment regimen did not have 
any record of a bacteriological test being performed after 
receiving 60 doses of treatment. Only 6.4% (6) of those 
patients who had results for bacteriological tests had either 
a positive sputum culture or direct microscopy results after 
60 doses of treatment. 
This indicates that the majority of patients who had results 
for bacteriological tests, had no active tubercle bacilli 
in their sputum after 60 drug doses had been administered, 
and were considered to be effectively cured. 
2.5 Follow-up Tests after Treatment: 
Patients are asked to return to the clinic 3 months after th-e com-
pletion of treatment, and again 6 months later, for radiological 
and bacteriological examinations. These tests are performed to 
ensure that no active tubercle bacilli remain. 
I) ADULTS: 
Of the 156 patients who completed their treatment regimen, 
44 (28.2%) defaulted from follow-up surveillance. The mean 





Table 111.20 Mean number of follow-up tests - Adults. 
TEST MEAN S.D 
X-ray 1.5 1.3 
Sputum Culture 0.4 0.8 
Direct Microscopy 0.5 0.8 
II) CHILDREN: 
Of the 74 patients who completed their prescribed TB treatment, 
19 (25.7%) defaulted from follow-up surveillance. The mean 
number of X-ray tests per patient was 1.2 (S.D. = 1.0). 
2.6 Relapse: 
10 (4.4%) of the 230 patients who completed treatment, relapsed· 
after a mean period of 8.2 months (S.D. = 5.8 Mths.). 
Of the 70 patients who did not complete the prescribed regimen 
of treatment, 15 ( 21.4%) presented themselves at a CDC clinic with 
active TB ( 'relapsed' ) , after a mean period of 6. 3 months ( S. D. 
= 3.3 months). 
These findings are used i-n the determination of the effectiveness 
of the treatment regimen administered . at CDC clinics ( section 2. 2 






3. Concluding remarks: 
The major finding of this sample of CDC TB patients is that the 
treatment regimen prescribed by the CDC health authorities, as 
described in section 3 of Chapter II, is not strictly adhered to 
by CDC clinic staff. 
In Chapter IV, the curative regimen cost calculations are based 
on the mean number of drug doses administered, the mean number 
of tests performed, etc. , as presented in this chapter. Relapse 
and compliance rates, and the proportion of positive bacteriological 
-
test results after the administration of 60 drug doses, are used 
in effectiveness calculations. (See section 2 of Chapter IV). 
The sample data findings are evaluated in more detail in Chapter 
IV. 
ADDENDUM III 86 
DATA FROM PATIENT RECORDS / DATE : 
CLINIC 
1. PERSONAL DETAILS: 
NAME : ......................................................... . 
ADDRESS : ...................................................... . 
.. . . . . . . . . . . . .. . .. . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
AGE: .. . .. . .. . SEX: Male CJ Female[] 
RACE: White[] Coloured(] Black(] 
EMPLOYED : Yes O No O Not Stated O N/ A O 
DISABILITY GRANT: Yes[] No Cl Period : ..................... . 
2. DETAILS OF DIAGNOSIS 
METHOD OF DISCOVERY DETAILS 
Contact Investigation[] 
Self-presentation [] 
Screening campaign O 
Not Stated [] 
DIAGNOSTIC TESTS OUTCOME 
X-Ray CI Observations 
Sputum Culture [] 
Direct Microscopy O 
Tuberculin Test [] 
Sensitivity Test [] 
Differential Test tJ 
Positive[] Negative[] Contaminated(] 
Positive[] Negative[] Contaminated[] 
Grade : ..................... . 
Positive CJ Negative(] 
Positive[] Negative[] 
DATE OF NOTIFICATION 
3. DETAILS OF TREATMENT: 
HOSPITALISED: Yes[] No[] Period of Hospitalisation : 
























ADVERSE REACTIONS: Drug ....... . Nature of reaction ......... . 
DETAILS OF ANY DEFAULT DURING TREATMENT : ...................... . 
COMPLIANCE: 
TESTS DURING TREATMENT OUTCOME DATE 
X-Ray 0 Satisfactory 0 Unsatisfactory o ...... '.. 
D Sputum Culture Positive 0 Negative D ....... 
Direct Microscopy 0 Positive D Negative 0 ....... 
Sensitivity Test tJ Positive 0 Negative 0 ....... 
DATE OF CONCLUSION OF TREATMENT: .............................. . 
REASON FOR TERMINATING TREATMENT: Regimen Completed [] 
Defaulted/Absconded[] 
4. POST-TREATMENT INFORMATION 
FOLLOW-UP TESTS: 
Other [] 
X-Ray ........................................................... . 
Sputum Culture ................................................. . 
Direct Microscopy 
RELAPSE: Yes[] No[] Number of months after completion of 
treatment 
5. DETAILS OF CONTACTS: 
No. of contacts recorded 
No. of contacts investigated : ................................. . 





CALCULATION OF COST-EFFECTIVENESS RATIOS OF PREVENTIVE AND CURATIVE 
PROCEDURES FOR TB IN THE CDC 
Introduction: 
This chapter will be devoted to calculating cost-effectiveness 
ratios for each of the preventive and curative procedures for TB 
used by the CDC. These are as follows: 
BCG vaccinations, secondary chemoprophylaxis, mass screening 
campaigns, investigation of contacts and suspects and the 'clinic' 
t . . 1 cura 1ve regimen. 
The calculations for each procedure will be presented in the following 
manner: i) The total cost of implementing the procedure at CDC 
clinics in 1983 will be calculated; ii) The effectiveness of the 
procedure in 1983 will be calculated. The unit of outcome in which 
the effectiveness of preventive procedures are expressed is •notifi-
cations' prevented while diagnostic and curative procedures are 
expressed in terms of 'notifications' . ( The relationship between 
these uni ts of outcome will be clarified in Chapter V); iii) Cost-
effectiveness ratios will then be calculated i.e. the costs of 
each procedure will be expressed in terms of the selected unit 
of outcome. 
1. As indicated in Chapter III, the curative regimen actually imple-
mented at CDC clinics is different to the regimen originally 
prescribed by the CDC authorities. These regimens will be referred 




The cost and effectiveness calculations are quite extensive for 
certain procedures. They are a necessasry basis for understanding 
the evaluation and analysis of the final cost-effectiveness ratios 
which is presented in Chapter V. Most of the cost calculations 
are contained in appendices. In circumstances. where such calcula-
tions are not extensive and would not impede the flow of the chapter, 
they are included in the main text. 
As outlined in section 4 of Chapter II, each preventive and curative 
procedure has a distinctive role in the overall TB control programme. 
The individual ratios provide a basis for policy-makers to assess 
the effectiveness of each procedure in counteracting the movement 
of people to higher TB risk levels, in relation to costs. 
The ratios will be evaluated and compared in Chapter V, to determine. 
what combination of preventive and curative procedures should be 
implemented. 
Note on Data sources: 
. The information and data used in the analysis presented in this 
chapter, was derived from three major sources: i) The results 
of the random sample of 300 patients treated at CDC clinics, ii) 
The annual reports of the CDC Medical Officer of Health (MOH), 
and iii) Unpublished records of the CDC and related institutions. 
The sample data, as summarised in Chapter III, will be used exten-
sively in the calculation of the cost-effectiveness ratios of 
curative procedures implemented by the CDC as it best describes 





The results of the sample also provide certain indicators of effect-
iveness. Reference will be made to data from other sources, such 
as journal articles and unpublished studies to substantiate the 
sample findings and to provide parameters for performing sensi ti vi ty 
analysis where applicable {see Appendix A). 
As explained in Appendix A, the recommended theoretical procedure for 
assessing costs is to calculate 'shadow prices' for each input based 
on the value of the input's marginal product. Since the market price 
of an input will only equal its marginal product under conditions of 
perfect competition, which do not apply to the market for health servi-
-
ces in S.A. which are largely government supplied, it is very difficult 
to estimate the marginal product of inputs in practice. Thus cpst esti-
mates are largely based on the market prices of inputs,with adjustments 
wherever necessary to ensure that they adequately reflect 'social opportu-
nity costs,' i.e.the cost to society in terms of resources which are no 
longer available for use in other projects. 
These estimates were derived from the departmental records of the 
CDC and other r:,elated institutions. All costs relating to drugs 
were obtained from Mr Ochse, the senior pharmacist at State Health, 
Bellville. Expenditure statements were examined to determine 
whether they reflected all relevant factors adequately, and adjust-
men ts were made where necessary in consul tat ion with the respective 
departmental accountants. For example, although drugs for the 
treatment of TB are supplied free of charge by State Heal th and 
are thus not accounted for by the CDC, they represent a cost to 
society and must . be taken into account. The cost of these drugs 
to the State was determined and a handling charge was added to 
account for the cost of _ dispensing and supplying the drugs to 
the clinics. 
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Capital outlays have been accounted for by depreciation charges 
on vehicles and equipment, and redemption on loans for buildings. 
The only factor for which inadequate provision was made, was in 
relation to the allocation of a portion of the expenses for office 
space to the Heal th department in the CDC head office. This does 
not significantly affectthe final cost-effectiveness ratios. 
It should be noted that the CDC and Brooklyn Chest Hospital, where 
TB patients are hospitalised, present their costs in terms of the 
1983/84 financial year. All other information concerning their 
activities is presented for 1983. Other costs e.g. cost of drugs, 
disability grants, etc. have been assessed at the midpoint of this 
financial period, to ensure consistency in the cost estimates. 
Costs may consequently have been somewhat overstated, but this 
will not be significant at the unit cost level. 
It must be stressed that all cost estimates supplied by TB author-
ities were scrutinised to determine whether they adequately reflected 
'social opportunity costs'~ 
Information with regard to the total number of TB patients and 
the number of diagnostic and curative procedures for TB performed 
during 1983, was obtained from the MOH's annual report and unpublish-
ed records of the CDC Health department. 
The major limitation of the information used in this analysis is 
that it applies specifically to 1983. This was neces_sary due to 
data availability and more importantly, as a suitable time period 
has to elapse after the completion of treatment of patients, to 
permit an accurate assessment of the relapse rate. I Current, trends 
/, 
and future prospects will be briefly examined in Chapte~ V. y 
\ 
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1. Cost-effectiveness analysis of preventive procedures for TB in the CDC: 
1.1 BCG vaccinations 
A special immunisation team visits schools falling within the 
jurisdiction of the CDC and administers vaccinations for TB (i.e. 
BCG ·vaccinations) as well as immunising children against Polio-
mielitis, Diphtheria and German measles. The team is also responsible 
for conducting tuberculin tests on certain children. 
In addition to the work of the schools immunisation team, i3CG 
vaccinations are administered at the clinics, and at hospitals 
shortly after the birth of a child. 
In 1983, 32037 BCG vaccinations were administered by the CDC. 
The breakdown of this figure according to race and whether the 
BCG vaccination was administered to a child for the first time 
or was a revaccination in accordance with CDC vaccination policies 
( see section 3 .1, Chapter II) is given in Table IV .1. 
Table IV.1 BCG vaccinations: 1983 
Race 1st BCG Repeat BCG Total BCG 
White 3287 3191 6478 
Coloured 4548 15437 19985 
Black 4093 1481 5574 
TOTAL 11928 20109 32037 
I (Divisional Council of 
I 







ThE, tool used to administer BCG vaccinations had a unit cost , of 
R0.56. Each tool can be used to administer approximately 100 
vaccinations. One 10 dose •ampule of BCG vaccine cost RO. 78. The 
cost of clinic services, and the cost of staff and transport for 
the schools immunisation team has been estimated, to account for 
the cost of administering these vaccinations in 1983 (see Appendix 
c) • 
The total cost of administering 32037 BCG vaccinations in 1983 






R 2 498.89 
R124 557.00 
Rl27 235.30 
An indirect cost of c:dministering BCG vaccinations is the adverse 
reaction which some children may suffer shortly after being immunised. 
No information on adverse rer:ctions was available from the CDC. 
However, the MOH of Cape Town City Council (CCC) records the incidence 
of adverse reactions in his annual report. It was assumed that 
there was no significant difference between the adverse reactions 
to BCG vaccinations administered within the jurisdiction of the 
CCC to thoseadministered by the CDC. 
In a four year period (1980-1983), 206471 BCG vaccinations were 
administerE-,d by the CCC. Only two children suffered from adverse 
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reactions during this period. One child suffered local itchiness 
and swelUng of the eyes and the other suffered a rash. (City 
of Ca~e Town 1980 : 147 & 150, 1981 : 161 & 165, 1982 : 145 & 149, 
1983 : 150 & 155). 
Thus, the incidence of adverse reactions to BCG vaccinations is 
approximately 0.01 per 1 000 vaccinations. It was assumed that 
the incidence was sufficiently small to simply state that adverse 
reactions are a factor which should be considered without attempting 
to quantify this indirect cost in a form whereby it can be included 
in the cost-effectiveness ratio. 
1.1.2 Effectiveness of BCG vaccinations 
There has been a very lively and controversial debate on the 
effectiveness of BCG vaccinations for the past few decades. Early 
studies revealed that BCG vaccinations provided effective protection 
against tuberculosis infection in up to 80% of the vaccinated 
population, the protection being afforded for approximately 15 
2 
years. These findings were challenged by later studies which 
indicated that BCG vaccinations could in certain situations provide 
no protection at all. Table IV. 2 summarises the results of some 
of these studies. 
2. The protective efficacy of BCG vaccinations is 
measure to indicate the proportion of TB disease 
is attributable to- the BCG immunisation. The 
to calculate this index is ( TB attack rate in 
attack rate in vaccinees)/TB attack rate in controls 
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Protective efficacy of BCG vaccination in eight 
controlled trials 
Year of Observation Efficacy 
intake period(years) % 
1934 10 80 
1943 18 75 
1947 20 0 
1950 6 31 
1950 14 14 
1951 15 78 
1955 12 31 
1970 7U 0 
(Kent 1982:9, Table 1) 
As yet, there is no generally accepted explanation for the conflicting 
results. Some researchers have argued that the nutritional status 
of the participants in the trials differed, that the BCG vaccines 
used had differ~nt degrees of potency, or that there were differences 
the prevalence of tubercle bacilli and atypical mycobacteria in 
the various communities studied. (Kleeberg 1984:6). There is 
no apparent common basis for distinguishing between communities 
where vaccinating the population with BCG has proved highly effective 
anc those communities where it is less effective. 
In 1983, Clemens, et al investigated the possibility that differences 
in methodology was the primary cause of the· conflicting results. 
in 
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Their analysis of the statistical basis and methodology of eight 
controlled BCG vaccination trials, concluded that 
" ••• ( 1) al though biased allocation of the vaccine appeared 
an unlikely explanation for the disparate results, adequate 
demonstration of unbiased detection of tuberculosis was 
available only for the three trials reporting 75% or 
greater protective efficacy; and (2) in most trials 
reporting low efficacy, the results had wide confidence 
intervals that could not exclude high efficacy but the 
trials reporting high efficacy all had narrow confidence 
intervals that excluded low efficacy. Because the trials 
with the best methodological quality and greatest statis-
tical precision reported high efficacy, the evidence 
suggests that BCG can confer a high degree of protection 
against tuberculosis and that bias or inadequate statis-
tical power may have contributed to the conflicting data." 
(Clemens, et al 1983:2362) 
Various aspects of the BCG vaccination policy in S.A. have been 
studied, but no controlled trial, comparable to the overseas studies, 
to determine the effectiveness of BCG protection in S. A. has been 
conducted. 
Coetzee and Fourie reported at the S. A. Medical Research Council's 
TBRI Symposium in 1985 that 
"The TBRI conducted a contact evaluation study to determine 
whether, in children exposed to confirmed adult TB cases, 
an association exists between the presence of BCG scars 
and a lowered risk of developing tuberculosis disease. 
A protective effect of BCG vaccination could be shown 
in the 0-4 year age group, where protection varied between 
47% and 81%. In. older children, the protective effect 
is uncertain because of small numbers investigated." 
(Townshend and Aalbers 1985:9) 
As the subjects of this study were child contacts, a group at high 
risk of being infected with ,tubercle. bacilli, the resu1 ts do not 
j 





the South African population in general. It shoulc also be noted 
that the absence of a BCG scar does not necessarily mean that the 
child has not received a BCG vaccination. 
Another factor which influences the effectiveness ·of the BCG 
vaccination programme is the extent of the coverage of the population. 
The TB infection surveillance programme conducted by the TBRI has 
shown that 42% of coloured children and 40% of Black children surveyed 
in the CDC area had BCG scars. (SAMRC 1983:22). 
The British Thoracic and Tuberculosis Association (1975) devised 
a method for estimating the number of TB notifications prevented 
by BCG vaccinations, i.e. the effectiveness of BCG vaccinations. 
This technique will be used to estimate the effectiveness of BCG 
vaccinations administered in the CDC in 1983, based on the above 
information ( the major assumption being that any results for S. A. 
as a whole are. similar to those for the CDC area). Al though the 
BCG vaccinations administered in 1983 will prevent a certain number 
of annual notifications for several years thereafter, i.e. the 
effectiveness of a BCG vaccination is not limited to one year, 
for the purposes of this study, only the notifications prevented 
in 1983 will be calculated. 
As thjs measure is based on the TB notification rate, three different 
cost-effectiveness ratios will be calculated according to race. 
The calculation of the notification rates for the vaccinated popu-
lation is as follows : 
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i) The British Thoracic and Tuberculosis Association ( 1975) 
study, found that 23.94% of TB notifications occurrf,d in the 
vaccinated population.
3 
Using this estimate, the notifications 
in the CDC vaccinated population can be calculated: 
Total number Number of notifications in 
of notifications* the vaccinated population 
Whites 43 10.3 
Coloureds 1 374 328.9 
Blacks 1 083 259.3 
(* see Table 11.1) 
ii) The TBRl has shown that BCG coverage of the Coloured and Black 
population is approximately 40%, based on the presence of 
BCG scars, i.e. a lower estimate than if '. based on actual 
vaccination status. BCG coverage is significantly higher 
in the white population as the majority of white children 
are born in hospitals where they will receive their first 
BCG vaccination. A 90% BCG coverage is assumed for whites. 
The vaccinated population in the CDC in 1983 and the noti-
fication rates for the vaccinated population can be calculFted 
as follows: 
3. The Coetzee and Fourie study indicated that the protective 
efficacy of BCG vaccinations in S. A. may be lov,er than in l3!'i tain. 
Thus, a higher proportion of TB notifications may occur in the 
South African vaccinated population. This estimate is thus 





Whites 195 579 
Coloureds 140 764 
Blacks 31 900 





(*White population data in Table II .1 x 90% and Coloured and Black 
population data x 40%). 
As there is some dispute as to the protective efficacy of BCG 
vaccinations, a midpoint estimate of 65%, based on the findings 
of the study conducted by Coetzee and Fourie, will be used in the 
calculation of notifications prevented. 
Whites: Given an assumed 65% protective efficacy, the 5. 27 notifi-
cations per 100 000 vaccinations would refer to the 35% of the 
vaccin&ted population not afforded effective protection by the 
BCG vaccination. Thus, 9.79 (i.e. (5.27 + 35%) x 65%) TB notifi-
cations pE·r 100 000, i.e. 0.63 per 6 478 vaccinations, would have 
been prevented in the 65% of the populat,ion effectively protected 
by ECG vaccination. 
Coloureds: Similarly, 433. 92 TB notifications per 100 000 and 
86.72 per 19 985 vaccinations would have been prevented if 65% 
of the vaccinated coloured population was effectively protected. 
Blacks: 1 509. 58 TB notifications per 100 000 and 84 .14 per 
5 574 vaccinat~ons would have been prevented through ECG vaccinations 







1.1.3 Cost-effectiveness ratios for BCG vaccinations 
The total cost of administering BCG vaccinations is divided on 
a proportional b,isi s according to the number of vaccinations admin-
istered to each race group. 
i) Cost of BCG vaccinations per TB notification prevented in 
whites -
R 25 727 .45 ·+ 1 = R 25 727 .45 per TB notification prevented 
by BCG vaccinations. 
ii) Cost of BCG vaccinations per TB notification prevented in 
coloureds -
R 79 370.65 ~ 87 R 912.31 per TB notification prevented 
by BCG vaccinations 
iii) Cost of BCG vaccinations per TB notification prevented in 
blacks -
R 22 137.20 84 = R 263.54 per TB notification prevented 
by BCG vaccinations. 
1.2 Secondary Chemoprophylaxis 
The total numbE·r of child· contacts of sputum posi ti Vt' cases to 
be prescribed a course of prophylactic treatment during 1983, was 
4 015. ( See appendix D) . Al though the usual point of di vision 
between adults and children is 15 years of age, a small number 
of children who were 15 years or older were prescribed chemoprophyl-
actic treatment and will be referred to as adults here. 
Of these contacts, 1 806 ( 45%) completed the prescribed course 
of 60 doses of !NH, 152 (3.8%) were transferred to a clinic or 
hospital outside of the CDC jurisdiction after prophylactic treatment 
4 
was prescribed and 2 057 (51.2%) absconded before treatment could 
be completed. The breakdown according to age is presented in 
Appendix D. 
1.2.1 Costs 
i) Cost of drugs -
Patients of 15 years of age or older received a dosage of 
400 mg of !NH. Children under the age of 15, received a 
variable dosage determined according to their weight at the 
time that treatment was started. A sample of dosages prescribed 
for children receiving chemoprophylactic treatment was not 
conducted. It was assumed that the distribution of ages, 
weights and thus dosages of !NH for children receiving chemo-
prophylaxis would be similar to that for children receiving 
a full TB regimen. It was noted in section 1 of Chapter II 
that most children develop active TB as a result of natural 
infection through contact with an infectious TB patient. 
4. In total, 2 120 chjldren receiving treatment absconded, of which 
63 were recovered. Tracing procedures for patients who abscond 
are conducted for two months .=:fter they abscond, and thus it 
was assumed that the majority of those who were recovered would 
be recorded as such within the same year ( 1983) in which they 
were originally recorded as new. patients .. To avoid double counting, 
net absconderf, i.e. the number of abscoJded patlents less those 




It is feasible that contacts who are merely infected have a similar 
age distribution to those who become infectic:us. ( See Appendix 
E for the distribution of drug dosages and relevant cost calcu-
lations.) 
The cost per dose of INH is R 0.0042 for adults and R 0.0017 for 
children 14 years of age and younger. Thus, the total cost of 
secondary chemoprophylaxis for those patients who completed their 
treatment, prescribed in 1983, is as follows : 
Adults : R 0.0042 x 60 doses x 108 patients= R 27.22 
Children: R 0.0017 x 60 doses~ 1 698 patients= R 173.20 
There is no available evidence to suggest that the behaviour of 
notified and prophylactic patients who default would differ. Thus, 
to calculate the cost of the drug regimen administered to patients 
who absconded/defc-,ul tea,' it was assur.,ec1 that the same proportion 
of prescribed doses of INH were taken before defeul t by patients 
receiving secondary c.:hemoprophylaxis as those receiving a full 
TB regimen. Based on this assumption, adults received 46. 5% of 
their prescribed 60 doses of INH (27.9 doses), while children received 
43.2% (2:',.9 do.ses of INH). 5 
ThE, total cost of prophylactic treatment for those patients who 
defaulted before completing the regimen prescribed for them in 
1983, is as follows : 
5. Adult and chj ld patients who absconded, received means of 51. 6 
and 38.1 doses respectively, compared to those who completed 
the treatment regimen and received means of 110. 9 and 88 .1 doses 
/, respectively. (See Appendix E and Tables III.15 and III.16). 
\ ,y The proportion · of these two sets of means, provided the abc,ve 
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Adults : R 0.0042 x 27.9 doses x 272 patients= R 31.87 
Children R 0.0017 x 25.9 doses x 1 785 patients= R 78.59 
ii) Cost of clinic services -
Secondary, chemoprophylactic treatment is not fully supervised 
at clinics. The patient's parent/ guardian is given a weekly 
supply of INH tablets and instructed how to administer them. 
If the parent/guardian does not present at the clinic to collect 
the tablets every week, it is recorded that the J:>atient has 
absconded. 
Thus, the cost of dispem;ing tablets to the patient's parent/ 
guardian and the administrative costs of recording details 
of treatment on patient folders are the only costs j ncluded 
in this section. All costs of investigation of the patient 
as a suspect or contact before chemoprophylaxis are included 
in section 1. 6. 
The estimated cost uf these clinic services in 1983· was 
R 93 080 (See Apendix C), i.e. approximately R24 per patient. 
iii) Indirect costs -
Indirect costs of secondary chemoprophylaxis consist of the 
time spent by parents/ guardians when collecting tablets from 
the clinic and the possible cost of transportation to clinics 
for this purpose. It was not possible within the scope of 
this paper to quantify these co:::.ts and it was felt that these 
costs would be relatively insignificant (th1~ pcirtnt/guardian 
is only required to make + 9 visits to the clinic during the 





1.2.2 Effectiveness of secondary chemoprophylaxis 
There, is no specific information on the effectiveness of the CDC 
prophylactic regimen. However, car.trolled trials using INH chemo-
prcphylaxis for differfog lengths of time (usually more than 60 
doses) have shown that this treatment decreases the risk of develop-
ing d: sease by 50-95%. (Grzybowski 1982 : 7-8). One eStudy estimated 
that the effectiveness of chemoprophylaxis prescribed for· household 
contacts was 60% (Grzybowskj 1982:7). It should be noted that 
the only contacts adm:i tted to this trial we1·e ones in which it 
was shown that infection had occurred. In S. A., the means by which 
infection in chi] dren is determined is the tuberculin test, the 
results of which have been shown to be d:i started by the effect 
of BCG vaccinations. Fourie (185:9) has shown that, 
"Under a prophylaxis prngr-amme using tuberculin tests 
as screening tools 85% of children selected for 
prophylaxis w~.11 be treated unnecessarily." 
As the tuberculin test is the only means of determining infection 
in children at present, the costs incurred in treating uninfectt,d 
patients arf, unavoidable. The above finding does however influence 
the effectiveness calculations. 
The patients prescribed chernoprophylaxis by CDC, contacts of sputum 
positive cases, are a high risk group and thus the number treated 
unnecessarily, i.e. the patients who were not infected, will possibly 
be lower. Thus, two estimates will be used; 85% based on the 
fir:dings of Fourie' s study, and 50%, an arbitrary estimate to indicate 
how tbe result will be affected by a lower estimate, i.e. a variable 





Of the 1 806 patients who completed chemoprophylactic treatment 
in 1983, 271 patients can be assumed to have been infected and 
in need of such treatment, using the 85% estimate. Approximately 
163 (60%) patients did not subsequently develop active TB as a 
result of receiving 60 doses of INH, while approximately 108 (40"A>) 
would have been notified as TB patients at some stage after corn-
pleting chemoprophylaxis. 
Similarly, approximately 309 of the 2 057 patients who absconded/ 
defaulted before completing chemoprophylactic treatment in 1983 
can be assumed to have been infected. If one assumes that the 
difference in the effectiven€ss of treatment of those patients 
who completed treatment and those who did not, was similar for 
notified patients6 and patients receiving chemoprophylaxis, 49.3% 
(152) of those patients who absconded before completing the prescribed 
chemoprophylactic regimen would not subsequently develop active 
TB while 50.7% (157) would. 
The same calculations are repeated here using the 50"A> estimate 
903 of those patients who completed treatment were infected 
542 of those patients who completed treatment did not subsequently 
develop TB 
361 of those patients who completed treatment would subsequently 
be notified as TB cases. 
6. The effectiveness of treatment for notified TB patients i.e. 
the number of patients who did not relapse, was 95.6% for patients 
who completed treatment and 78. 6% for patients who di,d not. 
(Based on relapse rates of 4.4% and 21.4% respectively ~ see 
section 2.2.3 of this chapter). 
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1 029 of those patients who absconded were infected 
507 of those patients who absconded would not subsequently develop TB 
522 of those patients who al;>sconded would subsequently be notified 
as TB cases. 
Using the 85% estimate a total of 265 patients who were prescribed 
secondary chemoprophylactic treatment in 1983 and who either 
completed treatment or absconded, would subsequently have been 
notified as active TB cases, while 883 would have been notified 
using the 50% estimate. Although the estimate that 85% of the patients 
prescribed prophylactic treatment were not in fact infected with tuber-
cle bacilli initially appeared to be rather high for contacts in the CDC 
area, it seems feasible that this could reflect the true situation. It 
in effect tndicates that approximately 25% of the children notified as 
TB cases in 1983 had previously been prescribed secondary chemoprophylaxis: It 
is doubtful whether the proportion of total notifications emanating 
from this particular group of people would have been significantly 
larger. The 85% estimates will thus be used in the following 
analysis. 
1.2.3 Cost-effectiveness ratio of secondary chemoprophylaxis at 
CDC clinics in 1983 
The total costs of secondary chemoprophylaxis in 1983 are as follows 
7. 238 child,ren under 15 years of age who would have been notified 
after receiving some chemoprophylactic treatment as a percentage 





Drug costs - Patients who completed treatment R 200.42 
- Patients who absconded R 110.46 
Clinic Services 
R ~3 390 .• .88" 
A total of 315 notifications were prevented by secondary chemopro-
phylaxis in 1983, based on the 85% estimate. 
The breakdown i.s as follows : 
Notifications prevented in patients who completed treatment 163 
Notifications prevented in patients who absconded 152 
315 
Cost of prophylactic treatment per notification prevented -
R93 39Q.88 ~ 315 = R 296.48 per notification prevented. 
1.3 Health education 
Heal th educators in the CDC are involved in community education 
relating to a wide range of health issues e.g. general hygiene, 
smoking, alcoholism, cancer, breastfeeding, cholera, tuberculosis 
etc. In 1983, 7.1% of the health education district work was 
devoted to Tuberculosis education. (Divisional Council of the 
Cape 1983:176). 
1.3.1 Costs of health education 
The total cost of heal th education conducted by the CDC in 1983 
was ~ 237 782. 
/; 
\ /)" 
(Unpublished CDC financial records.) This figure 
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includes a proportion of the CDC Heal th department administration 
costs. The cost of Tuberculosis health education was thus R 237 782 
x 7.1% = R 16 882.52. 
1.3.2 Effectiveness of health education 
It is difficult to determine the effectiveness of heal th ecucation, 
as it does not directly 'prevent' notifications. It can inform 
people of the means by which tubercle bacilli are transmitted which 
may ultimately result in fewer people contracting the disease, 
e.g. by encouraging TB patients not to spit or to cough behind 
their hand, the spread of disease may be somewhat limited. 
It is also not possible with the limited amount of information 
currently available, to determine the number of patients who sought 
medical attention at an early stage as a direct result of increased 
awareness of the symptoms of TB created by health education 
programmes. 
A few studies have been conducted in S.A. to determine the effective-
ness of heal th education. The study most relevant to this analysis 
is the one conducted by Thompson and Myrdal (1984c:6-7) which was 
based on interviews with 44 Black CDC TB patients, or the parents 
in the case of child patients. The overall finding was that the 
patients had a poor understanding of the disease from which they 
were suffering; e.g. 21% of the patients could not name any symptoms 
of TB, only 16% knew the mechanism of spread of tubercle bacilli, 
21% knew that TB was a preventable disease and were able to cite 
changes in socio-economic factors and personal habits as preventive 
techniques, and no-one in the sample knew what the duration of 




Given that it is difficult to quantify the implications of these 
responses and that much of · the TB heal th education is connected 
with the treatment of notified TB patients (see section 3.2 of 
Chapter II), it has been decided to combine the cost of TB heal th 
) 
education with the costs of the curative regimen to ensure that 
it is taken into account in the analysis. 
1.4 Socio-economic factors 
It is impossible within the scope of this paper to quantify the 
costs and effectiveness of socio-economic factors. Possibly the 
most important of these factors is the provision of adequate housing. 
An indication of the seriousness of the 'housing crisis' comes 
from the Cape Times ( 13 May, 1985) report that there was a backlog 
of 35 000 houses with 1 000 new applications per month in the CCC 
area and a backlog of 50 000 houses in the CDC area. 
This is a subject which desperately requires research, as the 
costs and effectiveness of changes in socio-economic conditions, 
with regard to their impact on TB, would be significant. This 
has been highlighted on numerous occasions in statements by those 
centrally involved with TB programs, e.g. Dr Tibbit, the MOH of 
the CDC was quoted in the Argus on 16 January, 1984 as saying that 
"If we did nothing medically and just improved housing 
and nutrition, we would do just as much good." 
1.5 Mass screening campaigns : 
There were three mass TB screening campaigns in 1983: i) An ongoing 






ii) A mass screening campaign in the Leonsdale residential area, 
part of Elsies River, which was conducted after statistics indicated 
that the largest proportion of admissions to the Brooklyn Chest 
hospital were from the Elsies River area; and iii) A mass tuberculin 
test survey conducted on behalf of the TBRI as part of their investi-
gation into annual rates of tuberculosis infection ( see sections 
2.1.3-2.2 in Chapter II). 
1.5.1 Costs of mass screening campaigns 
(SeeAppendix F for the calculation of costs per test.) 
i) Cost of pre-employment screening -
6 .256 X-rays were performed during pre-employment screening 
procedures in 1983. 
The total cost of these •· radiological investigations was 
6 256 X-rays x R 2.53 = R 15 827.68 
ii) Costs of the Leonsdale survey -
,' 
During the initial mass screening process, 2 325 radiological 
tests were performed. 156 people were X-rayed for further 
investigation. 1 358 children were given heaf tuberculin 
tests at the same time that they were X-rayed, of which 715 
returned to have the heaf tests 'read' within 48-72 hours 
of the test being performed. (Information from unpublished 
report on Survey). The cost of administering the test is 
the same for those children who had their test 'read' and 
for those who didn't; the cost of clinic services is adjusted 
to account for those children who did not return for 'reading' 
lll 
of tests i.e. children who returned to have their tests 'read' 
are assigned a cost estimate for two clinic visits and those 
who didn't return, an estimat,e for one clinic visit. (see 
Appendix C.) 
The total cost of these tests was 
2 481 X-rays x R 2.53 = R 6 276.93 
1 358 heaf tests x R 0.13 = R 176.54 
iii) Costs of TBRI survey -
1 573 tuberculin tests were conducted by the CDC on behalf 
of the TBRI in 1983. 
The cost of these tests was: 
1 573 tuberculin tests x R 0.13 = R 204.49. 
The total cost of tests performed during mass screening campaigns 
in 1983 was thus R 22 485.64. Clinic services costs of 
R 49 174 have .been allocated to mass screening procedures 
to account for administrative work in recording details of 
the person being screened, the administration and 'reading' 
of tuberculin tests, transport costs, etc. (see Appendix C 
for detailed clinic cost calculations.) 
1.5.2 Effectiveness of mass screening campaigns 
The only CDC mass screening campaign for which effectiveness indi-
cators are available is the Leonsdale survey. 12 cases were notified 
as a resu·l t of screening 2 325 people; a mean case yiel~ of O. 52%. 
I 
/: 
(Unpublished CDC report on the Leonsdale survey). \ 
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Studies conducted by the TBJU have shown that mass X-ray screening 
" of workers produces a mean case yield of 0.3%. (S.A. Medical Research 
council 1984: 14). 
Assuming that the case yield is similar whether the investigative 
procedure was by means of X-ray and/or tuberculin, it can 
be estimated that between 30.5 and 52.8 cases were notified as 
a result of investigating 10 154 people through mass screening 
campaigns in 1983. A midpoint estimate of 41.65 notified cases 
per 10 154 investigations will be used in the calculation of a 
cost-effectiveness ratio. 
1.5.3 Cost-effectiveness ratio of mass screening campaigns 
R 71 659 .!. 42 notifications = R 1 706 .18 per case notified as a 
result of mass screening procedures. 
1.6 Investigation of contacts and suspects 
The CDC does not distinguish in their records between investigations 
conducted on suspects, i.e. those people who present at a clinic 
with symptoms of TB, and on contacts. If a person presents at 
a clinic with strong clinical indications of TB and is confirmed 
as a TB case either radiologically and/ or bacteriologically shortly 
thereafter, they are immediately recorded as a newly diagnosed 
and notified case. Other cases are recorded as suspects under 
investigation. The majority of those recorded as a contact/suspect 
under investigation are contacts of confirmed TB cases. All of 
the contacts recorded on a newly notified patient's folder are 
included in the CDC records as cont~cts under investigation. 
The sample data indicated that a mean of 5.37 contacts per newly 
I 





investigated, i.e. a mean of 2.74 contacts per patient were investi-
gated. 
The total number of people who were registered as contacts or suspects 
under investigation, i.e. not diagnosed and notified immediately, 
in 1983, was 19 898. (See Appendix D). Of these contacts/suspects, 
10 646 ( 53. 5%) had their investigation procedures completed, 
8 781 (44.1%) absconded before investigation procedures were com-
8 
pleted, 463 (2.3%) were transferred to a hospital or clinic outside 
of the CDC jurisdiction, and 8 (0.1%) died before investigation 
could be completed. The breakdown according to age is presented 
in Appendix D·. 
It was noted in the CDC records that 205 child and 273 adult contacts/ 
suspects were notified as a result of radiological investigation 
in 1983. It can therefore be assumed that 723 child and 1 257 
adult suspects were diagnosed and notified immediately without 
f . t b . d d t d . t• t• 9 irs eing recor e as suspec s un er inves iga ion. Based on 
this information, it can be estimated that 5 670 children and 
8. In total, 4 560 children and 4 462 adults absconded from investi-
gation procedures, of which 126 children and 115 adults were 
recovered. As explained in footnote 4, net absconders are used 
here to avoid double-counting. The total of net absconders 
is 8 781 (4 434 children and 4 347 adults). It should also 
be noted that those who were classified as absconded, includes 
people who reported for investigation initially and then absconded, 
as well as those noted as a contact on a notified patient's 
folder who were never traced or did not present for investigation 
after being traced. 
9. A total of 944 children and 1 556 adults were notified in 1983. 
Section 1, 5 indicated that 42 patients were notified as a result 
of ma$ screening procedures. As children accounted for 37. 76% 
of TB notifications in 1983 and adults for 62. 24%, it can be 
estimated that 16 children and 26 adults were notified as a 
result of mass screening procedures. Total notifications 
[ contacts/suspects notified after investigation :.:+ · persons 
notified as a result of mass screening procedures] = suspects I \ 
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6 956 adults were fully investigated as contacts/suspects in 1983.
10 
1.6.1 Costs of fnvestigating contacts and suspects 
The CDC MOH' s annual report states that 23 153 radiological examin-
ations were performed on contacts of notified TB patients and suspect-
ed TB cases in 1983. (Divisional Council of the Cape 1983 : 153). 
As only 12 626 contacts/suspects were fully investigated in 1983, 
this indicates that some of. the contacts/suspects may have been 
X-rayed before absconding and that more than one X-ray may have 
been taken in cases where a conclusive diagnosis based on the first 
X-ray was not possible. 
A total of 7 420 tuberculin tests were performed in 1983. (Divisional 
Council of the Cape 1983 : 159). As the progress of notified patients 
is not assessed by means of tuberculin testing during treatment, 
all of these heaf tests will be attributable to investigation of 
contacts and suspects except for the 2 931 which were performed 
during mass screening procedures. Thus, the remaining 4 489 tuber-
cul in tests were performed on contacts and suspects in 1983. This 
supports the ~ample data finding that only 71. 7% of those child 
suspects/contacts who were notified had heaf tests performed on 
them. A small number of contacts/suspects who absconded before 
the investigation procedures were completed may also have had a 
heaf test. 
10. 10 646 people (4 947 children and 5 699 adults) who were initially 
registered as contacts or suspects under investigation were 
fully investigated. In addition, 1 980 people ( 723. children 
and 1 257 adults) were fully investigated as contacts or suspects 
but were notified immediately./ The sum of these two categories 




The CDC does not have composite figures for the number of bacterio-
logical tests performed in 1983. (These figures could not be obtained 
from the State Laboratory either. ) The sample data indicated that 
70.6% of contacts/suspects notified had results for Direct microscopy 
tests and 59.2% for sputum culture. tests. The. total number of 
bacteriolog:icaltests performed in investigation procedures can be 
estimated from this, given a small margin of error for those adult 
contacts/suspects who had these tests before absconding. 
Direct microscopy: 70.6% of 6 956 contacts/;3uspects = 4 911 
Sputum culture: 59.2% of 6 956 contacts/suspects= 4 118 
Differential tests, which are able to differentiate between M tuber-
culosis and other non-tuberculous bacilli, are not performed routinely 
in diagnostic procedures. They are usually performed on patients 
already diagnosed as suffering from TB as a means of confirming 
diagnosis. 13. 9% of the notified adult patients had a differential 
test result. It can thus be estimated that: 
13.9% x 1 556 notified adult patients 216 differential tests 
were performed on contacts/suspects in 1983. 
The total costsof these tests were therefore, as follows 
X-rays: 23 153 x R 2.53 = R 58 577.09 
Tuberculin tests: 4 489 x R 0.13 R 583.57 
Direct micro9copy: 4 911 x R 1.68 R 8 250.48 
Sputum Culture: 4 118 x R 4.20 = R 17 295.60 
Differential tests: 216 x R 2.10 = R 453.60 
I 
TOTAL cost of investigative tests = R 85 160.34 
I (Unit test cost calculations can be found in Appendix F) 
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Clinic services costs of R 160 357 have been allocated to the 
investigation of contacts/suspects to account for administrative 
work in recording details of the contact/suspect, administering 
the tuberculin tests, collecting sputum samples, recording resuilts 
of the tests, etc. (see Appendix C). 
1.6.2 Effectiveness of investigating contacts and suspects 
Of the 12 668 contacts/suspects who were investigated fully in 
1983, approximately 2 458 were subsequently notified.
11 
This g:i,ves 
a mean case yeild of 19.4%. This indicates that case-finding pro-
cedures in the CDC are relatively efficient when compared with 
the averages for large South African cities as a whole. Studies 
have shown that the,nean .case yield for family contact investigations 
in South African cities is 5% and for self-presenting symptomatic 
cases, i.e. suspects, is 7%. (S.A. Medical Research Council 1984:14). 
1.6.3 Cost-effectiveness ratio of investigating contacts and suspects 
R 245 517.34 . 2 458 notifications R 99.89 per notification. 
11. 2 500 patients were notified in 1983. In section 1. 5, it was 
estimated that approximately 42 patients were notified as a 
result of mass screening procedures. All other patients would 
have been notified as a result of investigation of contacts 
and suspects, including those who received secondary chemo-
prophylaxis before developing active TB. 
/1 





.2. Cost~effectiveness analysis of the 'clinic' curative regimen for 
TB in the CDC 
~· \. \, 
2 500 people were notified and received treatment in the CDC area 
in 1983. The breakdown according to 
\ 





Table IV.3 Number of adults and children notified in 1983 (CDC) 
:! 
Age group Numbe·r of patients 
Adults (15 years and older) · 1 556 
Children {14 years & younger) 944 
TOTAL 2 500 
2.1 Costs of the 'clinic' regimen 
Most of the cost calculations are contained in Appendix E and 
Appendix F. These calculations are based largely on the findings 
of the sample data. Details of mean doses of drugs administered 
and the mean number of tests performed per patient according to 
whether a patient completed treatment 
12 or. not , 
from the information presented in Chapter III. 
have been taken 
12. The sample data indicated that some patients who did not complete 
their prescribed treatment regimen were not classified as de-
faulters ( see reasons in section 2. 4. 2 of Chapter III). As 
the number of these patients was very small ( 6 adults and 1 






2.1.1 Cost of drugs 
The sample data indicated that 77.6% of the adult and 74.8% of, 
the child patients completed their prescribed treatment regimens. 
Thus it can be estimated that: , 
1 207 adult patients completed treatment 
706 child patients completed treatment 
349 adult patients defaulted 
238 child patients defaulted 
The total cost of the drugs administered in the CDC to notified 
patients during 1983 can be estimated as follows: 
Patients who completed treatment: 
1 207 adults x R 107.51 = R 129 764.57 
706 children x R 24.13 = R 17 035.78 
Patients who defaulted: 
349 adults x R 
238 children x R 
55.45 
10.80 
R 19 352.05 
R 2 570.40 
( See Tables E. 2, E. 3, E,6 and E. 7 in Appendix E for calculation 
of costs per patient). 
The total c~st of drugs administered to the 2 500 notified patients 
was thus R 168 722.80. 
An indirect cost of the drug regimen is the adverse reaction of 
some of the patients to the drugs. The drug regimen is altered 
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immediately any adverse reactions occur and the symptoms disappear 
quite rapidly thereafter. None of the adverse reactions displayed 
in the sample population resulted in permanent physical disability. 
7. 7% of the patients in the sample experienced an adverse reaction 
either to Streptomycin and/or PZA. (See section 2.4.4 in Chapter 
III for a breakdown of these reactions.) 
It should be noted that while a small proportion of patients receiving 
TB treatment at CDC clinics did experience discomfort/suffering 
for a limited period of time, due to adverse reactions to one or 
more drugs, no attempt will be made to quantify the cost of this 
discomfort. 
2.1.2 Cost of tests during treatment 
To monitor the progress of patients during treatment, radiological ' 
and bacteriological tests are supposed to be performed on adult 
patients, and radiological tests on child patients, after 60 doses 
of the regimen have been administered and again after 100 doses. 
In addition, drug sensitivity tests are sometimes performed if 
there are indications that the bacilli may have developed a resist-
ance to one or more drugs e.g. if a patient relapses or fails to 
respond to treatment. 
Using the cost per test as given in Appendix F and the mean number 
of tests per patient as presented in section 2. 4. 6 of Chapter III, 
the cost of these moni taring tests was calculated. The results 
for the 1 207 adults and 706 children who completed treatment and 
the 349 adults and 238 children who defaulted are presented in 









Table IV.4 Cost of monitoring tests for patients who completed 
treatment 
Test Adults Children 
X-rays R 7 114.36 R 3 590.07 
Sputum culture R 3 901.80 
Direct microscopy R 1 115.52 
Sensitivity R 3 654.00 
TOTAL R 15 785.68 R 3 590.07 
Table IV.5 Cost of monitoring tests for defaulters 
Test Adults Children 
X-rays R 741.29 R 457.93 
Sputum culture R 323.40 
Direct microscopy R 63.84 
Sensitivity R 176.40 
TOTAL R 1 304.93 R 457.93 
Thus the total ·cost of tests performed to assess the progress of 
the 2 500 notified patients during treatment, was R 21 138.61. 
2.1.3 Cost of follow-up tests 
The sample data indicated that 71. 8% ( 867) of the adult patients 
and 74.3% (525) of the child patients who completed their prescribed 
regimen of treatment, had follow-up tests after treatment to 
ascertain whether the tubercle bacilli were in fact inactive. 
Using the mean number of tests per patient as presented in Table 
III.20, and the cost per test (Appendix F), the total cost of 
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follow-up/surveillance tests on patients treated in 1983 was calcul-
ated to be R 7 071.95 (see summary of calculations in Table IV.6). 
Table IV.6 Cost of follow-up tests 
Test Adults Children 
X-rays R 3 291.53 R 1 593.90 
Sputum culture R 1 457.40 
Direct microscopy R 729.12 
TOTAL R 5 478.05 R 1 593.90 
2.1.4 Cost of treating relapses 
It has been estimated that approximately 84 patients who completed 
treatment during 1983 relapsed, and 126 patients who defaulted 
were retreated. ( See section 2. 2. 3 for further details of these 
calculations.) Al though some of these patients relapsed in 1983 
and some in 1984, it is assumed that the relapse rate was similar 
in 1982 and that there will thus be minimal discrepancies if the 
figures quoted above are used as estimates of the total number 
of relapses treated in 1983. (Note: Relapsed cases are not 
included in the figure of 2 500 notifications; this refers only 
to newly notified patients.) 
The same regimens and procedures are applied in the treatment of 
newly notified patients and relapsed cases, except that a sensitivity 
I 
test is performed on all adults who relapse. Given that the total 
cost of drugs and tests, excluding any sensitivity tests, used 
in the treatment of the 2 500 newly notified patients in 1983 is 
R 193 102.96 and the cost per patient is thus R 77.24, it can be 
/; 
I \ .,,,... 
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estimated that the cost of treating the 210 relapses will be as 
follows: 
R 77.24 per patient x 210 relapses = R16 220.40 
R 25.20 per sensitivity test x 131 relapsed adults= R 3 301.20 
R19 521.60 
2.1.5 Cost of clinic services 
The cost of staff and transport etc. involved in supervising and 
administering drugs to patients, collecting sputum samples for 
bacteriological tests, recording information about number of doses 
administered and test results on patient folders, etc. -was estimated 
to be approximately R 923 773 for 1983. (See Appendix C). 
2.1.6 Cost of hospitalisation 
The sample data indicated that the mean length of stay for hospital-
ised patients was 9 .1 weeks,{ 63. 7 days ( see section 2. 4 .1 in Chapter 
III). Records at the Brooklyn Chest Hospital, where CDC TB patients 
are hospitalised, confirmed this finding (average length of stay 
for all 1983 Brooklyn patients was 9.0 weeks.) 
26% ( 484) of the patients treated at Brooklyn Chest Hospital during 
1983 were from the CDC area. 
The Brooklyn Ch-est Hospital is funded by central government. All 
the costs incurred in treating · and caring for TB patients at the 




clinics where the drugs, bacteriological test services, etc. are 
provided free of charge by the government and thus only the services 
financed by the Divisional Council (partly through government grants) 
are reflected in their expenditure accounts. The cost of drugs 
etc. to the Brooklyn Hospital are in effect transfer payments from 
one government department to another, but must nevertheless be 
included to accurately determine the total cost of treating TB 
patients. 
The cost per patient per day was R 18. 99 in 1983 (personal communi-
cation with Brooklyn Chest Hospital). As mentioned earlier, this 
included ali costs ranging from food and laundry costs for patients, 
to occupational therapy sessions for adul~s, and school lessons 
for children. The only cost not included was the expense incurred 
in the upkeep of the grounds, a duty performed by the Department 
of Public Works. Attempts to determine this cost were unsuccessful. 
The total cost of hospitalisation for CDC TB patients in 1983 was: 
484 patients x 63.7 days x R 18.99 per patient per day= R 585 476.89. 
In addition to these costs directly related to TB treatment, there 
were a number of 'indirect' costs that must be accounted for. 
2.1.7. Disability grants 
Information on the total number of disability grants awarded to 
TB patients being treated at CDC clinics in 1983 was not available 
and thus figures were estimated from the sample findings. 
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It was estimated that approximately 1 438 ( 31 Whites, 902 Coloureds 
and 505 Blacks) of the 1 556 adult TB patients were of employable 
age. The sample indicated that 11. 3% of these patients received 
disability grants for a mean period of 5.9 months. Thus it can 
be estimated that approximately 4 white, 102 Coloured and 57 Black 
patients received disability grants in 1983. 
The monthly disability grant in 1983 was R 152 for Whites, R 93 
for Coloureds and R 57 for Blacks. (SAIRR 1983:516) 
Estimates of the total amount received by CDC patients in the form 
of disability grants during 1983 are presented in Table IV.7. 
Table IV.7 Total Estimated Disability grants received by CDC 
patients 
Race Disability grants 
Whites R 3 587.20 
Coloureds R 55 967.40 
Blacks R 19 169.10 
TOTAL R 78 723.70 
2.1.8 Other grants 
The Tuberculosis Council of the Cape Province fund provides financial 
assistance to families whose breadwinner has contracted TB and 
is unable to generate sufficient income. It is regarded as an 
interim grant before the results of a disability grant application 
are available. In 1983, R 23 225 was paid to assist 153 families 




2,1,9 Loss in economic performance or productivity 
With the procedures currently available to diagnose TB sufferers 
at the earliest possible stage and to successfully treat them, 
a TB patient's economic performance or productivity sh~uld not 
normally be significantly affected. The symptoms of TB which could 
be expected to affect a worker's productivity are: loss of weight, 
lethargy, dyspnoea (i.e. shortness of breath: - in severe cases) , 
pain in the chest and fever (usually 'low-grade'). (Glatthaar 
1982a:14). These will ordinarily only affect productivity once 
the disease is at a relatively advanced stage. 
It is important to note that it is CDC policy to attempt to ensure 
the least possible disruption in the TB patient's normal daily 
activities. Every effort is made to keep the ·· patient working and 
especially to allay employers' fears about the infectiousness of 
workers who have TB, to prevent their dismissal. ( See section 3. 2 
of Chapter II) . One patient included in the sample was dismissed 
as a result of contracting TB but was reinstated after a CDC doctor 
had spoken to his employer. Provision is made for treatment of 
patients at their place of work so that the only disruption to 
work occurs on the 2 or 3 occasions when the patient is X-rayed 
or examined by the doctor to assess progress. Certain other local 
authorities do not provide these services and all their TB patients 
receive daily supervised treatment at clinics, which often results 
in serious work disruptions. 
The age distribution of TB patients (see Tables III.3 and III.4 
for sample population age distribution) indicates that a large 





'prime' working years. 
were of employable age. 
62% of the patients included in the sample 
The sample data also indicated that 51. 6% of these patients were 
specifically noted as ,being employed, 17.2% were noted as being 
unemployed, and 31.2% had no reference to employment status on 
their folder. Although almost a third of the patients had no refer-
ence to employment status, it should be noted that the CDC clinic 
staff take great care to record details of employment to provide 
for treatment at the workplace. The majority of those who ·had 
no reference to employment status were women and it can be assumed 
that many of them were 'housewives' and not receiving an independant 
income. 
For those patients who . were unemployed at the time of contracting 
TB, there would be no decrease in economic activity directly 
attributable to the TB or the treatment thereof. It would possibly 
be more difficult to obtain a job if one was suffering from TB, 
but given the relatively high unemployment rate in 1983, it is 
debatable whether a factor for production loss/ decrease in economic 
activity should be ascribed to those TB patients who were unemployed. 
In fact, 3 of the 32 unemployed patients included in the sample 
found work after contracting TB and while still being treated. 
Details of the patients included in the sample who were employed 
when they contracted TB and were either declared unfit for work 
for differing time periods by a CDC doctor or had a change in employ-
ment status during TB tr~atment, are provided below: 
\ 
" 
Declared unfit for work for 
Change in employment status 
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1 week 2 patients 
2 weeks - 4 patients 
1 month - 6 patients 
1~ months - 1 patient 
1 patient resigned 
4 patients were dismissed as a result of 
TB. 
1 patient was retrenched (unrelated to 
TB.) 
1 patient was dismissed for alcoholism 
Thus, 13 ( 13. 5%) of the employed patients were declared unfit for 
work for a mean period of 3.1 weeks (S.D. = 1.5 weeks) and 4 (4.2%) 
of the employed patients were dismissed for reasons relating to 
TB. Losses due to decreases in economic activity for patients 
who were dismissed for other reasons or resigned, should not be 
included here as the analysis is concerned purely with evaluating 
costs which are a direct result of TB. 
Loss in economic performance is also relevant to patients who are 
hospitalised. Of the 20 patients of employable age who werehospital-
i sed, 13 ( 65%) were unemployed, 2 ( 10%) were employed when admitted 
and 5 (25%) were females for whom employment status was not recorded. 
Using the proportions presented in the sample findings ( see section 
2.2 in Chapter III), it was estimated that approximately 742 patients 
( 16 White, 465 Coloured and 261 Black) would have been employed 
at the time of contracting TB in 1983, of which approximately 100 
(13.5% 2 Whites, 63 Coloureds and 35 Blacks) would have been 





31 patients (4.2% - 1 White, 19 Coloureds and 11 Blacks) would 
have been dismissed for reasons relating to their having contracted 
TB, · assum:ing no racial effect on job loss probability. 
Average personal incomes will be used as a proxy for the marginal 
productivity of labour~2a These income figures are drawn from the 
1980 Census data for Cape Town : 
Table IV.8 Average monthly personal income in Cape Town (1980) 
Race Male Female 
White R 808.33 R 362.33 
Coloured R 229.87 R 130.78 
Black R 138.49 R 83.89 
(Patel 1984: 67, 68 and 90) 
Tab IV.9 Distribution of economically active population by race 
and sex (1980) 
Race Male Female 
White 63.0% 37.:0% 
Coloured .59,.9% :40.1.% , 
:s. 
Black 76.3% 23.7% 
I 
I 
(Patel 1984 142) \ 
'-
The combined average monthly personal incomes for each race group, 
irrespective of sex, based on the above information is presented 
in Table IV.10. 
12a. In the case of TB patients, average personal incomes may overstate 
the marginal productivity of these labourers, e.g. workers declared 
unfit for work would probably have been incapable of producing.at the 
marginal productivity level. The one exception may be where a TB: 
sufferer is dismissed due to employer prejudice rather than a, decrea-
se in the worker's productivity. (see p.125 & Addendum IV). 
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Table IV. 10 Average monthly incomes (1980 & 1983) by race 
Race 1980 
White R 643.31 R 948.88 
Coloured R 190.14 R 280.46 
Black R 125.55 R 185.19 
Thus, the total loss in productivity, based on incomes, for TB 
patients declared unfit for work or dismissed in 1983 was as follows: 
Declared unfit for work 
14 
Dismissed from work : 
R 18 584.58 
R 42 099.80 
R 60 684.38 
It was estimated that approximately 35 hospitalised patients (24 
Coloured and 11 Black) were employed when admitted. Assuming a 
mean leng~h of stay of 9.1 weeks (see section 2.1.6 of this chapter), 
the total loss in productivity for these patients was R 18 363.63. 
The total loss in productivity/economic performance experienced 
by CDC TB patients in 1983 was thus approximately R 79 048.01. 
13. The 1983 figures were calculated using the Consumer Price 
Index for Cape Town: Base year - 1975 ( 100) __ 1980 - 172. 0 
1983 - 253.7 (Hendrie 1985 : 8), assuming no loss of real income 
over time. 
14. This was calculated only for the average of 5.0633 months for 







2.1.10 Unquantified indirect costs 
There are a number of indirect costs which should be mentioned 
al though: not quantifiable for various reasons. Many of these costs 
were 'intangible' and their estimation would have required unrealistic 
effort and resources. 
a) Mortality cost is the most significant indirect cost of TB. 
The TB mortality rate was 2.07% in 1983. (Divisional Council 
of the Cape 1983 48) Section 2.2.1 of Chapter I contains a 
full discussion of the reasons for not estimating the mortality 
cost/'value of life' in this study. 
b) The cost of time spent at clinics to receive supervised treatment, 
for radiological and clinical examinations, etc. As stressed 
earlier, the CDC arranges for treatment at work and thus this 
cost would in general only be incurred by unemployed patients 
and 'housewives'. 
c) Transport to clinics - this should not be significant as there 
are clinics in each residential area and most patients are within 
walking distance of a clinic. If any problems are encountered, 
the patient is treated at home, i.e. receives 'domiciliary' 
treatment, the cost of which is accounted for in clinic services 
expenditure. 
d) The symptomatic suffering/discomfort and the possible effects 
of the stigma of having TB, experienced by TB patients. 
e) The problems associated with a patient being removed from his/her 
family. This applies to hospitalised patients and those patients 
who come from the 'homelands' specifically to obtain treatment. 
In the latter case, this may have economic implications if the 






f) The cost of health education programmes sponsored either by 
SANTA or some other organisation - over the past few years, 
these have taken the form of infc,rmation pamphlets, advertisem,ents 
and articles in magazines and newspapers , and TV programmes and 
advertisements. These are directed both at the general population 
and at specific groups, e.g. employers. (See Addendum IV). 
2.1.11 Total costs of CDC curative regimen 
The total cost of the CDC curative regimen in 1983 was R 1 923 
584. 08. ( The breakdown of this base:d on the above calculations, 
is tabulated on Table V.l, of Chapter V). 
2.2 Effectiveness of the 'clinic' curative regimen 
The three major indicators of the effectiveness of the treatment 
for TB patients are: i) the compliance rate, ii) the cure rate 
and iii) the relapse rate. 
2.2.1 The compliance rate 
The mean compliance rate of the patients in the sample who completed 
the prescribed treatment regimen was 89. 4% ( see Table III .17 in 
Chapter III). This is the mean of all patients' indj_vidual average 
attendance, as a percentage of the maximum possible attendances. 
This finding has been confirmed by a survey conduc+;ed by Dr Fisher, 
of all patients at the Ravensmead and Elsj es River clinics. These 
comprised :t 37% of all CDC TB patients, in 1981. The compliance 
rate of patients who completed treatment was 88.3%. (Fisher 1985:14). 




was 70.4%. Thus, the mean compliance rate for the total E:ample 
population ,~as 85.3%. This ind:5.cEtes that even patients who did 
not complete their TB treatment, were rece:i.ving their treatment 
on a fairly regular basis before defaulting. 
The CDC considers a patient's attendance of below 75% of the maximum 
possible attendances to be unacceptable. (Pearson 1979:420). 
This is based on the findings of various studies which have shown -
that the effectiveness of short-course treatment in curing a patient 
decreases as the frequency of administration of drugs decreases. 
(Angel 1983 and Aquinas 1982.) 
2.2.2 The cure rate 
Those patients who default before completing the p~escribed regimen 
of treatment are not considered as cured as they have not received 
what the CDC Health authorities consider to be an 'acceptable' 
regimen. (Fisher 1985:10). For other patients, if their compliance 
rate and general progress is acceptable, the CDC signs them off 
as cured when they have completed their prescribed treatment regimen. 
As indicated by the sample, some patients receive more doses than 
prescribed by the CDC Health authorities. This usually occurs 
when one of the clinic doctors prescribes further treatment due 
to inadequate progress by the patient. This is indicated either 
by inadequate clearing of the lungs as revealed on X-rays, or by 
a positive bacteriological test. 
A specific measure of the progress of patients is the 'sputum 









positive bacteriological result before treatment is commenced to 
a negative result after 60 doses of drugs have been administered. 
In the sample, 53 adult patients who completed the prescribed regimen 
were initially sputum positive and had a bacteriologic~l test result 
after 60 doses. 15 The results of the bacteriological tests conducted 
after 60 doses were as follows: 
Sputum culture-negative, Direct microscopy-negative 21(39.6%) 
Sputum culture-negative, Direct microscopy-no result 21(39.6%) 
Sputum culture-no result, Direct microscopy-negative 8(15.1%) 
Sputum culture-negative, Direct microscopy-positive 1( 1.9%) 
Sputum culture-no result, Direct microscopy-positive 1( 1.9%) 
Sputum culture-positive, Direct microscopy-contaminated 1(1.9%) 
Thus, 94.3% of the patients who were initially bacteriologically 
confirmed and completed treatment, 'converted' to either a negative 
sputum culture and/or a negative direct microscopy result after 
60 doses. 
Although this information pertains to a relatively small group 
of patients and does not account for the possibility that the doctor 
may consider the clearing of the lungs to be unsatisfactory (based 
on a radiological examination) despite a negative bacteriological 
test, it does indicate that a large proportion of the most significant 
15. 109 adult patients were originally sputum posi tive/bacteriologi-
cally confirmed ( see Table III .11). 33 of these. patients did 
not have a sputum test result after 60 doses, 20 defaulted 
before completing treatment and 3 did not complete treatment 
for reasons other than default. 
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group of TB patients, i.e. those who are bacteriologically confirmed 
as having active tubercle bacilli and are the more infectious cases 
(see section 3.3.1 of Chapter II), are bein~ rendered uninfectious 
and are ultimately cured. 
At a more general level, the sample data indicated that 76. 7% of 
the TB patients in the sample completed the regimen specifically 
prescribed for them by a CDC doctor and were signed off as cured 
on the basis of satisfactory test results (see Table III.14). 
Thus, it can be estimated that approximately 1 913 of the 2 500 
notified patients were signed off as cured in 1983. 
2.2.3 Relapse rate 
The relapse rate of patients who completed TB treatment at a CDC 
clinic in 1983 was 4.4%, according to the sample data findings. 
Thus, of the approximately 1 913 patients signed off as cured during 
1983, it is estimated that 84 relapsed after a mean period of 8.2 
months (see section 2.6 of Chapter Ill). 
16 The mean number of doses of INH received by patients who relapsed 
was compared to the mean number of doses for all patients who 
completed treatment to ascertain whether there were any significant 
differences. 




of doses of INH is used as an indicator of the total 
administered. INH is the most consistently adminis-
at CDC clinics. It is prescribed for the entire 
treatment in the majority of cases and is only 









Relapses - 113.6 doses, all patients - 110.9 doses 
Children: 
Relapses - 63.7 doses All patients - 88.1 doses 
Children who relapsed received relatively fewer doses than the 
mean for all patients. 
The .96 .5% .mean compliance rate of those patients who relapsed was higher 
than the 89. 4% mean compliance rate for all patients who completed 
treatment. This indicates that compliance was not a contributing 
factor to relapse in the case of patients who completed the regimen 
prescribed for them. 
The sample data indicated that· 21.4% (15) of the patients who did 
not complete the prescribed treatment regimen relapsed, or more 
correctly, re-presented themselves at a CDC clinic with active 
TB, a mean period of 6. 3 months after defaulting. Generalising 
this to the approximately 587 patients who did not complete treat-
ment, it is estimated that 126 would have begun a second course 
of TB treatment. 
There are certain significant factors concerning the defaulters 
who 'relapsed' and were included in the sample that should be noted. 
The mean number of doses of INH received by 'relapsed' defaulters 
is compared to the mean for all defaulters: 
Adults: 






Relapses - 37.0 doses All defaulters - 38.1 doses 
Adult defaulters who 'relapsed' received relatively fewer doses 
than the mean number of doses for a.11 defaulters. 
The compliance rate for patients who did not complete treatment 
and subsequently relapsed was 66.7%. This was lower than the 
mean compliance rate of 70.4% for all patients who did not complete 
treatment. 
It is significant that 10 of the 13 adult defaulters ( 76. 9%) in 
the sample who 'relapsed' were bacteriologically confirmed as TB 
sufferers, i. e they were found to have a relatively high concen-
tration of active tubercle bacilli, whereas only 54.2% of the total 
adult sample population were bacteriologically confirmed. This 
indicates that bacteriological status is an important determining 
factor in the relapse of defaulters. 
The number of doses received before default is also important. 
This can be illustrated by comparing the bacteriologically confirmed 
adults in the sample who defaulted and 'relapsed' with those who 
did not 'relapse'. A total of 24 adults who defaulted were initially 
confirmed as TB cases by means of either a positive sputum culture 
and/or direct microscopy result. The mean number of doses and 
the compliance rates of these patients were as follows: 
10 patients 'relapsed': Mean number of doses of !NH= 34.7 
Compliance rate= 64.6% 
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14 patients did not 'relapse': Mean INH doses= 89.1 
Compliance rate= 81.9% 
These findings indicate that, in general, only those patients who 
defaulted after receiving a relatively low proportion of the total 
possible doses of TB drugs (approximately one third of the prescribed 
regimen) and in addition had an unacceptable compliance rate would 
subsequently relapse. Patients who did not complete the prescribed 
regimen, either by ·default or for other reasons, but nevertheless 
received a relatively large proportion of the prescribed drug doses 
and who complied well with the treatment regimen during this period, 
would in general not 'relapse'. 
This deduction is supported by findings documented by Dr Zabow 
and Dr Pearson, CDC doctors, in 1982: 
" over the last 8 years we have seen a considerable 
number of patients who defaulted early (between 40 and 
80 daily · doses) but who have been shown on examination 
of radiographs and sputum specimens to have remained 
in a stable condition for periods of up to 5 years ... " 
(Zabow and Pearson 1982:870) 
It may thus be inferred that although patients who did not complete 
treatment were not signed off as cured by a CDC doctor, those who 
did not 'relapse' were in effect· cured. The total relapse and 
retreatment rate, based on the sample findings was 8.4%, which 








2.2.4 Summary of measures of effectiveness 
The most i'mporta:nt · measure of the effectiveness of TB treatment 
is the proportion of TB patients regarded as cured that did not 
subsequently relapse. Treatment compliance rates are not the primary 
determinant of effectiveness, but remain a useful auxilliary 
indicator. 
Before calculating the effective cure rate, it should be noted 
that of the 2710 newly notified and relapsed patients, 56 died, 
i.e. there was a mortality rate of 2.07% (Divisional Council of 
the Cape 1983:48). Given a 8.4% relapse ra~e, the estimated effective 
cure rate was 89.54% i.e. all patients who did not relapse or die 
wereconsidered to be effectively cured. 
2.3 Cost-effectiveness ratios for the CDC curative regimen: 
Four cost-effectiveness ratios are presented here which will indicate 
how ratios are changed by selecting different units of outcome, 
and which may be useful to other analysts and decision makers who 
may require one of a range of possible ratios to evaluate a specific 
problem. 
i) Cost of curative regimen per newly notified patient -
R 1 923 584.08 ~ 2 500 new notifications 
R 769.43 per newly notified patient 






R 1 923 584.08: 2 238 newly notified patients cured 
= R 859.51 per newly notified patient cured. 
iii) Cost of curative regimen per newly notified/relapsed patient -
R 1 923 584.08 ~ 2 710 new notifications/relapses 
R 709.81 per newly notified/relapsed patient 
iv) Cost of curative regimen per newly notified/relapsed patient cured 
R 1 923 584.08 7 2 426_newly notified/relapsed patients cured 
= R 792.90 per newly notif1ed/relapsed patient cured 
3. Summary: 
Cost-effectiveness ratios were calculated for each of the preventive 
and curative ~rocedures for TB used by the CDC. These ratios provide 
the raw-material for policy-makers to base their decisions upon 
regarding which TB procedures should be given priority. These 
individual ratios are evaluated and compared in Chapter V, to indicate 
what combination of preventive and curative procedures should be 
implemented. 
It is important to note that data for certain procedures was very 
limited. A number of assumptions were made to.facilitate the esti-
mation of variables for which no values were available. 
There is an urgent need for more research ~f preventive and curative 
TB procedures in S. A. The analysis in this chapter indicates two 





i) Evaluation of the effectiveness of BCG vaccinations in S.A., 
and 
ii) Determination of the effectiveness of secondary chemoprophylaxis. 
In addition, TB authorities should ebe encouraged to compile more 
information on notified TB patients e.g. total number of defaulters, 









. If you rire a worke~_with susp~cte~ TB, . · · . . · .. :he is no lon~er a danger to either·w~rker or employer . 
. ·mstead of helprng to cure him you assist rn . :.. ..• :· · .·· · . · He 1s as capable of demandrng manual · 
· spreading TB in your ar~. The untreated victim is . : · · ·1abolir or skilled work .as he was before he .contracted · . 
:~angerous to others. The worker be!na:tr~ted_for TB .. · . TB: ~o you needn't go·to the expense of findin_g and 
: ts 100% safe. Your workers and their fam,_lles are -: trarnrng a new worker. · · . · ·. . · 
depending on you. . . . . . . . . , , .. However. it's vital he takes his medicine daily. · . 
· .. ~B 1~ a v~ry serious problem facing · · ,.,..: _jtlis is y.,h~re. the employ~r can once again help. 
· South Afnr.a. There,are-62 000 reported new cases , · • .. ·. · If your company ,s Sf!lall ch·ec~ that he takes 
every year, _10 d~hs~daily and thousarios and · · -hitmedicine paily. _ff.your company is large appoint 
thousands of uorQp~rted. cases. · . · · . someone to check on this for you. · · ·.. · .. 
. If you're a.n employer ctfances are it's already : . . . You'll have helped keep_~ yalu_al)le _employee. 
· ·affecting your company. Which puts you in And a:fa.mily will have kept a valuable"breadwinner. · 
. an·invaluable position to help curb this epidemic. · · -'- · · · · 
. !:Fg~rci~1~!f ;~1P:1t~1epr\~t e~ery 1eve1.pu11 their .... ·-: ;
1
• • • ~ • • • •.• • • • ... I 
· . . · · · Please ·send me the · I 
· What can you do? · . I "H · · beat TB B kl t" · · ·· 
Firstly help us find the workers with TB and · ow yo~ ~n oo e · · · I 
~indhther to f~e·n~ar~_st cli_nic for a free h th·. h . . I Name .. : .... : .... '.'''·· ............ ; .............. '.... . . :I 
. c ec up.· e warning signs are a coug . at as · · · Address ................... : ... ;.................... I 
1
1
astedfmore tt~tan th.ree ~eehks, hlosst owf hwe
1
i_ght, d . _I _..: .. : .. .-:: .... : ............. ;· ....... · ............... .-.. ~ .. - . .:1 
oss. o. appe I e, parns .m t e c es . a ever you o, I . ; . · · . .. · . 
don t fire the worker with suspected TB: I .·soum AFRICAN NATIONAL · SANTA 
This will just spread the pro.ble_m ~(thout curing it. I · TUBERCULOSIS ASSOCIATION I ti 
· Yet the cure for TB 1s so simple. . · · · . , · . . . .· 
A course of tablets taken every day, for up to I• ii• • • Iii Ii••••••. I 
6 months.Jrom the day the worker takes his first pill Send this coupon to SANTA, PO BOX 10so1. JOHANNESBURG 2000 
Help Fight TB. 
FINANCIAL MAIL 30 May,1986 
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CHAPTER V 
ANALYSIS OF COST-EFFECTIVENESS RATIOS OF PREVENTIVE AND 
CURATIVE PROCEDURES FOR TB IN THE CDC 
Introduction: 
As information was severely limited in some areas and a number 
of assumptions had to be made to permit the quantification of various 
factors, the cost-effectiveness ratios calculated in Chapter IV 
should be seen as general indicators of the relative magnitude 
of each curative and· preventive procedure, and conclusive policy 
decisions should not be drawn purely on the basis of these ratios. 
They do however, provide a basis for certain comparisons, analysis 
and evaluation subject to the recognition of data limitations. 
As stressed in section 4 of Chapter II, the most important. task 
facing policy-makers is the determination of the most cost-effective 
combination of preventive and curative TB procedures. To facilitate 
this decision-making process and to emphasise what policy· decisions 
the ratios point towards, two sets of evaluations are performed 
in this chapter: 
a) The two purely preventive procedures, BCG vaccinations and second-
ary . chemoprophylaxis, are compared,. as are the two diagnostic 
procedures, mass screening and contact/suspect investigation. 
As the treatment of notified patients comprises the major part 
of the CDC TB programme the 'clinic' curative regimen is evaluated 
in detail. The first area of consideration is whether any 1983 





cases due to inadequate diagnostic techniques, and were thus 
treated 'unnecessarily'. The 'clinic' regimen is then compared 
with the 'official' regimen to determine whether the flexibility 
in application of the curative regimen prescribed by CDC author-
ities influences the cost-effectiveness of TB treatment signifi-
cantly. 
Finally, the ratios for two categories of patients, those treated· 
at clinics only and those who are hospitalised for part of· the 
treatment, are compared. 
b) The ratios for preventive and curative procedures are then compared. 
The BCG vaccination and prophylactic treatment ratios are 
expressed in terms of notifications prevented while the diagnostic 
and curative ratios are expressed in terms of notifications. 
To make this comparison, it must be recognised that the benefit 
of preventing one notification is the averted cost of diagnosing 
and treating/curing one notified patient. 
All of the cost effectiveness ratios are expressed in terms of 
the cost per notification prevented or the cost per notified patient 
diagnosed and treated. The · relative priority of each procedure, 
i.e. how extensive each 'catch net' should be ( see Section 4 of 
Chapter II), can be determined by comparing the cost-effectiveness 
ratios of preventive and curative procedures and shifting resources 




1. Summary of cost-effectiveness ratios: 
To facilitate comparison and discussion, the .cost-effectiveness 
.ratios calculated in Chapter IV are summarised here: 
BCG vaccinations -
R25 727.45 per TB notification prevented in Whites 
R 912.31 per TB notification prevented in Coloureds 
R 263.54 per TB notification prevented in Blacks 
Secondary chemoprophylaxis -
R 296448 per TB notification prevented 
Mass screening campaigns -
R 1 706.18 per notification arising from mass screening activities 
Investigation of contacts and suspects -
R 99.89 per notification arising from contact and suspect investi-
gation activities 
Curative regimen for notified TB patients 
R 769.43 per newly notified patient (i.e. per notification) 
R 859.51 per newly notified patient cured 
R 709.81 per newly notified/relapsed patient 
R 792.90 per newly notified/relapsed patient cured 
As stated in Chapter I, the primary purpose of producing these 
ratios is to provide support for the decisions of policy makers. 
The ultimate responsibility for deciding whether the cost per outcome 
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unit is justified or worthwhile rests with the policy makers. 
Thus, the responsibility of the analyst is not to determine whether 
each procedure is economically feasible, but rather to indicate 
what policy conclusions the analysis points· towards. 
It is important to evaluate ratios of purely preventive,investigative/ 
diagnostic procedures. and curative regimen ratios separately, 
before comparing the ratios for preventive and curative procedures. 
2. Evaluation of preventive procedures: 
The cost per notification prevented by secondary chemoprophylaxis 
and by administering BCG vaccinations in the Black population are 
similar. However, the costs per notification prevented by vaccin-
a ting the White and Coloured populations are significantly higher 
than the cost per notification prevented by secondary chemoprophyl-
axis. This is partly attributable to the higher cost of clinic 
services involved in administeri~g BCG vaccinations. The possibility 
of changes in the BCG policy to reduce the White and Coloured ratios 
will be considered in section 5.2. 
3. Evaluation of Investigative/diagnostic procedures 
In the case of mass screening campaigns and contact/suspect invasti-
gation, the same procedures are used and the cost-effectiveness 
ratios are ,directly comparable. It has been generally accepted 
for many years that the case yield of mass screening campaigns 
is substantially lower than investigation of contacts and suspects. 







As noted in Chapter II (section 3.~.2, point iii), efforts are 
being made to limit the pre-employment screening of workers. The 
Leonsdale survey was defined as a once-off campaign in its terms 
of reference, and given the low mean case yield of O. 52% :im a geograph-
ical area with a high TB incidence, this method of screening should 
not be used again. (Unpublished report on the Leonsdale survey.) 
The TBRI survey was primarily for research purposes to establish 
measures of TB incidence and prevalence, but was also used to find 
cases of TB. Given the urgent need for more TB research, this 
particular mass screening procedure should be continued despite 
its low mean case yield. 
'.4.· Evah1ati6n of'the 'clinic'' curative regimen: 
The cost-effectiveness of curative procedures will be examined 
in some depth as they accounted for 78% of the total cost of 
R 2 462 561.48 for the TB preventive and curative procedures in 
the CDC in 1983. 
Table V.l presents a summary of the costs involved in treating 
notified patients. 
The cost of drugs, clinic services and hospitalisation account 
for the largest proportions of the total cost of treating notified 
patients. Before evaluating these factors in more detail, a few 
comments on the loss in economic performance resulting from TB 
are necessary. 
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Table V .1 Breakdown of the costs of treating notified CDC patients 
in 1983 
Cost category Cost % 
Drugs R 168 722.80 8.77 
Tests during treatment R 21 138.61 1.10 
Follow-up tests R 7 071.95 0.37 
Treating relapses R 19 521.60 1.01 
Clinic services R 923 773.00 48.02 
Hospitalisation R 585 476.89 30.44 
Health Education R 16 882.52 0.88 
Disability grants R 78 723.70. 4.09 
Other grants R 23 225.00 1.21 
Loss in economic 
performance R 79 048.01 4.11 
TOTAL R 1 923 584.08 
4.1 Loss in economic performance:. 
Under the old treatment regimen, i.e. before Rifampicin was introduced 
as a first-line drug and included in the preferred treatment regimen, 
many patients were hospitalised for up to six months. Pearson 
(1980:589) indicated that the loss in economic performance for 
500 of these hospitalised patients amounted to R 372 000 per annum. 
Thus, the current CDC policy of only hospitalising certain categories 
of patients and instead treating the majority of patients by means 
of ambulatory/clinic based treatment has resulted in significant 






The loss in terms of earnings foregone of R 42 099. 80 due to the 
dismissal of workers suffering from TB, is a cost that can be averted. 
As indicated in Chapter IV (section 2.1.9), this cost was only 
calculated for the approximately 5 months of treatment. The period 
for which these: patients would be unemployed after dismissal could not 
be estimated. Given the high unemployment rate, the monetary and 
emotional costs of dismissals could have been higher than the 
estimated amount. 
Thompson and Myrdal (1984c:3) found that 7 of the 14 adults included 
in their survey who were employed at the time of contracting TB 
were dismissed for reasons associated with their disease, which 
indicates that dismissals are an important consideration for TB 
patients. 
By intensifying the health education programmes directed at 
employers, which are of low cost in comparison with the loss 
from dismissals, the number of dismissals can be reduced. In 
particular, employers should be reminded that it is unlawful and 
an unfair labour practice to dismiss an employee who has TB, unless 
they are unable 
. 1 
to perform the work required of them. None of 
the dismissed employees in the sample had been declared unfit for 
work. 






In general, the CDC should be commended on their efforts to minimise 
disruption of employed patients' work patterns .and to explain the 
nature of the disease to employers, and in particular for the steps 
taken by some of the doctors to persuade employers to reinstate 
workers suffering from TB who had peen dismissed. 
4.2 Drug costs and clinic services: 
It is noteworthy that despite the CDC treatment regimen containing 
Rifampicin, a relatively expensive drug, the drug costs only con-
tributed 8.77% to the total costs of treatment. When health author-
ities originally consfdered the use of Rifampicin as a first-line 
drug, many decision makers felt that the substantially higher unit 
cost of Rifampicin in comparison with other drugs used in TB treat-
ment, outweighed the gains in effectiveness. (Fox & Nunn 1979) 
Such considerations suggest that heal th care policy decisions should 
be based on analytical frameworks such as cost-effectiveness analysis 
to ensure that all factors affecting costs and effectiveness are 
taken into com;ideration. For example, although drug costs per 
patient increased with the introduction of Rifampicin, the cost 
of clinic services per patient was reduced due to the shorter duration 
of the new treatment regimen; in addition, the cure rate increased 
and the relapse rate decreased. 
To evaluate the drug and clinic services costs in more detail, 
two comparative analyses are performed. 
4.2.1 Treatment of uninfectious patients: 
An important consideration in analysing · the cost-effectiveness 
of TB treatment regimens is whether any patients are being treated 
unnecessarily, i.e. whether there are any false positive diagnoses. 
Chapter II (section 3.3.1) details the findings· of studies which 
have shown that X-rays are a relatively unreliable.form of diagnosing 
patients with active tubercle bacilli. In the case .of patients 
diagnosed as TB sufferers on the be-Sis of an X-ray but who neverth-
less had negative bacteriological results, the lesion visible on 
the X-ray may contain inactive tubercle bacilli or may be due to 
a lung disease other than tuberculosis. In some cases, the bacterio-
logical test may have produced a false negative result, due to 
factors such as inadequate sputum collection or inadequate storage 
of sputum specimens. (Toman 1979:10-11). Bacteriological tests 
are however generally regarded as being significantly more accurate 
and reliable than radiological tests. 
To illustrate the effect of treating patients with inactive tubercle 
bacilli diagnosed on the basis of an X-ray, the worst possible 
scenario will be examined, i.e. that all patients with negative 
bacteriological test results are not in need of treatment. 
The sample data indicated that 148 of the adult patients had recorded 
results for bacteriological tests. (A report that the sputum specimen 
was contaminated is not regarded as a 'result' . ) 109 (73.6%) had 
at least one positive test result whJle ·39 (26.4%) had at least 
one negative result while the other result was not positive. If 





if they were given bacteriological tests, then it can be estimated 
that approximately 660 (26.4%) of the patients notified in 1983 
need not have been treated. 
All the costs involved in the treatment of TB patients, as reflected 
in Table V .1, would be reduced proportionately if no patients are 
treated unnecessarily except for the cost of clinic services due 
to the cost of overheads and staff which are difficult to alter 
proportionately. 
If one however assumed that the clinic services costs were also 
reduced proportionately because fewer patients would require daily 
supervised treatment and other clinic services, R 507 826.20 (26.4% 
of the total 1983 treatment costs) would have been spent on treating 
patients unnecessarily in 1983. The cost-effectiveness ratio per 
notified patient would be unchanged. 
Conversely, if it is assumed that the cost of clinic services would 
be unchanged, i.e. would have been incurred even if only the 1 840 
notified patients who were bacteriologically confirmed were treated, 
R 263 950.13 (13. 7% of the total 1983 treatment costs) would have 
been spent on treating patients unnecessarily in 1983. 
It must be stressed that the objective here is not to dictate who 
should or should not be treated but rather to indicate that by 
not bacteriqlogically confirming diagnoses and thus treating some 
patients unnecessarily, a considerable misapplication of the limited 







Given the high incidence of TB and the apparent efficacy of heal th 
services in the CDC, it seems unlikely that such a large proportion 
of patients are treated unnecesarily. The responsibility rests 
with the CDC authorities to assess the significance of this factor. 
It is important to note that the major reason advanced by clinic 
staff and the heal th authorities of the CDC when questioned about 
the low rate of bacteriological confirmation, particularly at the 
Black clinics, was clinic staff shortages. This sometimes prevented 
the collection of sputum specimens from adult patients and also 
resulted in administrative inefficiency with respect to recording 
the results of tests that were conducted, once they became available 
from the State Health Laboratory. 
Unfortunately, the present study is unable to present specific 
data on additional staff needs, but it does appear that inefficiencies 
were largely a result of clinic staff shortages rather than training 
inadequacies. It is important for the CDC to generate more funds 
for this purpose. Once this initial step has been taken, it may 
emerge that a higher proportion of patients are in fact bacteria-
logically positive and thus not treated unnecessarily. 
Improving the staffing of clinics would also have other repurcussions. 
It would result in a higher proportion of defaulters and contacts 
being traced. As stated in section 1.6 of Chapter IV, the sample 
indicated that only 51% of the contacts recorded by clinics are 
! 
being investigated due to time limitations. Given the relati yely 
high mean case yield of contact investigation, its effectiveness 




The State Health authorities, who are the providers of a large 
proportion of the CDC funds for TB treatment, should be persuaded 
that an initial outlay for improved staffing is necessary. This 
would result in greater effectiveness of TB preventive and curative 
procedures at the CDC clinics and could reduce other cost compcments , 
such as the cost of treating patients 'unnecessarily', if the rate 
of bacteriological confirmation is increased. This could feasibly 
result in a reduction of the cost-effectiveness ratios. 
A major conclusion of this analysis is to reiterate the recommendation 
by Glatthaar (1982a:15) that all adult patients should be bacteriolog-
ically confirmed, to reduce misdiagnosis. In addition, it should 
be ensured that all clinic staff are given the appropriate standard 
of instruction in the collection and storage of sputum specimens 
to reduce the number of false positive and false negative results. 
4.2.2 Treatment using the 'official' CDC regimen: 
The major distinction between the findings of the sample data and 
the 'official' treatment regimen is the number of doses of drugs 
administered and the number and type of tests performed. In this 
analysis, the cost-effectiveness ratios of treating notified patients 
according to the 'official' regimen are calculated; It is important 
to note that the patients who would receive this hypothetical treat-
ment regimen are the 2 500 patients notified in 1983, of which 
300 were included in the sample described in Chapter III. One 
can assume that factors such as hospi talisati.on, clinic services, 
disability grants, etc. will be similar for 'official' and 'clinic' 
regimens. Thus, this section will be devoted to evaluating the 
drug regimen and prescribed testing procedures. 
I 




for the purpose of this analysis, that rates of default from treatment 
and follow-up procedures will be the same as that reflected in 
the sample data, i.e. will be the same for both the 'clinic' and 
'official' regimens. 
COSTS: 
i) Cost of drugs: 
The drug costs per patient using the original CDC treatment 
regimen are given in Tables E. 8 and E. 9 in Appendix E. The 
total costs of drugs for patients receiving this regimen would 
be as follows: 
Patients who completed treatment -
Adults 
Children 
1 207 patients x R 75.64 
706 patients x R 25.99 
Patients who defaulted -
349 patients x R 51.80 
R 91 297.48 
R 18 348.94 
R 18 078.20 Adults 
Children 238 patients x R 16.60 = R 3 950.80 
Total drug cost for the 2 500 notified patients 
ii) Cost of tests during treatment: 
R 131 675.42. 
The tests recommended by the CDC health authorities for assess-
ment purposes during treatment are: X-ray, sputum culture 
and direct microscopy for adults and X-ray for children after 
60 doses and again after 100 doses. (Fisher 1985:6). As 
sesi ti vi ty tests are only performed in specific circumstances 
and at the discretion of the doctor, it can be assumed that 
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the same number would be performed irrespective of whether 
patients were treated according to the 'clinic' or 'official' 
regimen. 
Based on this information and the cost per test as detailed 
in Appendix F, the costs of these tests will be as presented 
in Tables V. 2 and V. 3 ( assu'ming a similar proportion of tests 
before default to the 'clinic' regimen as reflected in the 
sample - 36 .05% of X-rays for adults and 37 .8% for children). 
Table V.2 Cost of monitoring tests for patients who completed 
treatment 
Test Adults Children 
X-rays R 6 107.42 R 3 572.36 
Sputum Culture R 10 138.80 
Direct microscopy R 4 055.52 
Sensitivity R 3 654.00 
TOTAL R 23 955.74 R 3 572.36 
Table V.3 Cost of monitoring tests for defaulters 
Test Adults Children 
X-rays R 636.62 R 455.22 
Sputum culture R 1 056.84 
Direct microscopy R 422.74 
Sensitivity R 176.40 






iii) Cost of follow-up tests: 
Follow-up X-rays are performed on both children and adults 
3 and 9 months after completion of treatment. Bacteriological 
tests are sometimes performed on adults in addition to the 
X-rays at the discretion of the doctor, and will thus be assum~d 
to be the same as in the 'clinic' regimen. 
Table V.4 Cost of follow-up tests 
Test Adults Children 
X-rays R 4 387.02 R 2 656.50 
Sputum culture R 1 457.40 
Direct microscopy R 729.12 
TOTAL R 6 573.54 R 2 656.50 
iv) Cost of treating relapses: 
It can be estimated that approximately 100 p8tients would 
have relapsed on the 'official' regimen, given a combined 
relapse rate of 4% for patients who completed treatment and 
defaulters. (Tibbit 1982:32). 
The total cost of ·drugs and tests, excluding any sensitivity 
tests, for the treatment of the 2 500 patients notified in 
1983 using the 'official' regimen, would have been R 167 350.98 
and the cost per patient would have been R 66.94. 
Thus it can be estimated that the cost of treating relapses 
would have been as follows: 
/1 
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R 66.94 per patient x 100 relapses 
2 R 25.20 per sensitivity test x 62 adult relapses 
v) Total costs of treatment: 
R 6 694.00 
R 1 562.40 
R 8 256.40 
If all other costs involved in the treatment of notified 
patients are assumed to be the same for the two regimens, 
the total costs of treating patients using the 'official' 
regimen would have been approximately R 1 886 566. 90 in 1983. 
EFFECTIVENESS: 
An effective cure rate of 96% is the most accurate estimate of 
the effectiveness of the 'official' regimen available. It is based 
on the relapse rate of 4%, including defaulters, determined a mean 
period of 20 months after completion of treatment, which was calcula-
ted from various studies conducted by CDC personnel. (Tibbit 1982:32). 
COST-EFFECTIVENESS RATIOS: 
The same set of ratios calculated for the 'clinic' regimen are 
presented here to facilitate comparison of the two regimens. 
2. This is based on the fact that 62% of the notified patients 
in 1983 were adults. Sensitivity tests are performed on a sputum 
specimen. In general, children are unable to produce sufficient 
sputum for a bacteriological investigation. 
/ 
I \ .,,.., 
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i) Cost of 'official' regimen per newly notified patient -
R 1 886 566.90 7 2 500 new notifications 
= R 754!63 per newly notified patient 
ii) Cost of 'official' regimen per newly notified patient cured -
R 1 886 566.90 ~ 2 400 newly notified patients cured 
= R 786.07 per newly notified patient cured 
iii) Cost of 'official' regimen per newly notified/relapsed patient 
R 1 886 566.90 7 2 600 newly notified/relapsed patients 
= R 725.61 per newly notified/relapsed patient 
iv) Cost of 'official' regimen per newly notified/relapsed patient 
cured -
R 1 886 566.90 7 2 496 newly notified/relapsed patients cured 
= R 755.84 per newly notified/relapsed patient cured 
The differences between these cost-effectiveness ratios for the 
'clinic' regimen and the 'official' regimen are not significant 
which lends support to the CDC policy of allowing a certain degree 
of flexibility in the application of the official regimen, based 
on the doctor's assessment of a patient's progress during treatment. 
4.3 Hospitalisation costs: 
It is significant that 30.44% of the total costs of treating 
2 500 notified patients in 1983 arise from the treatment of 484 
I 
patients in hospital for a mean period of 9.1 weeks each. To investi-
gate this factor further, cost-effectiveness ratios are calculated 
for patients who are hospi taliied and compared to the ratios for 
' 
/; 
patients who receive purelY, ambl,blatory treatment. 
I 
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The sample data showed that adult and child patients who were 
. hospitalised received a mean of 95. 5 and 88. 3 doses of INH respect-
i vely at CDC clinics after being discharged from hospital. This 
was not considered to be significantly different from the combined 
means for hospitalised and ambulatory patients, which indicated 
that their utilisation of clinic services upon discharge from 
hospital was similar to that for ambulatory patients. 
Thus, the total curative regimen costs, less the costs of hospi tali-
sation and the loss in economic activity attributable to hospitalised 
patients, are divided between the 484 (19.4%) patients who were 
initially hospitalised and 2 016 (80.6%) purely ambulatory patients, 
on a proportional basis. Hospitalised patients are treated in 
the same way as ambulatory patients when receiving clinic treatment 
and are subject to the same possibilities of dismissal from work 
etc. The cost which may be different is the cost of treating 
relapses. However, the relapse rate of hospitalised patients could 
not be accurately determined, due to the relatively small number 
of hospitalised patients included in the sample. 
hospitalised patients in the sample relapsed.) 
(1 of the 28 
The costs are then as follows: 
Hospitalised patients -
Costs of hospitalisation 
Loss in economic activity while in hospital 
Proportion of clinic treatment costs 
TOTAL 
R 585 476.89 
R 18 363.63 
R 256 030.25 
R 859 870.77 
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Note: These costs do not take the indirect non-pecuniary costs 
arising from the separation from families, etc. into account. 
Ambulatory patients -
Proportion of clinic treatment costs R 1 063 713.31 
As an accurate relapse rate estimate for hospitalised patients 
was not calculable because of sample limitations, the only cost-
effectiveness ratio calculated is the cost per newiy notified 
patient. 
Cost-effectiveness ratio for hospitalised patients -
R 859 870.77 7 484 patients= R 1 776.59 per notified patient 
Cost-effectiveness ratio for ambulatory patients -
R 1 063 713.31 . 2 016 patients= R 527.64 per notified patient 
The cost-effectiveness ratio for purely ambulatory patients is 
significantly lower than the ratio for hospitalised patients and 
the ratio for a combination of hospitalised and ambulatory patients 
- R 769. 43 per newly notified patient as calculated from the CDC 
'clinic' regimen. The 'hospitalisation policy should be reconsidered 
and every effort made to hospitalise only those patients who cannot 
be effectively treated by ambulatory means e.g. chronic defaulters 
and patients with advanced TB who are seriously ill. 
The importance and practical relevance of this finding is evident 
when it is noted that .certain local authorities, other than the 
CDC, are at present negotiating for the expansion of TB /hospitals 
/, 
and hostels. \ 
',t',' 
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It has been internationally accepted for many years that ambulatory 
treatment of TB patients is preferrable to and more cost-effective 
than hospitalisation. One study found that 
"The results in the former [Sani torium treatment], despite 
good accommodation, nursing, rich diet, and prolonged 
bed-rest, were not superior to those in patients treated 
in overcrowded homes, who had a poor diet, much less 
rest, and often very long working hours." 
(Toman 1979:128) 
There are two major arguments advanced in favour of increasing 
TB hospital facilities i) some local authorities disagree with 
the findings of the above-mentioned study as they have found that 
their ambulatory treatment regimens are not as effective as 
hospitalisation, especially in terms of the default rate. Authorities· 
should be encouraged to investigate methods of improving the default 
rate within the framework of ambulatory treatment. .For example, 
health education could be improved to emphasise the importance 
of receiving regular treatment and of completing the prescribed 
regimen; defaulters could be given domiciliary treatment i.e. if 
a patient ceases to attend a clinic for daily treatment, they could 
be treated .at home. The emphasis should be on making ambulatory 
treatment as convenient as possible for TB patients. The reasons 
for default must also be researched so that effective strategies 
for combatting it can be devised. ii) The TB notification rate 
is increasing and thus more patients require hospitalisation. 
It is once again stressed that only those patients who cannot be 
effectively treated by ambulatory means should be hospita~ised. 
r 
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5. Comparison of preventive and curative cost-effectiveness ratios: 
Section 4 of Chapter II indicated that there are in general, three 
TB risk levels. One or more of the TB preventive and curative 
procedures can be applied to each risk group to counteract the 
movement to higher risk levels. (see Figure II.8). The purpose 
of this analysis is to determine what combination of preventive 
and curative procedures should be implemented in the CDC TB control 
programme. 
Although diagnosis is usually regarded as a 'secondary preventive 
3 
procedure, for tne purposes of this analysis· diagnosis and treatment 
of patients will be combined. (Figure II.8 indicates that these 
are the two procedures applied to infectious TB cases.) 
The total cost of diagnosing the 2 500 newly notified TB patients 
in 1983, through mass screening and investigation of contacts and 
suspects, was R 317 176. 98 and thus the cost per notification of 
diagnosis is R 126.87. Al though this figure is somewhat overstated 
due to certain rpass screening procedures which are being eliminated 
at present, it does reflect the situation in 1983. The cost of 
diagnosing and curing one notified patient is R 986.38. 
3. Diagnostic procedures are preventive in the sense that by finding 
infectious cases at an early stage, the transmission of tubercle 
bacilli to others can be limited and the patient can be treated 
to reduce the risk of death. Primary ~reventive procedures 
such as ECG vaccination and secondary chemoprophylaxis can actually 




The cost per notification prevented by BCG vaccination or secondary 
chemoprophylaxis must be compared with the cost per notified patient 
diagnosed and cured. This comparison of preventive and curative 
procedures is based on the following relationship: the benefit 
of preventing one notification is the averted cost of diagnosing 
and treating one notified patient. 
5.1 Comparison of secondary chemoprophylaxis and the curative 
regimen: 
The cost of R296.48 per notification prevented for secondary chemo-
prophylaxis is less than the cost of diagnosing and curing one 
notified patient. Secondary chemoprophylaxis can therefore be 
considered economically feasible or cost-effective and should 
be an important component of the CDC TB control programme. 
5.2 Comparison of BCG vaccination and the curative regimen: 
The costs per notification prevented by vaccinating the Black 
and Coloured populations are less than the cost of diagnosing 
and curing one notified patient. 
However, the cost of R25 727.45 per notification prevented by 
BCG vaccinations in the White population is significantly higher 
than the cost of R986.38 per notified patient diagnosed and cured. 
This indicates that TB policy-makers need to assess the economic 
feasibility of vaccinating whites. 
As stated in Chapter IV ( section 2 .1.10) there are some indirect 
costs of notification such as the cost of symptomatic suffering 







costs can be included in the evaluation by calculating the difference 
between the quantified costs of , BCG vaccinations i.e. the 
cost per- notification prevented, and the quantified benefit i.e. 
the cost per notified patient diagnosed and cured. This 
can be restated as follows: is it a rational resourc:;e use to spend 
R 24 741.03 in averting the indirect symptomatic and mortality 
costs which may be incurred if one additional notification occurs 
in the white population. 
Two points should be noted here: a) Research is urgently required 
to determine the duratic:n of the protective efficacy of BCG vaccin-
ations to the South African population and whether revaccination 
significantly increases the protection afforded by BCG vaccinations, 
i.e. the policy of administering three BCG vaccinations to White 
children should be reviewed; b) Chapter II explained that socio-
economic factors were a major determinant of TB incidence which 
accounted to some extent for the racial differences in notification 
rates, but it is possible that if signific_ant changes were made 
in the vaccination policy for whites, TB incidence in this race 
grc,up may increase. 
The issue is thus very complicated ·and it is difficult to make 
conclusive policy decisions in the absence of comprehensive research 
into the protective efficacy of BCG vaccinations in S.A. One con-
clusion that can be drawn is tha't when considering the marginal 
TB notificatic:n prevented, given limited resources, more effor~ 
and funds should be expended on ensuring greater BCG coverage in 
the Black and Coloured population groups than for Whites. 
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6. Summary of analysis: 
In general, it is more cost-effect.i ve to prevent TB notifications 
than to diagnose and cure a notified TB patient. Heal th authorities 
must re-assess certain aspects of the TB control programme, based 
on the cost-effectiveness ratios for each procedure. 
These ratios are expressed in terms of the average cost per 
notification prevented or the average cost per notified patient 
diagnosed and cured. Resources should be -re-allocated, gi-v-i-ng 
priority to those procedures with the lowest cost-effectiveness 
ratios. Once this resource re-allocation takes effect, the 
disparities between the cost-effectiveness ratios will be reduced. 
It will then be important to base any further cost-effectiveness 
analysis on the marginal cost per notification prevented/notified 
patient diagnosed and cured, as the most cost-effective combination 
of curative and preventive procedures will be achieved when the 
marginal costs of all procedures are equal. 
Waaler (1978:2-3)
4 
explains that when determining the allocation 
of limited resources, 
"The relevant thing is the marginal impact, or rather 
the marginal epidemiological impact that one can obtain 
for a given amount of money. It is not a question of 
whether BCG can produce 10% or 90% of the problem reduction, 
but how much problem reduction one can obtain with $1 
in the direction of BCG as compared with another direction. 
The solution is in fact achieved when the marginal 
impact is the same in all directions, because if this 
is. not the case, it would pay to transfer some resources 
from one direction into another direction." 
4. Although Waaler argues in terms of the marginal notification 
prevented/notified patient diagnosed and treated per unit c~st 
I 
rather than the marginal cost per notification prevented/notified 
patient diagnosed and treated, the principle of equ~ting/ the 
marginal ratios is the same. \ ' 
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Certain policy conclusions are indicated by the analysis presented 
in this chapter: 
i) Vaccination of the Black and Coloured populations and secondary 
chemoprophylaxis should be prioritised in the overall TB control 
programme. 
ii) The policy of administering vaccinations in the white population 
and of conducting mass screening campaigns must be reconsidered. 
iii) Patients should only be hospitalised if they cannot be effect-
ively treated by ambulatory means e.g. if the TB is in an 
advanced stage or if the patient is a chronic defaulter. 
iv) Bacteriological confirmation of patients must be improved 
to reduce the number of 'false-positive' cases treated 
'unnecessarily' . 
7. Changes in preventive and curative TB procedures since 1983: 
As the analysis presented in this study is based on 1983 data, 
it is necessary to determine whether there have been any significant 
changes in TB policy since 1983 which could influence the findings 
summarised above. 
There have byen few changes in the curative and preventive procedures 
prescribed by __ the CDC since 1983, other than an attempt to reduce 
the number of mass screening investigations performed. However, 




average annual increase in TB notifications between 1983 and 19855 
and thus more patients requiring treatment, and ii) inflationary 
6 cost pressures. 
The major changes in TB treatment and preventive, activities since 
1983 are related to political factors, more specifically the 
'political unrest' in Cape Town since August 1985. During the 
initial 'unrest' in August 1985, many of the CDC clinics in both 
the Coloured and Black areas were closed for various time periods, 
as the CDC authorities felt that the safety of the staff was 
uncertain. 
Clinic services returned to normal within a few days in the Coloured 
areas. However, the Nyanga and Crossroads clinics were closed 
for longer periods of time which resulted in quite severe disruptions 
in the provision of TB clinic services. 
7 
These two clinics were 
also affected by the 'squatter crisis' in May/June 1986. 
5. CDC TB notifications, according to race, in 1984 and 1985 were 
as follows; 
1984 1985 
Whites 28 36 
Coloureds 1 520 1 820 
Blacks 1 202 1 555 
TOTAL 2 750 3 411 
6. For example, the drug costs for treating one adult patient accord-
ing to the official CDC regimen were R 122.83 in 1986 comr,ared 
with R 75. 64 in 1983, i.e. an average annual drug price increase 
of 20.8%. 
7. The daily TB clinic attendances at Nyanga for the period July-
October 1985 were: July - 8 487, August - 2 077, September -
2 861, October - 3 251. (Unpublished CDC records). 
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The provision of TB services was affected in the following ways 
during the unrest: i) The treatment of TB patients was interrupted 
as no drugs were administered while the Nyanga and Crossroads clinics 
were closed. This could have reduced the effectiveness of the 
CDC treatment regimen. In addition, other TB services such as 
the administration of BCG vaccinations, contact tracing and prophyl-
actic treatment were adversely affected by the closure of clinics. 
ii) CDC X-ray uni ts and doctors did not enter the Black townships 
for a year (August 1985 - September 1986). Black patients were 
transported from Nyanga and Crossroads to either the Vasco (Goodwood) 
or Philippi clinics for radiological and clinical examinations. 
This would have resulted in greater transport· costs and an increased 
work-load for staff at the Black clinics. In addition, the indirect 
cost to patients in terms of time spent at clinics for examination 
purposes was increased. 
The Nyanga and Crossroads clinics lost contact with many TB patients 
during the 'unrest'. This was a particularly significant factor 
during the 'squatter crisis', when squatter refugees were sheltered 
in halls in many different residential areas in the Cape Peninsula. 
Some of the refugees suffering from TB were too far from a TB clinic 
and thus did not report for daily treatment, while others feared 
ostracism from fellow-refugees. The latter reason was highlighted 
by St. John's ambulance who stated that 
" it was "obvious enough" 
facilities and rations with 









This loss of contact with TB patients and the resulting treatment 
disruptions would also have adversely affected the effectiveness 
of TB treatment. 
In summary, inflationary increases in TB treatment costs since 
1983 were unavoidable, as were the effects of the unanticipated 
'unrest' situations. However, given that the incidence of 'political 
unrest' is unpredictabl~, and based on the experiences of the 
1985/86 'unrest', contingency plans should be considered now to 
avert certain of the increased costs and changes in effectiveness 
related to interruptions in treatment regimens and loss of contact 
with patients. For example, increased co-operation between the 
various relief organisations and heal th authorities during 'unrest' 
could result in speedier tracing of TB patients and recommencement 
of treatment. 
The influence of 'unrest' on the costs and effectiveness of preventive 
and curative procedures for TB cannot be quantified at present, 








The primary objective of this study was to evaluate, in cost-
effectiveness terms, the various preventive and curative TB pro-
cedures currently used by the CDC. 
The major findings of this analysis were as follows: 
i) It is more cost-effective to prevent TB notifications by means 
of secondary chemoprophylaxis and BCG vaccination of the Black 
and Coloured populations, amongst whom the highest incidence 
of TB is recorded, than to diagnose and cure notified TB 
patients. 
ii) In the case of screening procedures, it was found that contact 
and suspect investigation should be prioritised. Conversely, 
mass screening campaigns were found to be costly and to have 
a low mean case yield and should thus only be used as a method 
of investigation in exceptional circumstances. 
iii) The sample data indicated that the TB treatment regimen origin-
ally prescribed by the CDC heal th authorities ( called the 
'official' regimen in this study) is not strictly adhered 
to by clinic staff. CDC doctors are permitted a degree of 
flexibility in the application of the drug regimen, based 
on their assessment of a patient's progress during treatment. 
I 
The regimen is also affected by the availability of drugs 
from State Health. The comparison of the 'official' and 
'clinic' regimens indicated that there was no significant 
difference in the cost-effectiveness of the two regimens and 
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thus, that strict adherane:e to the 'official' drug regimen 
should not be a primary concern of CDC Health authorities. 
iv) The sample also indicated that a relatively large proportion 
of adult patients are not bacteriologically confirmed as TB 
cases. Diagnosis on the basis of radiological examinations 
alone could result in a significant number of 'false-post ti ve' 
diagnoses. These patients would be treated 'unnecessarily' , 
resulting in a considerable misapplication of the lim:. ted 
funds availab1e for TB control. This analysis therefore suggests 
thc1t all adult patients should be bacteriologically confirmed 
to reduce misdiagnosis. 
v) It was found that ambulatory treatment of TB patients was 
considerably more cost-effective than hospitalisation. Thus, 
only those patients who cannot be effectively treated by 
ambulatory means should bE, hospitalised. 
In summary, resources available for TB control should be reallocated 
in the directipn of secondary chemoprophylaxis, BCG vaccination 
administration in the Black ;;md Coloured populations, investigation 
of contacts and suspects and ambulatory treatment of notified TB 
patients. Conversely, vaccinating the White population, mass screen-
ing campaigns and hospitalisation of TB patients should be given 
relatively less emphasis in the overall TB control programme. 
In addition, this study found that the incidence of 'political, 
unrest' since August 1985 has adversely affected TB control measures, 
especially in terms of interruptions in the treatment of TB patients 





to continue in the foreseeable future, the realities of the political 
situation should be borne in mind when evaluating TB control 
techniques. 
These findings essentially relate to ~hort-term policy considerations, 
i.e. they would be affected by major changes in the socio-:-economic 
and political climate. Thus, in the longer term, two factoric, seem 
likely to influence the cost-effectiveness ratics presented in 
this study. 
i) Current increases in factors such as unemployment indicate 
that the incidence tif TB, particularly amongst the Black and 
Coloured populations, could increase. 
ii) The problems faced by the CDC heal th authorities are likely 
to be enhanced by the liberalisation if influx-control measures. 
The 'homeland' areas provide a continual source of infectious 
cases which will contribute to the increasing incidence of 
TB in the CDC Black population. 
As TB notifications increase, not only will the staff quotas at 
existing clinics be expanded, but the number of clinics will also 
be forced to rise, with the attendant overhf,ads that this will 
entail. Few, if any, economies of scale can be expected in anti-
tuberculosis services, given that population expansion is likely 
to be accompanied by the formation of new townE.hips/suburbs in 
addition to increaE:ed density in existing areas. The problems 
of contact and defaulter tracing will increase with population 
density, while new clinics will have to attend geographical spread 
of the townships. 
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A study of this nature is based on certain ceteris paribus assumptions. 
The findings wi 11 thus be affected by factors such as changing 
socio-econcmic conditions and the introduction of new preventive 
and curative procedures for Tuberculosis. 
Cost-effectiveness ratios should be re-evaluated when changes i-n 
these ceteris paribus assumptions occur, and the combination of 




APPENDIX A COST-BENEFIT ANALYSIS THEORY 
The most conunon form of the equation used for determining 
whether a project is economically feasible (i.e. the CBA 
decision rule) is: 
T T 
~ > 0 
t=l t=l 
where Bt = Benefits in time period t; 
ct = Costs in time period t; 
r = discount rate; 
and T = time horizon/period over which benefits and 
costs are calculated. 
Taking into account the fact that CBA has its roots in welfare 
economics, and has been closely linked to the concept of pareto 
optimality in particular, the decision rule could be restated 
as follows: A project will be considered economically feasible 
if it is able to generate an excess of benefits over costs, so 
that by a costless redistribution of the gains, no one will be 
made worse off by the project while some will be better off. 
(Mishan 1975: xii and Pearce 1983: 16). 
It should be noted that as CBA is merely an aid to judgement and 
is balanced by the judgement of decision makers, economic feasi-
bility is not a sufficient condition for the adoption of a progrannne. 
As the 'costless redistribution' described above is in general 
merely hypothetical, the lobbying power of either those who would 




project under consideration could infl~ence the final decision. 
The starting point for the actual calculation of costs and 
benefits is the concept of 'willingness-to-pay'. Thfs can 
be defined as the maximum sum of money a consumer would be 
willing to pay'for a given quantity of a good which is equal 
to the amount he/she actually pays plus the consumer surplus~ 
(Mishan 1975: 27). 
This can be represented diagramatically as follows: 
Price 
Quantity 
AC= Demand Curve 
OPBQ = amount ac,tually paid for quantity Q of the good at price P 
PAB = consumer surplus 
OABQ = OPBQ + PAB = 'willingness-to-pay' 
The use of a simple Marshallian demand curve 1n these calculations 
could produce a margin of error, as it does not take the income effect 
into account. Most CBA advocates recorranend that an adjusted demand 
curve (as originally introduced by Hicks), be used. This curve depicts 
changes in the consumer's utility in response to price variations, 
while the money income is varied to ensure that the consumer remains 






adjusted demand curve is known as the compensating variation. 
(Peatc~ 1983: 28). 
Mishan (1972: 16) defines the compensating variation, emphasising 
the pareto basis of CBA, as 
II the sum. of money (which) if 
paid or received after the economic 
change in question, would make the 
individual .no worse or better off 
than before the change." 
Thus, benefits are estimated by calculating the 'willingness-to-
pay' for the project, which is composed of the actual amount paid 
(i.e. the market pric;e of the project output x the quantity of the 
output) plus the compensating variation (CV). In circumstances where 
this procedure is difficult to implement due to information constraints, 
'shadow prices' are used to estimate the benefits. Pearce (1983: 33) 
describes this process as the measurement of 
II the gain in the value of some 
objective if we increase expendi-
ture on a given project by one 
unit." 
The costs of a project can be similarly estimated if they are viewed 
as opportunity costs. In this case, the 'willingness-to-pay' for 
the forgone benefits of an alternative project would be calculated. 
However, the practical problems involved fn such a procedure 
generally prohibit its use. Thus, costs are normally estimated by 
calculating the marginal product of each project input, although the 
market price of an input will only equal its marginal pro9uct under 
conditions of perfect competition. This has resulted in the use of 







in a specific project. 
In addition to the estimation of direct project costs and 
benefits, the less obvious spillover effects and externalities 
must also be included in the analysis. Care must be exercised: 
so that only the difference in an individual's welfare which 
results from the particular spillover effect in question is 
considered. 
Benefits and costs which will only materialise a year or more 
after the implementati:on of the project, must be discounted to 
obtain the net present value (NPV) of all costs and benefits. 
There is a continuing debate about which discount rate is most 
appropriate for use in CBA. (See ·for example: Layard 1980: 243-332 
and Pearce 1983: 37-58). The two options most frequently considered 
are: 
1) The marginal net product of capital/the social opportunity 
cost of capital (r) and 
2) The social time preference rate/the rate at which society is 
prepared to trade present for future consumption(s). 
Whichever rate is selected, it must be expressed in real terms using 
the same base year that was used to express the costs and benefits 
in real terms. If a society is operating at the constraint maximum, 
i.e. is on the highest possible social indifference curve given the 
constraints of the specific transformation function, 'r' will equal 
's'. (Pearce 1983: 40-44). 
178 
" There is some controversy over whether distributive effects 
should be taken into account in a CBA. Pearce (1983: 62) 
stresses that the use of distributional weights in a CBA 
will not ensure that income distribution is improved once 
a selected project is implemented, but the purpose is rather-
to reco_gn~se the importance of both distributional and 
efficiency factors. Most conunentators agree that if distributive 
weights are used in a.CBA, a range of different weights should 
be compar~d by means.of sensitivity analysis, as there is no 
single, generally accepted method of calculating the value of 
these weights. 
Mishan is opposed to the use of distributional weights. He 
argues that the correct way to take distributional factors into 
account is to include other criteria in the .decision rule. Not 
only should benefits exceed costs before a project will be 
considered economically feasible, but the resulting distributional 
changes should not be regressive and no_ gross inequalities should 
be perpetrated. (Mishan 1972: 13) 
With regard to risk and uncertainty in the estimation of variables, 
there are numerous proposals but no agreement on how this problem 
should be taken into account, other than reconnnendations that a 
sensitivity analysis be performed to indicate how the outcome of a 
project evaluation would be affected by changes in these variables. 
/; 
\ \ .,,,, 
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APPENDIX B - DISTRIBUTION OF DRUG DOSES TO PATIENTS IN SAMPLE - - --- -
The following figur·es illustrate the distribution of doses of each 
drug administered to patients included in the random sample. They 
are presented according to age i.e. adults ( 15 years of age and 





· INTERVAL - - NA '.rv, E- - . . ------- 5 1 0 1--S- 2 0 2 5 3 0 3 5 4 0 4 5 , U 5 5 6 0 6 5 7 0 7 5 S 0-
+ - - - - + - - - - + - - - - + - - - - + - - -~+----+----+----+----+----+----+----+----+----+----+----+ 
OTOS + 




____ 26T030 ... ____ + ·-----------·-




. 4oT050 ____ +A _________ ---------------------------




















-------.. ~--·· ~--------·-·------------ --








.. 1 8 6 TO :1 9 0 __ + ___ _ ------- - - -- ----- -··-- --- ··---- .. -----·-·- -- .... - -~·-- - ~----· --~-. - - -- ------- .-------· 
191T0195 +A 
196T0200 +AA 
201 T0205 + 









-----·-··--- --·-· ·-----~---- ---·· ------·------
- - -· ····-' --· -- . ----·----- ... -~·--. -----.246T0250 + 
OVER250 + +----+----+----+----+----+----+----+----+----+----+----+----+-~--+--~-+----+----+ 80 5 10 1 5 20 25 30 35 40 45 50 55 60 65 70 75 





































.TNTERV.AL. __________ ..... ------~ . .. . .. 
NA M E 5 1 0 1 5 ~--z,-·-·-:nr- 3 5 -·-4(J- -4""5" 5 0 ·,s~-U 6 5 7 0 7·,---s-c, 
+----+----+----+----+----+----+----+----+~---+----+----+----+----+----+----+----+ 
OTOS + ... . ~T~ 6 ~ 5 .... ····! A ___ -- ... ··---------· -----···------------·· ··------------
16TO20 + 
21T025 + 
. 26T.0.30 _____ +.AA. 
31T035 + 
36T040 + 
41 T045 +A. 
4 6 T 05 0 .. +.AA ....... --· ___ _ 
51T055 + 
--- ----- -----------
----·--------- ··-·-··- --- - -- ·- -- ·-- ·- -------- -------
56TOb0 +AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
61T065 +AAAAAA 
~~+8~~ - <t:~:---------------- -------·-- --------
76T080 +AAAAAAA 
81T085 +AAAA 
... 86 T090 + A.AA __ ---·-·· 
91T095 +AAA 
96T0100 +AAAAAAAAAAAAAAAAAAAAAA~AAAAAAAAAAAAA 
101T0105 +AAAAAAA . --1-~ ~-+g ~+~--!-!A.A A.AA.AA. ________________ . ____________________ _ 
116T0120 +AAAAA 
121T0125 +AAAA 
' ' ... 126 T.0.1.3.0 .. _ +.A A A AAA.A A A AA _________________________ _ 
· --131T0135 +AAAA 
136T0140 +AAAAA 
141T0145 +AA 








.. 18 6TOl.9 0 __ + 
191T0195 + 
. 19oT0200 +A 
201T0205 + 
-----------·-------·-----·--------------------~ 









. -~~~i~§5°- !--··-···-- .. --- -------------·-------- -------------------- ------------------------
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 














0 / :::, 
0 
Hi 






















- ....... - .- ;·'>?- s,-,,c, ,·_c.,;~~'~. ,,....· ,., ·.•h 
-· .. IN.TERVAL ..... __ -------------------------------NAME 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 +----+----+----+----+----+----+----+---.-+----+----+----+--~-+----+----+----+--~-+ 
OTOS +AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 




____ 2 6 JO 3 Q ______ +_AAA.._ .... ______________________ _ 
31T035 +AA 
36T040 +A 
41T045 + ~ t~ +8 ~ ~ -· ! ~ ~~A ti -- -- -- -- ------ ------------- --------------- --- --------- ---------------
5bT060 +AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
61T065 +AAAAAAAAA 
















-·---·-·--- -------- - ------













-- --·------ ------ ---- -·--·--··-------------------·-·-·-------








------------- --------· ---- ·-----·--· ------~----
---··--- ---- ----·----·---- ---------<--~-------
---- ___________ , ______________ _ 
8~~~-~~6° --:--------·--------- --- ------------------ ...... ----·-·- ------ ----
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 













































_. INT E RXA L __________ ------ -- - -------- __ - _ ____ . -· . _ _ ... --- . ·--· ----' ... - . . ... 
NAME 5 · 10 1 5 20 2 5 30 3 5 40 - -z;,- ,u- ,5- ocr--o5 70 -75----8--0-· 
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 
OTOS +AA 












~ ~ + g ~ ~ ____ ! ~~AA A_A A _____________________________________________ _ 
76T080 +AAA AAA 
81T085 +AAAA 




























226T0230. + - . -- ---------- .... --- ----- ---------------
2 3 1 T O 2 3 5 + --
2.S6TO240 + . 
241T0245 + 




5 10 15 20 25 30 35 40 45 50 SS 60 65 70 75 80 



















































. 46 TOSO __ +AA~ ___ ---------------------------------------___ .......... 
51 TOSS +AA 
56T060 tAAAAAAAAAA 
61T065 AAAA 
"_,_6.61:070 _____ +AAA _____________________ _ 






































-· - -------·--·----- ·-·--·------------. -----------------
-8 ~ ~ ~ ~ ~ 6 Q ___ !-------- -- -- ----------- ----- -------- ·------------------·--- ---------- -------- . -------------- --- ------
+ - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - + - - - - +- - - - +- - - - + - - - - + 
5 10 15 20 25 30 35 40 45 so 55 60 65 70 75 80 







































-~~~@RVAL ___________ ·3- ---·ra·-:--·-rs·-- 20 ___ z,·--·--)n--5)--z.l)-----z;y---,u---s,~cr 65 ?o rs----a-o-
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 
OTOS + 








46T050 ... _+ ___ .. -------- -----
51 TOSS +A 
56T060 +AAAAAAAAAAA 
o1T065 +AAAA 










1 0 6 TO l l O .+A. ___ -------·--------------------------- ______________________ _ 
111T0115 +AAA . 
116T0120 +AAA 
121T0125 +A 

























- ---- _ _.~------ ------~--~- -- ---- ·-·-
--··--- ---- ------------
8~ ~ ;~ § 8 ° ! . ······ -- ·----- -·· -----------------------· ------ ·- ----------------------------------· ---------- -----. ---
+--- - +- -- -+----+-- -- +-- -- ·----+--- -+- -- -+----+----+----+----+----+----+----+----+ 
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 













































-----~~-~§RVAL_ -----··s·----1(}--1·5~2~-· 25 30 35· 40 45 so 55 oer 65 7.0 ...... 75 a-o-
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 
OTOS +AAA. 




----- .2 6 T 03 Q ________ +A A.A.A.A.AAA ___________________ _ - ··- -·- - - - ·- -------- -- ---------- ------------------31T035 + 
36T040 +AAAAAA 
41T045 +A 






















--------------- ~---- . ---------------------------·--------------
------- -· - . - ----- --- -------- ---------- ------------ ------ -- ----------------------
141T0145 ,+ 
14 6 TO 15 0.J.t_ . - _ --- ------- _____________ _ 
, , 151T0155 + 
156T0160 + 
-,61T0165 + 









2 iJ 6 TO 210- + -- ------------------------ ---------------------
211 TO 21 S + 
216T0220 + 
221T0225 + 




.24 6 TO 2 5 Q ____ t __ ---------------------------- --------- ----------------------------------
0Vi::R250 + +----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 


















..... ' 0 
CXl H, 
O'> 


















-· .-. w ..,_ ... ~ ~ • -· ···.,.r··...-::.i.i .. c1:5",·.:'e,•- ... ·- '-lit:'!-·"'""'; 
~~-AgRVA.Ll . . s 10 15 20 . 25 30 35 40 45 - 50 55 60 65 70 ;5--ro-:-
+----+----+----+----+----+----+----+----+----+----+----+----+----·----+----+----+ 
-0105 +AAAAAAAA -




---26T0.30 ______ +.AA_ - ··-- ----------
31 T035 + 
361040 +All 
41T045 + . 












































·----·-------- --- --- .. ------------------------~-













































INTERVAL .. -······--····-···------··------------·----·-·=--=--NA ME 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5 5 0 5 S ou-~ 7 0 ,, 8 0 
+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+----+ 
OTOS +AAAAAAAAAAAAAAAAA 




... 2-6-T 0.3.0- _____ + A A ....... _ -- - -
31T035 + 
36T040 +AA 
41 T045 +. 




·- ~-~- f g-~ ~--- --: ~-~AA A-----------------------------------------------
76TO80 +A 
81T085 +AA 
.. 86.T090 ... ___ +_AAA..A .. -----------------------·--····--
91 T095 +A 
96T0100 +AAAAAAAA 
101T0105 +AAAAA -·-l ~ ~+811~ : A A------------------ --- --- . ------------· 
116T0120 +AA 
121T0125 + 









• . 166T O 1 7 0 + 
171T0115 + 
176T0180 + 
-- ..... _______ . -· --- - .. ------- --------------
131T0185 + 








- ·- -·-··. - --- -- . ------·----- ----- --- -·· .. ---- ---· - - . ------~------------··------------------------------




246T0250 + ----- --- -- -, - ·-----~------ ------ ----------
















































APPENDIX C - APPORTIONING THE COST OF CLINIC SERVICES TO VARIOUS 
PREVENTIVE AND CURATIVE PROCEDURES FOR TB 
The c·osts of staff, facilities, transport etc. for all the CDC 
clinics are combined into one expenditure figure. A range of 
different services are provided at the clinics, e.g. services for 
Tuberculosis, child health, sexually transmitted diseases and 
family planning. A survey has been conducted in an attempt to estimate 
the amount of time spent by clinic staff on each servLce, but the final 
results are not yet available and the researcher (Dr Fisher of the CDC) 
considered the response to the questionnaire to be inadequate, 
The CDC does however record the number of people who attended clinics, 
according to the particular service rendered. These figures are 
reproduced in the M, O. H. 's annual report and will be used in this 
study. 
There are five main categories into which ,services provided by CDC 
clinic staff for the prevention and treatment of TB are divided: 
i) Established sessions at which doctors are present and which 
are devoted to the examination and investigation of contacts 
and suspects, the evaluation of the progress of notified TB 
patients during treatment and to follow-up investigations of 
TB patients who have completed treatment; 
ii) Daily attendance, which reflects the supervision of daily treat-
ment of notified patients and the dispensing of weekly supplies 
of INH tablets to parents or guardians supervising the 






iii) Domiciliary treatment, which accounts for the provision 
of supervised daily treatment at a patient's home if 
they are unable to attend a clinic, or at work if alternate 
supervision cannot be organised; 
iv) Mobile cl_inics, which are mainly concerned with the prelimi-
nary investigation of suspects; and 
v) Home visits, which record the number of visits made by clinic 
staff to trace defaulters and contacts. 
In addition to these clinic services which are concerned only with TB 
prevention and treatment, BCG vaccinations are performed during the 
child health sessions and are thus included in this category. Heaf 
tests and BCG vaccinations performed at schools by the schools immuni-
sation team are not included under clinic attendances and thus have to be 
specifically taken into account. 
Table C.l gives the breakdown of the clinic attendances according to 
the five main categories of services: 















(Data from Divisional Council of the Cape 1983: 64 & 108-128, and 
unpublished records of CDC). 
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1 15 945 BCG vaccinations and 1 573 tuberculin tests were 
performed by the immunisation team at schools in 1983. The 
other 16 092 BCG vaccinations were included in the clinic 
attendance figure for child health services. 2 
The total number of clinic attendances, mobile clinic services 
and home visits for all other non-Tuberculosis clinic services, 
except family planning which has a separate expenditure account, 
was 506 237 in 1983. When the BCG vaccinations given at chfld · 
health sessions are deducted, the total is 490 145. 






Sunnnary of services provided by CDC clinic staff in 1983 
No. of people utilising these services 






Total 837 715 
1. Two attendances are necessary for every tuberculin test - one when 
the test is originally performed and another to' read' the test 
(48-72 hours later). Thus, the number of attendances for tuberculin 
testing at schools is 3 146. 
2. The 32 037 and 3 146 clinic attendances for BCG vaccinations and 
tuberculin tests respectively, are added to the 312 387 other TB 






Note: By combining all the figures for clinic attendance, one is 
assuming that all attendances require the same time and thus that 
each attendance has the same cost value. This is not necessarily. 
true as dispensing and supervising the administration of drugs to 
a notified TB patient would take less time than the examination and 
investigation of a contact/suspect at an 'established session'. When 
the conside~able administration involved in recording the number of 
doses administered, results of bacteriological tests,_ etc. is taken 
into account, these discrepancies will not necessarily be that signi-
ficant. Given that clinic services have to be accounted for when 
evaluating each procedure and that no viable alternative method for 
apportioning costs exists at present, these deficiencies are merely 
noted and it is stressed that every precaution has been taken to 
ensure that all available, relevant information has been taken into 
account. 
The total CDC clinic services expenditure for the 1983/84 financial 
year was R2 756 916. (The cost of the schools innnunisation team is 
included in this figure). The only other CDC Health department expen-
diture item that needs'to be taken into account here is administration 
costs. The costs of the head office of the Health department, which 
' 
is responsible for the administration of clinic, family planning, __ 
heal-th inspectorate and health education services as well as the 
mobile X-ray unit etc., were apportioned to the respective sub-depart-
ments on a proportional basis, according to the total expenditure of 
each sub-department, In general, the head office administration 
responsibilities are proportionately related to the size, in terms of 
staff, of the respective sub-departments. As the major expenditure 
item in each sub-department is staff costs, it was decided that sub-. 
department expenditure totals should be used to apportion administration 
costl,. The proportion of administration costs attributable to clinics 
; 
wa~ 'R499 148. 
,y 
193 
" The total expenditure on CDC clinic services, including an admini-
stration fee, of R3 256 064 for the 1983/84 financial year can be 
divided between TB ·and 'other' services in the following way: 
Cost of TB clinic services= R3 256 064 X 41.49% = Rl 350 941 
Cost of 'other' clinic services= R3 256 064 X 58.51% = Rl 905 123. 
The Rl 350 941 must now be apportioned to account for the services 
provided for each preventive and curative procedure for TB. The 
proportion of procedures falling 1.nto each category of TB clinic 
services is estimated using information from the sample findings 
and other sources. These calculations are closely linked with infor-
mation presented on each procedure in the body·of the text and thus 
the reader should refer to the relevant section in Chapter IV if any 
calculation is unclear. It is suggested that this appendix be read 
after Chapter IV to avoid unnecessary cross-referencing. 
a) Established sessions: 
As radiological examinations are performed at 'established 
sessions', .-the total number of X-rays in 1983 provides a 
good indication of the breakdown of these sessions. 
Table C. 3 Numb-er of radiological exminations performed .1n 1983 
Category of people investigated . No. of X-rays 
Notified patients 10 475 
Contacts/suspects 23 153 
'Other' (mass screening) 8 737 
Total 42 365 





These figures need to be adapted as some patients, contacts 
and suspects are required to make an additional clinic visit 
after being X-rayed. Notified patients: Each time a notified 
patient is X-rayed, they must also see a doctor who wili assess 
their progress based on the X-ray, once it ha!;l been developed, 
i.e. two clinic attendances for every X-ray taken. Thus the 
. number of 'established session' attendances by notified patients 
is 20 950. 
Contacts/suspects: Those whose X-rays were normal did not have 
to return to see a doctor •. However, the 2 500 notified patients 
who were originally X-rayed as contacts/suspects would have 
returned to see a doctor as their X-rays indicated the presence 
of active TB. Child contacts/suspects may be given a tuberculin 
test at the same time as the radiological investigation and must 
return to have the test 'read' within 48-72 hours. 4 489 such 
tests were performed in 1983. By.adding these additional visits 
to the number of X-rays performed on contacts/suspects, it is 
estimated that there were 30 142 'established session' clinic 
attendances by contacts/suspects in 1983. 
Mass screening: 6 256 X-rays were performed during pre-employment 
screening and 2 481 during the ''Leonsdale Survey'. When the· 
. . 
additional clinic ettendances for 'reading' of 715 tuberculin 
tests performed during the 'Leorisdale Survey' are added to the 
number of attendances for radiological examinations, it can be 
estimated that there were 9 452 'establishe<l session' clinic 
attendances for mass . .screening purposes. 
Table C.4 presents these revised figures and the respective 
proportions, and the reyvlts of allocating the total established 
\ ~ 
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session attendances, 60 852, to each category. 
Table C,4 Breakdown of 'established session' attendances 
























Parents/Guardians of patients receiving secondary chemoprophylaxis 
would have made an average of 9 visits to the clinics to collect 
tablets if the patient completed treatment and 3.7 visits if they 
3 absconded before completing treatment. Notified patients' 
attendances were calculated in terms of the mean number of doses 
they received, as reflected in the sample findings, according to 
age and whether they completed treatment or not. 
3. A week's supply of INH tablets are dispensed to parents/guardians 
at each visit. As a total of 60 doses of INH are administered to 
prophylactic patients who complete treatment, 9 clinic visits are 
necessary. Children who absconded from prophylactic treatment 
received a mean of 25.9 doses of INH. The estimated mean number 






1 806 finished treatment X 9 visits 16 254 
2 057 absconded X 3.7 visits 7 611 23 865 
Notified patients: 
1 207 adults finished treatment X 111 doses 133 977 
706 children II " X 88 doses 62 128 
349 adults defaulted X 52 doses 18 148 
238 children II X 38 doses 9 044 223 297 
247 162 
As some of the notified patients received domiciliary treatment, 
i.e. they were treated at home, the 39 682 domiciliary treatment 
visits must be deducted from the above estimate to determine the 
daily clinic attendances. The revised figures are then 
Prophylactic patients: 23 865 
Notified patients: 183 615 
Total daily clinic attendances: 207 480 
Prophylactic patients accounted for approximately 11.5% of the 
daily attendances and notified patients for 88.5%. Given the 
recorded number of daily attendances for 1983 (199 155), it can 
. be estimated that 22 903 were attributable to patients receiving 




c) Domiciliary treatment: 
All these services relate to the treatment of notified 
patients. 
d) Mobile clinics: 
All these services relate to the investigation of contacts 
and suspects. 
e) Home visits: 
4. 
These estimates are based on the total number of contacts and 
defaulters to be traced. Not all contacts and defaulters are 
followed up in tracing_ procedures due to time limitations. 
Thus, the final estimates of the number of home visits devoted 
to each activity are somewhat lower than the number of tracing 
procedures that could have been conducted if all contacts and 
defaulters were followed-up. The estimates are presented in 
Table C.5. 
Table C.5 Breakdown of home visits 
:' 
Tracing :erocedure No. of contacts % Estimated no. of 
and defaulters home visits 
Contacts 19 898 85.1 9 901 
Prophylactic patient 
defaulters : 2 120 9.1 1 059 
Notified patient 
defaulters 4 1 364 5.8 675 
Total 23 382 11 635 
Each defaulter may be visited more than once to encourage them to 
return to a clinic for daily treatment. This figure thus reflects 
the-total number of-home visits that should have been conducted for 
for t:racing notified patient·.defaulters. (Unpublished CDC records). 






In addition, 32 037 BCG vaccinations were performed and were 
not specifically included in the totals for TB clinic services, 
and there were 3 146 attendances for the administration and 
reading of tuberculin tests at schools. 
Table C.6 summarises these estimates of the breakdown of TB clinic 
services according to the various preventive.and curative procedures. 
Table C.6 Breakdown of CDC TB clinic services for 1983 
Procedure for prevention or treatment of TB 
BCG.vaccinations 
Secondary chemoprophylaxis 
- Dispensing tablets 
- Tracing defaulters 
Mass screening campaigns 
- Pre-employment screening and Leonsdale survey 
- Schools tuberculin testing 
Contacts and suspects 
- Tracing procedures 
- Investigation during 'established sessions' 
- Initial investigation at mobile clinics 
Notified patients 
- 'Daily treatment at clinics 
- Domiciliary treatment 
- Progress assessment and follow-up procedures 































clinic services, as presented in Table C.7. 
Table C.7. Breakdown of TB clinic services costs 
TB prevention/treatment procedure 
BCG vaccinations 
Secondary chemoprophylaxis 
Mass screening campaigns 
Contact and suspect investigations 














Rl 350 941 
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APPENDIX D - EXTRACTS FROM UNPUBLISHED CDC RECORDS TO DETERMINE 
THE NUMBER OF SECONDARY CHEMOPROPHYLAXIS PATIENTS 
AND CONTACTS/SUSPECTS IN 1983 
Information contained in unpublished CDC records with respect to the 
number of contacts and suspects investigated and the number of patients 
who·were prescribed a course of secondary chemoprophylactic treatment 
during 1983, is summarised here'. 
Note: For the purposes of this appendix, '~14' refers to people who are 
14 years of age or younger a~d '15+' refers to those who are 15 years 
or older i.e. children and adults respectively. 
Totals 
Prophylactic treatment: -14 15+ -14 · 15+ 
Number on prophylaxis at beginning 
of 1983: 887 148 
Patients gained: 
- New patients 3 495 387 
- Transferred in from hospital/clinic 117 16 
- Recovered from being lost 57 1 3 669 404 
4 556 552 
Patients lost: 
- Treatment completed/discharged 1 567 121 
- Transferred out to a hospital/clinic 119 26 
·-.Absconded 1 705 308 (3 391) (455) 
Number of patients on prophylaxis 
at end of 1983: 1 165 97 
/1 
\ \ ,,,,., 
201 
Totals 
'Contacts/suspects: -14 15+ -14 15+ 
Number under CDC control at 
beginning of 1983 1 656 2 510 
Suspects/contacts gained: 
- New 
- Transferred in from hospital/clinic 
- Recovered from being lost 
Suspects/contacts lost: 
- Investigation completed 
- Transferred out to a hospital/clinic 
- Absconded 
- Died 















9 752 10 386 
11 408 12 896 
(9 184)~0 886) 
2 224 2 010 
This data includes not only those patients investigated and treated 
during 1983, but also those patients who were initially included in 
these procedures in 1982 but were 'carried forward' to 1983, and those 
patients who were similarly 'carried over' from 1983 to 1984. All the 
other calculations in this study are concerned only with those people 
who were initially recorded as being investigated as possible TB cases 
and treated for TB, during 1983 (e.g. the calculations for treatment of 
TB patients are based on the 2 500 patients who were notified during 1983, 
irrespective of whether their treatment regimens were completed in 1983 
or 1984, and excluded all patients notified in 1982 who were still 
receiving treatment in 1983). 
To ensure data consistency throughout this study, the number of people 
recorded .as either being investigated as TB suspects or contacts of a 
notified TB patient, and those beginning secondary chemoprophylactic 
treatment during 1983 are used as the basis of all calculations. To 
estimate the number of these patients who absconded/defaulted, completed 
treatment etc., proportions are calculated from the data supplied above 
I 
I 





Total number of patients incoporated in records during 1983: 
Patients B/F from 1982 
New patients in 19831 









148 1 035 
403 4 015 
551 5 050 
(97) (1 262) 
454 3 788 
Number of patients and proportions, according to outcome: 
-14 15+ 
Outcome No. of Patients % No. of Patients % 
Course completed 1 567 47.00 121 26.65 
Transferred out 119 3. 57 26 5.73 
Absconded 1 705 51.14 308 67.84 
Recovered from 
being lost (57) (1. 71) (1) (0.22) 
,. 
Total 3 334 454 
1. This consists of new patients who either reported directly to a CDC 
clinic or were transferred to a CDC clinic from a hospital or clinic 
outside of the CDC jurisdiction. Patients recorded as 'recovered 
from being lost' were absconders who had been successfully traced by 
clinic staff. Tracing procedures for absconders are conducted for a 
period of two months after they abscond, and thus the majority of 
those who were 'recovered' would be recorded as such within the same 
year (1983) in which they were originally recorded as new patients. 
To avoid double-counting, patients who are 'recovered from being lost' 
are deducted from absconders instead of including them as new patients. 
The same procedure applies to contacts/suspects. 
2~. 
The outcome of patients prescribed prophylactic treatment in 
1983.i.e. whether they completed treatment, absconded etc., is 
estimated using the proportions calculated above: 
No. of Eatients · No. of patients Total 
Outcome -14 15+ 
Course completed 1 698 108 1 806 
Transferred out 129 23 152 
Absconded 1 847 273 2 120 
Recovered from being lost (62) (1) (63) 
Total 3 612 403 4 015 
Contacts/Suspects: 
Total number of contacts/suspects incorporated in records during 1983: 
-14 15+ Total 
Contacts/suspects B/F from 1982 1 656 2 510 4 166 
New contacts/suspects in 19831 9 633- 10 265 19 898 
11 289 12 775 24 064 
Less: Contacts/suspects C/F to 1984 (2 224) (2 010) (4 234) 





Number of contacts/suspects and proportions, according to outcome: 
-14 15+ 
Outcome No. of Patients % No. of Patients % 
Investigation 
completed 4 656 51.36 5 977 55.52 
Transferred out 233 2.57 225 2.09 
Absconded 4 291 47.34 4 680 43.47 
Recovered from 
being lost (119) (1. 31) (121) (1. 12) 
Died 4 0.04 4 0.04 
Total 9 065 10 765 
-
The outcome of investigations into contacts/suspects registered 1.n 1983, is 
estimated using above proportions: 
Outcome No. ·of Eatients No. of Eatients Total 
-14 15+ 
Investigation completed 4 947 5 699 10 646 
Transferred out 248 215 463 
Absconded 4 560 4 462 9 022 
Recovered from heing lost (126) (115) (241) 
Died 4 4 8 







"' APPENDIX E ~ CALCULATION OF COST OF DRUGS USED IN THE TREATMENT OF 
'TB PATIENTS AT CDC CLINICS IN 1983 
a) Cost of drugs administered in the 'clinic' regi~en: 
The sampl~ data presented in Chapter III indicates that the drug 
regimen received by patients treated at CDC clinics (called the 
'clinic' regimen in this study) differs from the regimen actually 
p~oposed by the CDC health authorities (called the 'official' 
regimen in this study). Drug regimens a~e adapted at the discretion 
of the clinic doctors and based on their assessment of the patient's 
response or progress during treatment. The availability of drugs 
also influences the regimens. The mean number of doses of each drug 
administered to patients, as reflected in the sample results (see 
section 2.4.3 of Chapter III) will be used in the determination of 
the drug costs for the clinic based regimen. 
Table E.l lists the unit costs of the drugs used in the treatment 
of TB patients at CDC clinics. These costs have been examined to 
ensure that they reflect competitively determined market prices. 
Table E.l 1983 unit costs of drugs (including handling charge) 
Drug Cost (Rand) 
INH (100 mg) 
INH (200 mg) 
Rifampicin (150 mg) 
Rifampicin (450 mg) 
'Rifampicin syrup ·(60 ml) 
Streptomycin (5 g) 
PZA (0.5 g) 
Ethambutol (100 mg) 















As Streptomycin is administered by means of an i_njection, the 
cost of disposable syringes (R0.063) and needles (R0.032) also 
need to be accounted for. 
Total drug costs for adults: 
Adults are prescribed the following drug dosages:
1 
!NH 400 mg 
Rifampicin 450 mg 
Streptomycin 1 g 
PZA 2 g 
Ethambutol 1 200 mg 
The total drug costs per patient are calculated as follows: 
Cost per dose x mean number of doses administered. 
Table E.2 Drug costs per adult patient who completed treatment 
('clinic' regimen) 







1. A dose is defined as: a quantity of a drug administered at one 
• I • d time. Dosage refers,to the proper size of a drug dose expresse 
. usually in te~ms of grams or milligrams. 
\ y 
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Table E.3 Drug costs per adult patient. who did not complete 
treatment ('clinic' regimen) 







Total drug costs for children: 
There is no uniform drug dosage prescribed for children, and 
dosages are determined according to the weight of each child 
in terms of the following guidelines: 
10 mg/kg for INH and Rifampicin, 
25 mg/kg for Ethambutol, and 
30 mg/kg for PZA. 
The dosage of each drug received by children in the sample was 
tabulated, the cost per dosage was calculated and then an 
average cost per dose was calculated (see Table E.4 for calculations). 
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Tab le E.4 Sunnnary of drug dosages for children and cost calculations 
Cost Eer dose 
for all 
No. of.;eadents Eatients 
Cost ;eer receiving receiving 
Drug Dosage dosage+ this dosage this dosage 
!NH 50 mg 0.00065 2 0.0013 
75 mg 0.00098 6 0.0059 
100 mg Q.00130 44 0.0572 
150 mg 0.00195 31 0.0605 
200 mg 0.00210 9 0.0189 
300 mg 0.00340 6 0.0204 
400 mg 0.00420 1 0.0042 
Rif ampicin* 50 mg 0.1413 2 0.2826 
60 mg 0.1696 1 0.1696 
75 mg 0.2120 4 0.8479 
80 mg 0.2261 1 0.2261 
100 mg 0.2826 40 11. 3050 
150 mg 0.2290 34 7.7860 
200 mg 0.5653 5 2.8263 
300 mg 0.4580 5 2.2900 
450 mg 0.6869 2 1. 3740 
Streptomycin 500 mg 0.1509 1 0.1509 
750 mg 0.1789 1 0.1789 
PZA 125 mg 0.0135 11 0.1485 
250 mg 0.0270 40 1. 0800 
500 mg 0.0540 25 1.3500 
750 mg 0.0810 5 0.4050 
1 000 mg 0.1080 4 0,4320 
1 250 mg 0.1350 1 0.1350 
1 500 mg 0.1620 1 0.1620 
Ethambutol 100 mg 0.0318 3 0.0954 
+ 
'* 
,!' 150 mg 0.0477 8 0.3816 
200 mg 0.0636 20 1. 2720 
250 mg 0.0795 9 o. 7155 
300 mg 0.0954 18 1. 7172 
350 mg 0.1113 5 0.5565 
400 mg 0.1021 8 0,8168 
450 mg 0.1180 1 0.1180 
500 mg 0.1339 2 0.2678 
600 mg 0.1532 2 0.3063 
800 mg 0.2042 1 0.2042 
1 200 mg 0.3063 2 0.6126 
These calculations are based on the unit cost of drugs (Table E.1) 
e.g. a patient who is prescribed 50 mg of INH_is given! a 100 mg !NH 
tablet. Thus the cost per 50 mg of INH is R0.0013 x !, 
Those patients receiving 100 mg or less and those receiving 200 mg 
were given Rifampicin syrup (1 ml= 20 mg). Those receiving 150 mg, 
300 mg, or 450 mg were given capsule,s. (Rifampicin is only available 
in 150 mg and 450 mg capsules and syrup form.· Th~ capsules are not 





The dosage specific costs per dose (i.e. last column of Table E.4) 
are totalled for each drug, to estimate the cost per dose for all 
children in the sample, Each total is divided by 99, the number of 
child patients in the sample, to estimate the average cost per dose 
per patient. Table E.5 sunnnarises these calculations. The cost per 
dose per patient is then multiplied by the mean number of doses that 
each of the 99 patients received as reflected in the sample findings 
·(see section 2.4.3 of Chapter III), to estimate the cost of each drug 
per patient (see Tables E.6 and E.7). 
Table E.5 Cost per dose for child patients 
Cost per ·dose Cost per dose per 
Drug for all child patientg child patient 
INH 0.1684 0.0017 
Rifampicin 27.1075 0.2738 
Streptomycin 0.3298 0.0033 
PZA 3. 7125 0.0375 
Ethambutol 7.0639 o. 0714 
Table E.6 Drug costs per child patient who completed treatment 
('clinic' regimen) 









Table E.7 Drug costs per child patient who did not complete 
treatment ·('clinic' regimen) 







b) Cost 0£ drugs administered in the 'official' regimen: 
The drug regimen prescribed by the CDC health authorities is as 
follows: 
Adults - INH 100 doses 
PZA 100 doses 
Rifampicin 60 doses 
Streptomycin 60 doses 
Children - INH 100 doses 
Ethambutol 100 doses 
Rifampicin 60 doses 
PZA. 60 doses 
The sample indicated that very few patients actually receive this 
regimen. Drug costs calculated here for the 'official' regimen 
are used to compare the cost-effectiveness of the 'clinic' and 
'official' regimens, to determine whether the flexibility in 









of TB treatment significantly. This analysis is performed 
in section 4.2.2 of Chapter V. 
Costs are, calculated using the procedure described above and 
with reference to Table E.l and Table E.5 (mean number of 
doses administered is replaced by the number of doses prescribed). 
Table E.8 Drug costs per patient who completed treatment 
('official' regimen) 
Cost per adult 
patient (Rand) 
0.42 
Cost per child 
patient (Rand) 
0.17 
Rifampicin 41. 21 16.43 
Streptomycin 12.41 
PZA 21.60 2.25 
Ethambutol 7.14 
Total R75~64 R25.99 
To estimate the number of doses of drugs administered to patients 
receiving the 'official' regimen who did not complete treatment, 
either by default or for other reasons, a proportion is calculated 
from the means reflected in the sample data, in the following manner: 
Tables III.15 and III.16 indicate that a wide range of drug doses 
and combinations of drugs were administered. The most consistent 
drug administration was that of !NH - this drug was prescribed in 
the majority of cases for the entire duration of treatment, for 
both children and adults, -and was not subject to change due to 
adverse reactions or to facilitate treatment at work/school, as 




if a patient had developed a resistance to it. Thus the 
proportion of mean doses of INH administered to patients who 
did not complete treatment, to mean doses of INH ..administered to 
those who completed treatment, gives the most accurage estimate 
of the proportion of drug regimen completed before default. 
Using this method, 46.5% of the regimen was completed in the 
case of adults and 43.2% for children. Although different mean 
doses of each drug are reflected in t"he sample for defaulters, 
this is largely as a result of differences in the combination of 
drugs administered e.g. most adults received INH but the other 
three drugs were selected from four possible alternatives, and 
children were sometimes treated with only two or three drugs. 
As the CDC regimen specifies four drugs in each case and all 
drugs are administered from the connnencement of treatment, it 
can be assumed that a mean of 46.5 doses of each drug was 
administered to adults before default and 43.2 doses to children. 
Table E.9 Drug costs per patient who did not complete treatment 
('official' regimen) 
Cos-t per adult Cost per child 
Drug patient (Rand) patient (Rand) 
INH 0.20 0.07 
Rifampicin 31. 94 11. 83 
Streptomycin 9.62 
PZA 10.04 1. 62 
Ethambutol 3.08 
Total RSI. 80 Rl6.60 
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APPENDIX F - CALCULATION OF THE UNIT COSTS OF TESTS USED TO 
INVESTIGATE POSSIBLE TB CASES AND TO ASSESS THE 
PROGRESS OF TB PATIENTS AT CDC CLINICS IN 1983 
a) Radiological investigations: 
According to the CDC records for the 1983/84 financial year, the 
total cost of operating and ma:intaining the mobile X-ray units, 
including staff costs, depreciation charges and a proportion of 
the Health department administration costs was R95 026. The 
total number of radiological investigations during this period 
was 37 623. Thus the cost per X-ray was R2.53. 
b) Bacteriological investigations: 
The State Health Laboratory in Cape Town provided the following 
unit cost estimates, which were based on 1983 expenditure and 
considered to be the most accurate reflection of total costs 





Drug sensitivity tests: 




R25.20 (RS.04 per drug - done 
routinely for five drugs) 
1 ampule of Tuberculin PPD (Purified Protein Derivative) cost R3.26, 




ampule are performed at CDC clinics (personal communication 
with Sister Theron, head of the CDC schools immunisation team). 
It was difficult to estimate the cost of heaf guns, as they were 
bought over a number of years and have a relatively long lifespan. 
The average unit cost of the heaf guns bought by the CDC was 
R30.32. There are approximately 30 heaf guns in use at the various 
clinics. Each apparatus can be used for approximately 5 years 
(personal communication with technical adviser at Hospital Products 
(Pty) Ltd) and the lifespan is dependant on frequency of use. 
Assuming linear depreciation, ·the annual cost of heaf guns can be 
estimated as Rl81.92. 
The total cost of tuberculin testing in 1983 is thus: 
R806.31 for Tuberculin PPD for 7 420 tests 
Rl81.92 for heaf guns 
R988.23 
The cost per tuberculin test can then be approximated as: 
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